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1. INTRODUCTION 
 
1.1 Mastitis as a challenge in general immunology 
Mastitis is an inflammation of the mammary gland. According to the clinical symptoms, 
mastitis is classified into two categories, acute and chronic mastitis. The apparent clinical 
symptoms, such as swelling, heat, redness and pains, usual appear in the acute cases. 
Subclinical, chronic mastitis is always a moderate and persistent inflammation and makes a 
great impact on dairy industry. Acute mastitis is caused commonly by Escherichia coli (E.
coli), but also Klebsiella pneumoniae, Pseudomonas aeruginosa, Enterobacter sp., Fungi and 
yeasts. In contrast, Gram-positive bacteria, such as Staphylococcus aureus, Streptococcus
agalactiae and Streptococcus uberis, are the most prevalent pathogens causing chronic 
mastitis. 
Mastitis remains a highly prevalent disease, although people take efforts to control it. It is also 
a costly disease in dairy industry (Seegers et al., 2003). It is estimated that financial losses 
resulting from mastitis amount to US$ 2 billion in the USA alone (Nash et al., 2000), and 
worldwide losses are estimated at US$ 25 billion annually. The major economic losses are 
from reduction of milk yield and quality, usage of massive antibiotic, extended calving 
intervals and high culling rate. Hence, prevention and treatment of mastitis becomes a serious 
burden to producers and are of primary concern to the dairy industry. Subclinical mastitis 
remains at the forefront of interest in the international scale. 
The establishment and persistence of an infection depend on both intrinsic virulence factors of 
the pathogen (Hornef et al., 2002) and capacity of the host’s immune response to the pathogen 
(Burvenich et al., 2003). Unlike the adaptive immune system, which is long-lasting and 
specific for microorganism, the innate immune response is ubiquitous, non-specific and short 
acting. It mediates the predominant defence at early stages of an infection. Moreover, the 
innate immunity represents the first line of active defence against invading pathogens after 
their penetrating the physical barriers. Hence, it is crucial to comprehensively understand the 
immune mechanism, especially innate immune mechanism of bovine mammary gland, for 
developing strategies to reduce incidence of udder infections. 
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1.2 Innate immunity of the bovine mammary gland 
The bovine mammary gland is a secretory organ with an organ-specific immune competence. 
Although mammary gland is always exposed to copious microorganisms, individual pathogen 
rarely causes mammary gland infection. The main reasons are from the physical barrier 
function of the epithelia of mammary gland and the presence of antimicrobial substances. 
However, once the barriers are breached, the host initiates immune defence against the 
invading pathogens.  
Innate immunity mechanisms contribute to humoral immunity and cellular immunity. The 
former includes activation and/or release of various humoral mediators, such as complement 
cascade, cytokines and antimicrobial substances. The latter involves the activation of immune 
cells and/or their recruitment to sites of infection and inflammation, for example, neutrophils, 
macrophages, natural killer cells (NK) and dendritic cells (DC).  
The contribution of the complement system to the defence of the bovine mammary gland has 
been reviewed (Rainard, 2003). Complement is present in milk of the healthy mammary gland 
at the low but significant concentration. The chemotactic complement fragment C5a is 
reported to induce the migration of neutrophils through the mammary epithelium in vitro and 
in vivo (Persson et al., 1993; Smits et al., 1996). It is also a potent stimulator of neutrophils 
(Rainard et al., 2000), which is important for the efficient phagocytosis in milk during 
infection. But the role of C5a in the initiation of the inflammatory response of the mammary 
gland remains questionable.  
Lactoferrin (Lf) is firstly known for its iron-chelating property which is thought to establish 
its bacteriostatic function to protect against oxygen radical catalyzed by free iron (Legrand et 
al., 2004).  Bovine Lf may suppress the LPS-induced IL-6 response of inflammatory cells 
(MattsbyBaltzer et al., 1996), but the contribution of Lf in inflammation control during E. coli 
mastitis remains to be specified. Lf may cooperate with other defence components, such as 
complement or lysozyme. For example, bovine Lf has been shown to modulate complement 
activation. The Lf binding to S. agalactiae activates the classical pathway of complement 
system, resulting in the opsonization of the bacteria (Rainard, 1993). Interestingly, activation 
of the alternative pathway by bovine Lf results in an increase of C3 deposition on S. aureus 
(Kai et al., 2002).  
Neutrophils and macrophages are the predominant recruited cells into the milk or the 
mammary gland, although their abundances vary at the different physiological stages. For 
example, Neutrophils are the major cell type in colostrum, while the macrophage dominates in 
dry standing and lactating cows (Lee et al., 1980; Sordillo et al., 1991). Although milk 
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macrophages are less efficient than milk neutrophils in phagocytosis, they can ingest the 
common mastitis pathogens (Mullan et al., 1985). Moreover, they are potential antigen-
presenting cells, and are implicated in the detection of invading pathogens and the initiation of 
the inflammatory response. Interestingly, the function of macrophages in mammary gland 
markedly decrease during the periparturient period, and this alteration has been linked to the 
increased mastitis incidence (Sordillo and Streicher, 2002; Waller, 2000). 
Mammary epithelial cells (MEC) are another crucial cell type in mammary gland. It has been 
demonstrated that bovine mammary epithelial cells (bMEC) are able to produce a variety of 
inflammatory mediators or effectors in response to invading pathogens. They are composed of 
cytokines (TNF etc.) and/or chemokines (interleukin 8, CXCL5, CXCL6 etc.) (Pareek et al., 
2005; Strandberg et al., 2005; Wellnitz and Kerr, 2004; Yang et al., 2008), antimicrobial 
peptides (BNBD, LAP, etc) (Goldammer et al., 2004; Swanson et al., 2004). Hence, bMEC 
provides a relevant model for the research of innate immunity of bovine mammary gland. So 
far, the established two bMEC cell lines include MAC-T (Huynh et al., 1991) and BME-UV 
(Zavizion et al., 1996). Then, how do these cells recognize the extracellular pathogen? 
 
1.3 Toll-like receptors (TLRs): main receptors perceiving the pathogen presence 
Toll-like receptors (TLRs) have been identified as major receptors recognizing conserved 
bacterial structures known as pathogen-associated molecular patterns (PAMPs) (Kopp and 
Medzhitov, 2003). Mammalian TLRs family comprises 13 transmembrane receptors (TLR1 to 
TLR13). These TLRs were reported to specifically recognize different PAMPs. For example, 
TLR2 is the receptor for peptidoglycan and lipoteichoic acid (LTA) of Gram-positive 
bacteria. TLR4 recognizes lipopolysaccharides (LPS) of Gram-negative bacteria, TLR5 binds 
bacterial flagellin, and TLR9 recognizes bacterial CpG DNA (Van Amersfoort et al., 2003). 
Upon recognition of PAMPs by specific TLR or multiple TLRs, the signal transduction 
pathway is initiated. This features activation of downstream adaptors, such as Myeloid 
differentiation marker 88 (MyD88) or the TIR-domain-containing adaptor protein (TRIF). As 
a result, nuclear factor B (NF-B) is activated and transcription of the immune-related 
genes, such as chemokines and -defensins, is enhanced (Takeda et al., 2003). Given the 
important functions of chemokines and -defensins in innate immunity system, it is valuable 
to elucidate the molecular mechanisms regulating their expression in response to pathogen 
stimulation. In the following sections, I focus on the mechanisms regulating expression of the 
chemokine interleukin 8 and -defensins.  
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1.4 Interleukin 8 (IL-8): a chemokine 
The chemokine family consists of functionally diverse proteins mediating inflammatory 
responses. They are small proteins (8-10 kD) with similar 3-dimensional structures. Four 
subfamilies are classified according to the presence of a cysteine containing signature motif 
near their N-terminus (CXC, CC, C and CX3C) (Mackay, 2001; Rossi and Zlotnik, 2000). To 
date, 18 bovine chemokines are known. 
Interleukin-8 (IL-8), a member of the CXC chemokine family, is an important activator of 
neutrophils and a chemoattractant for neutrophils, T-cells and basophil cells. Hence, it plays a 
crucial role in inflammatory disease (Harada et al., 1994; Matsushima and Oppenheim, 1989). 
It is not constitutively but  inducibly produced by pathogen signal in many cell types, 
including macrophages, epithelial cells, monocytes, dermal fibroblasts, endothelial cells, 
keratinocytes, mesangial cells and several human tumour cell lines (Roger et al., 1998).  
  
1.4.1 Inducible expression of IL-8  
It has been reported that IL-8 is induced by LPS (Yoshimura et al., 1987), S. aureus 
entertoxin A (Schmid and Weissmann, 1987), cytokines (IL-1 and TNF- (Matsushima et 
al., 1988) and phorbol myristate acetate (PMA) (Mukaida et al., 1989). In mammary epithelial 
cells, IL-8 mRNA expression is up-regulated by LPS and LTA (Strandberg et al., 2005). An 
increase in IL-8 was also reported in milk from quarters stimulated by LPS (Bannerman et al., 
2003).  
IL-8 is also inductively produced by whole bacteria. In milk cells from mammary glands 
infected with Gram-negative E. coli bacteria, IL-8 mRNA transcription is increased (Lee et 
al., 2006). Primary bovine MEC cells markedly increase IL-8 transcription upon induction 
with heat-inactivated E. coli (Yang et al., 2008). In contrast to Gram-negative bacteria, 
intramammary infections with Gram-positive or wall-less bacteria are shown to induce a 
delayed and/or diminished IL-8 response. In two studies using different S. uberis strains, milk 
IL-8 is not increased until 30 h and 66 h after infection (Bannerman et al., 2004a; Rambeaud 
et al., 2003). Another S. aureus strain does not increase milk IL-8 following experimental 
intramammary infection (Bannerman et al., 2004b). However, the differential transcription of 
IL-8 mRNA has also been confirmed in experimental mammary tissue infected with other 
strains of E. coli and S. aureus (Yang et al., 2008). Hence, the IL-8 gene expression is cell-
type and stimulus specific (Roebuck, 1999). 
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1.4.2 Molecular regulation of the human IL-8 expression 
How can cells respond dynamically to a variety of stimuli? One view is that the ubiquitous, 
stimulus- and cell type-specific activators can be assembled into a nucleoprotein complex 
called enhanceosome (Carey, 1998). In the enhanceosome model, the binding of different 
activators to their recognition sites generates a unique network. Each enhanceosome provides 
a specific activation surface, which is chemically and spatially complementary to the target 
surfaces of coactivators and to the basal transcriptional machinery. In this way, they can be 
recruited to DNA to generate synergistic transcription. 
IL-8 regulation is concentrated on the transcriptional level. Since stimulus- and cell-type 
specific activators are involved in the course of IL-8 transcription, the regulation pattern is 
altered owing to different cell types and stimuli. The regulation of the human IL-8 gene has 
been well documented. Functional studies show that the human IL-8 transcriptional responses 
to inflammatory stimuli are rapid and require approximate 150 nucleotides upstream of the 
TATA box. The region possesses DNA binding sites of Activator protein 1 (AP1), 
CCAAT/enhancer binding protein (C/EBP) and NF-B. Among them, NF-B is an important 
factor to activate the human IL-8 promoter in most cases. AP-1 might be involved in 
inflammatory response in epithelial cells. It is demonstrated that AP-1 and NF-B are 
essential transcription factors for IL-1-induced the IL-8 gene expression in human vascular 
smooth muscle cells (Jung et al., 2002). In human airway smooth muscle cells, transcriptional 
regulation of IL-8 by bradykinin involves AP1, C/EBP and NF-B (Zhu et al., 2003). 
Transcription factors C/EBP and NF-B synergistically activate the human IL-8 
transcription in the cited examples (Kunsch et al., 1994; Mahe et al., 1991; Matsusaka et al., 
1993). In contrast, cyclic mechanical stretch does not increase the NF-B activity, but AP1 
and C/EBP are required for IL-8 activation in the same cell type (Kumar et al., 2003). Hence, 
the three transcription factors may play an important role in the modulation of the human IL-8 
gene. The types of factor(s) implicated in the IL-8 activation appear to be dependent on the 
cell types and stimuli types.  
The modulation of the bovine IL-8 gene is poorly understood. Therefore, it is valuable for 
rational control mastitis to investigate the regulatory mechanism of the bovine IL-8 gene 
under pathogen stimulation.   
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1.5 Antimicrobial peptides: -defensins 
1.5.1 Classification and structures of defensins  
In contrast to IL-8, defensins are small, cysteine-rich, cationic antimicrobial peptides widely 
expressed in nearly all higher eukaryotes, from insects and plants to amphibians and 
mammals. Defensins constitute a large, highly conserved multigene family. On the basis of 
the numbers and patterns of disulfide bridges, defensins are divided into three groups, -, - 
and -defensins (Ganz, 2003). 
-defensins are abundant in neutrophils (Ayabe et al., 2000). They are small polypepetides 
with 29-35 residues and a six-cysteine motif that forms three intramolecular disulphide bonds 
(Cys1-Cys6, Cys2-Cys4, Cys3- Cys5)  (Lehrer and Ganz, 2002). 
-defensins differ from -defensins in size (> 30 amino acid residues) and cysteine pairing 
(Cys1-Cys5, Cys2-Cys4, Cys3- Cys6). They are expressed in several organs, such as tongue, 
airways, skeletal muscles, esophagus, intestine and skin. However, - and -defensins have 
similar tertiary structures, featuring triple-stranded antiparallel  sheets (Pardi et al., 1992; 
Zimmermann et al., 1995). 
-defensins are identified only in rhesus monkeys so far. They are circular mini-defensins (18 
amino acids) generated by two -defensin mRNA precursors, which acquired a stop codon 
between the third and the fourth codon for cysteine (Lehrer and Ganz, 2002). 
 
1.5.2 -defensin in mammal 
In mammal, copious -defensins have been identified. The first mammalian -defensin 
designated TAP (tracheal antimicrobial peptide) was isolated from cow trachea (Diamond et 
al., 1991). Lingual antimicrobial peptide (LAP) was subsequently purified from cow tongue 
and shown to be expressed in various epithelia (Schonwetter et al., 1995). Apart from TAP 
and LAP, 13 different bovine -defensins (BNBD1-13) are identified from neutrophils 
(Selsted et al., 1993), and EBD from enteric epithelium cells (Tarver et al., 1998). In a recent 
report, six novel-defensin members (named DEFB401-DEFB405 and LAP-like) in bovine 
are characterized (Roosen et al., 2004). In mouse, four -defensins are expressed in 
keratinocytes or various epithelial cells (Bals et al., 1999; Jia et al., 2000; Morrison et al., 
1999). Six human -defensins (hBD1-6) have been characterized (Bals et al., 1998; Bensch et 
al., 1995; Garcia et al., 2001a; Harder et al., 1997; Kao et al., 2003; Yamaguchi et al., 2002). 
Among them, hBD-1, 2 and 3 are produced by keratinocytes and various epithelial cells 
(Diamond et al., 1996; Harder et al., 1997; Liu et al., 1998; Russell et al., 1996; Zhao et al., 
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1996). hBD-4 is strongly expressed in the testis and gastric antrum (Garcia et al., 2001b), 
whereas hBD-5 and hBD-6 are specifically expressed in the epididymis (Yamaguchi et al., 
2002). 
 
1.5.3 Inducible expression of -defensins 
Unlike - and -defensins, -defensins transcription is inducible. hBD-2 expression is 
induced in monocytes by bacteria, LPS  and interferon-	 (IFN-	) (Duits et al., 2002; Fang et 
al., 2003). IL-1markedly stimulates hBD-2 mRNA increase in tracheal epithelial cells 
(Hiratsuka et al., 2003). hBD-3 mRNA concentration is strongly induced by IFN-	 in 
keratinocytes (Harder et al., 2004). hBD-4 mRNA in respiratory epithelial cells is upregulated 
by bacterial exposure or PMA (Garcia et al., 2001b). It was also reported that both TAP and 
LAP transcription are enhanced in bovine tracheal epithelial cells (TEC) challenged with LPS 
or TNF (Russell et al., 1996). A lot of -defensins are expressed in mammary gland or 
mammary epithelial cells in response to mastitis, including LAP, -defensin 5 (BNBD5), 
TAP, DEFB1, BNBD3, BNBD9, BNBD12 and DEFB401 (Goldammer et al., 2004; Roosen 
et al., 2004; Strandberg et al., 2005). The data indicate that -defensins may play a significant 
role in host immune response (Fellermann and Stange, 2001). 
 
1.5.4 Roles of -defensins in mammalian immunity 
-defensins can kill or inactivate bacteria, fungi or some enveloped viruses in vitro and are 
generally considered to be direct effectors of innate antimicrobial immunity (Ganz and 
Lehrer, 1998; Lehrer and Ganz, 1999). For example, hBD-2 exhibits a potent antimicrobial 
activity against Gram-negative bacteria E. coli and Pseudomonas aeruginosa, but only a 
bacteriostatic activity against Gram-positive S. aureus (Schibli et al., 2002). Although the 
antimicrobial mechanism of -defensins remains poorly understood, it is commonly thought 
that their antimicrobial activities result from their spatially separated charged and 
hydrophobic regions. These enable the peptides to insert into the cell membrane to impair 
membrane integrity and functions, which ultimately leads to the lysis of microorganism cells 
(Sahl et al., 2005). In addition to potent antimicrobial activity in innate immunity, -defensins 
also seemingly play roles in adaptive immunity, which provides a link between innate and 
adaptive immunity (Yang et al., 1999). For example, hBD-1 is chemotactic for immature, but 
not mature DCs (Yang et al., 1999), hBD-2 for CD45R0+ memory T cells (Yang et al., 1999). 
Murine -defensins 2 and 3 (mBD2 and mBD3) can act on murine immature but not mature 
DCs (Biragyn et al., 2001). 
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1.5.5 Regulation of -defensins expression 
The regulation of the human hBD genes has been well documented. Different from the hBD-3 
gene, the hBD-2 promoter contains NF-B response element (Becker et al., 2000; Harder et 
al., 1997). Moreover, NF-B binding to the pB1 attachment site (-205 to -186) was found to 
be crucial for the transcriptional regulation of the hBD-2 gene in response to IL-1and TNF-
in A549 cells (Tsutsumi-Ishii and Nagaoka, 2003).  
In bovine primary TEC cells, the induction of TAP is regulated at the transcriptional level in 
response to LPS and the mutant strain (WD3) of B. bronchiseptica. NF-B p50 and p65 were 
found to be involved in the regulation, but C/EBP has no alteration after stimulation in 
EMSA assay (Diamond et al., 2000; Legarda et al., 2005). A more recent report shows that 
NF-B and NF-IL6 (C/EBP) are indispensable for expression of the bovine BNBD5 gene 
under different stimuli (Yang et al., 2006).  
 
1.6 Nuclear factors (NF-B) 
Nuclear factors (NF-B) or Rel proteins are a family of structurally-related eukaryotic 
transcription factors, which are implicated in the regulation of inflammatory and immune 
responses, developmental processes, cellular growth and apoptosis. In mammals, the NF-B 
family is composed of five transcription factors: RelA (p65), RelB, c-Rel, NF-B1 (p105/p50) 
and NF-B2 (p100/p52) (Ghosh et al., 1998). All of them possess a highly conserved ca. 300 
amino acids DNA-binding/dimerization domain called the Rel homology domain (RHD) (Fig. 
1). The NF-B members can form homodimers and heterodimers via RHD and bind to NF-B 
binding sites to modulate gene expression. The consensus sequence of the common NF-B 
site is GGGPuNNPyPyCC, where Pu stands for purine base, Py is pyrimidine and N 
symbolizes any nucleotide (Ivanov et al., 1995; Weih et al., 2001). Three members p65, c-Rel 
and RelB contain transactivation domains (TADs) in C-terminal, which enable them to 
activate target gene expression. In contrast, p50 and p52 have no TAD (Fig. 1). Homodimers 
or heterodimers of p50 and p52 were reported to repress NF-B-site-dependent transcription 
in vivo (Lernbecher et al., 1993), possibly by competing for DNA binding with other 
transcriptionally active dimers (e.g. p50/p65). p50 or p52 also often forms heterodimers with 
the other NF-B members to activate transcription. Alternatively, they might interact with the 
other proteins possessing a TAD, such as Bcl-3 to enhance target gene transcription. 
Surprisingly, p50/p50 homodimer has been demonstrated to activate NF-B-site-dependent 
transcription in vitro (Lin et al., 1995).  
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NLSp50 443 AA
NLSp52 447 AA
NLSLZRelB TAD 579 AA
NLSp65
(RelA)
TAD 551 AA
NLSC-Rel 619 AATAD
DNA binding Dimerization
Rel Homology Domain (RHD)
 
Figure 1. Members of the NF-B (or Rel) family 
All members encompass a well-conserved RHD, which comprises DNA-binding and 
dimerization domains, and a nuclear localization signal (NLS). RelB has a unique N-terminal 
leucine zipper (LZ) domain. TAD: transactivation domain only in p65, RelB and c-Rel, The 
above image is adapted with minor modification  (Xiao, 2004). 
  
1.6.1 Inhibition of NF-B 
NF-B factors are generally been thought to reside in the cytoplasm in an inactive form bound 
by its inhibitory proteins, the members of the IB family (Finco et al., 1994; Verma et al., 
1995). However, serial findings have demonstrated that NF-B may shuttle between the 
nucleus and cytoplasm (Carlotti et al., 2000; Huang et al., 2000; Tam et al., 2001; Tam and 
Sen, 2001). Hence, the majority of NF-B-IB complexes are present in the cytoplasm, since 
potent nuclear export signals (NES) in the IB proteins overcome the NLS of the NF-B 
subunits (Tam et al., 2000). The crystal structures of IB and IB revealed that the IB 
proteins mask only NLS of p65, whereas the NLS of p50 remains accessible (Chen et al., 
1998; Croy et al., 2004; Huxford et al., 1998).  
  
1.6.2 Activation of NF-B 
NF-B can be activated by various extracellular stimuli, including inflammatory cytokines, 
bacterial components (such as LPS), viral infection, physiological, physical or oxidative 
stresses, a variety of mitogens among others (Ghosh et al., 1998; Pahl, 1999). In general, two 
events are considered in NF-B activation. One is the release of NF-B from the NF-B-IB 
complex and its translocation into the nucleus. During the event, the activated IB kinase 
(IKK) complex phosphorylates IB to make the latter degraded by proteasome. As a result, 
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NF-B is released from the NF-B-IB complex. Two pathways may be involved in the 
course, the classical pathway or the alternative one. It was reported that the former is involved 
in innate immunity and the latter maybe in adaptive immunity. Since the alternative pathway 
of NF-B activation is required for B cell maturation and formation of secondary lymphoid 
organs (Senftleben et al., 2001).The post-translational modification of NF-B is another 
activation event. I will explain the type in details in the following part. 
   
1.6.3  Phosphorylation and acetylation of NF-B 
Phosphorylation and acetylation of NF-B p65 are main molecular events in post-translational 
modification of NF-B factor, which controlling the strength and duration of the NF-B 
transcriptional response. It has been documented that NF-B p65 is phosphorylated at least at 
4 different serine sites, including Ser276 and Ser311 in the RHD and Ser529 and Ser536 in the 
TAD (Duran et al., 2003; Hu et al., 2004; Sakurai et al., 2003; Zhong et al., 1998). Mitogen 
and stress-activated protein kinase (MSK1 and MSK2) and protein kinase A (PKA) are 
involved in phosphorylation at Ser276 (Chen and Greene, 2004; Vermeulen et al., 2003). 
Phosphorylation of p65 at Ser276 enhances the interaction of p65 with the coactivator CREB-
binding protein (CBP) and its structural homolog p300 (Zhong et al., 1998). PKC 
phosphorylates p65 at Ser311. However, in PKC –deficient cells, p65 fails to interact with 
CBP in response to TNF (Duran et al., 2003). Ser529 and Ser536 are catalyzed by IKK and 
casein kinase II (CK2) respectively (Chen and Greene, 2004; Perkins, 2006). Similar to 
Ser276, phosphorylation at Ser536 increases assembly of p65 and CBP/p300. However, the 
mutation of Ser536 into Ala abrogates this interaction (Chen et al., 2005).  
Similarly, NF-B acetylation has been demonstrated to be important for NF-B function 
(Chen et al., 2001; Kiernan et al., 2003). The acetylation of NF-B p50 at lys431, lys440 and 
lys441 seems to enhance the transcriptional activity and DNA binding activity of modified 
heterodimers (Deng et al., 2003; Deng and Wu, 2003; Furia et al., 2002). Three acetylation 
sites (lys218, lys221 and lys310) have been identified in NF-B p65, and they play distinct roles 
in the transcriptional activities of NF-B p65 (Chen et al., 2002). For example, acetylation at 
lys310 is required for the transciptional activity of p65, but has no effect on its DNA binding or 
interaction with IkB
The acetylation of p65 at lys218 and lys221 enhances its DNA-binding 
activity and impair the assembly with IB, thereby extending the duration of the NF-B 
response in the nucleus. Deacetylation of p65 at lys218 and lys221 by HDAC3 greatly enhances 
the binding to IkB
 The reversible acetylation of p65 serves as an intranuclear molecular 
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switch regulating the strength and duration of the NF-B response (Chen et al., 2001). A 
recent study provides a link between acetylation and phosphorylation of p65. It demonstrates 
that phosphorylations at Ser276 and Ser536 increase the p65 acetylation at lys310 (Chen et al., 
2005). Taken together, phosphorylation and acetylation play key roles in NF-B activation. 
     
1.6.4 Transcriptional coactivators and interactive proteins of NF-B 
Although NF-B is an essential transcription factor involved in the expression regulation of 
many genes, it does not function alone. It is just one component of the complicated regulation 
complex required for gene transcription. Some important transcriptional coactivators are also 
implicated in the complex. It was reported that NF-B p65 binds to the CBP and p300 
(Gerritsen et al., 1997; Perkins et al., 1997; Zhong et al., 1998). Additionally, CBP can also 
associate with the CBP associated factor (p/CAF) (Yang et al., 1996) and with the RNA 
polymerase II holoenzyme (Nakajima et al., 1997). Other components of the transcriptional 
complex may associate with CBP to form a large regulatory complex by facilitating the 
sequence-specific activators to the basal transcriptional machinery. These alter the chromatin 
structure in two ways, since both CBP (Bannister and Kouzarides, 1996) and p/CAF (Yang et 
al., 1996) contain histone acetyltransferase (HAT) domains and have strong HAT activities. 
Hyperacetylated histones have been identified in transcriptionally active chromatin, whereas 
hypoacetylated histones exist in the heterochromatin (Turner, 1998). 
Many transcription factors have been reported to interact with NF-B, including C/EBP 
(Ruocco et al., 1996; Stein et al., 1993b), AP-1 (Stein et al., 1993a) , Sp-1 (Perkins et al., 
1993; Perkins et al., 1994), signal transducer and activator of transcription 6 (STAT6) (Shen 
and Stavnezer, 1998) among others. Since NF-B in genes regulation is frequently 
accompanied with C/EBP factors, I would like to introduce C/EBP as follows.  
 
1.7 CCAAT-enhancer binding proteins (C/EBP) 
 The C/EBP is a family of transcription factors involved in the regulation of cellular 
differentiation in multiple tissues. Six different members (C/EBP to ) have been isolated 
and characterized  (Akira et al., 1990; Cao et al., 1991; Descombes et al., 1990; Poli et al., 
1990; Ron and Habener, 1992; Williams et al., 1991). All members contain a basic DNA-
binding domain and a leucine zipper motif (bZIP) in the C-terminal 55-65 amino acid residues 
(Akira et al., 1990; Landschulz et al., 1988a; Poli et al., 1990; Ron and Habener, 1992). Due 
to the high identity in the bZIP domain, the members of C/EBP can form homo- or 
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heterodimers (Chumakov et al., 1997; Williams et al., 1991) binding to a consensus C/EBP 
binding site (Landschulz et al., 1988a; Landschulz et al., 1988b). 
Conversely, the N-terminal in the C/EBP factors are divergent (<20% sequence identity).The 
C/EBP-, -, - and -	 genes are intronless, whereas C/EBP- and - contain two and four 
exons respectively. Importantly, most members of the C/EBP family can be translated into 
different isoforms from the same mRNA molecules. C/EBP may be translated into two 
protein isoforms, 42 kD and 30 kD, with the latter having a lower transcriptional activity (Lin 
et al., 1993; Ossipow et al., 1993). C/EBP mRNA produces at least three different protein 
isoforms: the liver-enriched transcriptional activating proteins (LAP1, 39 kD), LAP2 (36 kD) 
and liver inhibitory protein (LIP, 20 kD). LIP always acts as a dominant-negative (DN) 
transcriptional repressor due to lack of most of transactivation domain. LAP2 and LIP are the 
major forms (Descombes and Schibler, 1991). At least four isoforms can be produced (32 kD, 
30 kD, 27 kD and 14 kD) by the same C/EBPmRNA molecule. The activation potential of 
the 30 kD form is lower than that of the 32 kD form, and the 14 kD form lacks an intact 
transcriptional activation domain (Lekstrom-Himes, 2001; Yamanaka et al., 1997b). 
1.7.1  Role  of C/EBP in inflammatory and immune response 
C/EBP-, - and - are differentially regulated by inflammatory agents, including LPS and 
cytokines. It was shown that C/EBP and C/EBP mRNA concentrations are increased by 
inflammatory stimuli in a number of cell types, such as hepatocytes, macrophages, renal 
mesangial cells and astroglial cells, whereas C/EBP transcription is decreased (Akira et al., 
1990; Alam et al., 1992; Cardinaux et al., 2000; Granger et al., 2000; Kinoshita et al., 1992; 
Poli et al., 1990; Poli, 1998; Ramji et al., 1993; Tengku-Muhammad et al., 2000). C/EBP-
deficient mice show that expression of serum amyloid A (SAA), the stress associated protein 
(SAP), -acid glycoprotein, complement C3 and TNF was impaired (Poli, 1998; Screpanti 
et al., 1995; Tanaka et al., 1995). Delayed migration of neutrophils along with an impaired 
bactericidal response was observed in the C/EBP-deficient mice (Lekstrom-Himes and 
Xanthopoulos, 1999). Additionally, a number of inflammatory/immune-related genes are 
down-regulated in the C/EBP-deficient mice (Tavor et al., 2002; Yamanaka et al., 1997a). 
These findings clearly demonstrate that C/EBP factors play a crucial role in inflammatory and 
immune response. 
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1.7.2 Autoregulation and phosphorylation of the C/EBP family factors 
The autoregulation of C/EBPgene expression is known in a species-specific manner. The 
murine C/EBPgene expression is autoregulated by C/EBP or C/EBP via the C/EBP 
binding site in its proximal promoter region (Christy et al., 1991; Legraverend et al., 1993). 
The human C/EBP promoter lacks a C/EBPbinding site, however, its expression can still be 
autoregulated by C/EBP indirectly via stimulating the DNA-binding activity of upstream 
stimulatory factor (USF) to its binding site in the proximal promoter region (Timchenko et al., 
1995)
Likewise, the promoters of the C/EBPgenes in mouse, rat and chicken are also 
autoregulated (Chang et al., 1995; Mink et al., 1999; Niehof et al., 2001).  
Phosphorylation modification is also involved in the regulation of C/EBPfunction. C/EBP 
is normally repressive since negative regulatory regions mask its transactivation domains 
(Kowenzleutz et al., 1994; Williams et al., 1995). However, phosphorylation of the negative 
regulatory regions can abolish the repression. A typical example relevant to 
inflammation/immune is that the transactivation potential of C/EBPis induced by 
phosphorylation at Thr235 through the Ras/mitogen-activated protein kinase (MAPK) pathway 
(Nakajima et al., 1993; Zhu et al., 2002).    
1.7.3  Interaction of C/EBP with NF-B  
A number of transcription factors have been reported to physically and functionally interact 
with C/EBP factors. Here I only introduce the interaction of C/EBP with NF-B factors. It has 
been demonstrated that the C/EBP and NF-B factors synergistically enhanced expression of 
the inflammatory/immune-related genes encoding SAA1, A2, A3, and 1-acid glycoprotein, 
as well as the cytokines IL-6, IL-8, and IL-12 and Granulocyte-Colony Stimulating Factor (G-
CSF) (Betts et al., 1993; Dunn et al., 1994; Lee et al., 1996; Li and Liao, 1992; Matsusaka et 
al., 1993; Plevy et al., 1997; Ray et al., 1995; Vietor et al., 1996). The interaction is also the 
main event in the modulation of the human immunodeficiency virus (HIV) long terminal 
repeat (LTR) (Ruocco et al., 1996). Apart from the cooperative activation, C/EBP and NF-B 
factors have also showed antagonistic effects (Brasier et al., 1990; Stein et al., 1993b). It is 
general thought that promoter structure and cell-type specificity are likely to play a major 
role. Although the mechanisms for cooperative effects have not yet been entirely clarified, an 
efficient interaction requires the integrity of both the NF-B RHD and the C/EBP leucine 
zipper domain (Leclair et al., 1992). 
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The conformation of chromatin is also known to contribute to gene regulation and is best 
studied in the endogenous context. Therefore, in the following parts, I will focus on the roles 
of chromatin remodeling and the related DNA methylation status in transcription. 
 
1.8 Chromatin remodeling 
1.8.1 Overview of chromatin remodeling 
In eukaryotes, DNA and protein complex are assembled into higher-order structures 
designated as chromatin, which maintains the majority of genes in an inactive state. The main 
reason is that the cell-type specific transcription factors and RNA polymerases are restrained 
from access to the respective binding sites. However, under some situations, the chromatin 
encompassing that gene and its regulatory regions must be remodeled to make them 
accessible to cell-specific transcription activators, which also permits the complicated 
transcription machinery containing RNA polymerases to initiate transcription. There are two 
broad types of enzymes involved in chromatin remodeling. They are ATP-dependent 
remodeling enzymes and HAT. Although the mechanisms of chromatin remodeling are 
unclear, the enzymes are believed to involve in alteration of the chromatin structure and in 
acetylation of histones or non-histones that somehow increase accessibility to transcription 
factors. Now, I will focus on the link between acetylation and genes transcription.  
 
1.8.2 The link between acetylation and transcription 
The core histones, particularly H3 and H4, can be acetylated by HAT at the -amino groups of 
lysine residues in the N-terminal tails. The charge neutralization may cause an affinity 
reduction of DNA for histone but an increase for transcription factors to activate genes. Given 
are positive examples, but not universal, correlation between the extent of core histone 
acetylation and inducible gene activity. For example, the transcriptional activation of the IFN-
 gene is associated with the localized hyperacetylation of histones H3 and H4 (Parekh and 
Maniatis, 1999). Similarly, histone acetyltransferase activity of yeast Gcn5p is required for 
the activation of targets genes in vivo (Kuo et al., 1998). However, a detailed acetylation 
analysis of histone H4 in Drosophila polytene chromosomes reveals that acetylation of H4 at 
lys5 or lys8 is distributed throughout euchromatin, whereas acetylation at lys12 is preferentially 
associated with heterochromatin, which is generally thought to be transcriptionally repressed 
(Turner et al., 1992). Hence, the correlation between histone acetylation and transcriptional 
activity does not appear to be simple and general. 
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Apart from the histone acetylation, it is reported that there is a link between nonhistone 
acetylation and transcription. For example, the factor p300 and its homolog CBP, p/CAF 
contain HAT activity. However, they not only acetylate histones, but also acetylate general 
transcription factors (GTFs) (e.g. TFIIE), activator/repressors (e.g. p53), and architectural 
proteins (e.g. high mobility group protein [HMG] I (Y)). p300 and CBP interact with the 
activation domains of numerous transcription factors and the nuclear receptors, and acetylate 
the transcription factors to enhance genes transcription (Torchia et al., 1998). These 
interactions provide a direct means of targeting the acetylation to a surrounding regulatory 
region.  
  
1.9 DNA Methylation  
1.9.1  Methods for DNA methylation analysis 
In mammalian DNA, approximate 80% of all CpG dinucleotides are methylated. DNA 
methylation seems to be part of a system affecting chromatin structure and transcriptional 
regulation. The methylation reaction is common catalyzed by DNA methyltransferase (Dnmt) 
by adding a methyl group to carbon 5 of the cytosine ring. Methods for DNA methylation 
analysis can be divided roughly into two types: global and gene-specific methylation analysis. 
Chromatographic methods and methyl accepting capacity assay are two methods for 
measuring the overall level of methyl cytosines in genome. In order to analyze gene-specific 
methylation, a large number of techniques have been developed. Most early studies used 
methylation-sensitive restriction enzymes (e.g. HpaII) to digest DNA followed by southern 
detection or PCR amplification. Recently, bisulfite reaction-based methods have become very 
popular such as methylation specific PCR (MSP) (Herman et al., 1996) and bisulfite genomic 
sequencing PCR (BSP) (Clark et al., 1994; Frommer et al., 1992). In the study, I have adopted 
BSP (Fig. 2). This technique begins with the treatment of genomic DNA with bisulfite. Under 
appropriate reaction conditions, bisulfite converts cytosine into uracil, but 5-methylcytosine 
remains nonreactive. After bisulfite treatment, the DNA region of interest is amplified by 
PCR and the PCR products are sequenced (either directly or after cloning into a plasmid 
vector). By comparison with the known DNA sequence, the cytosines that were methylated 
within the genomic DNA can be identified because they will be the only cytosines that were 
not converted into uracil.  
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GATCAG mCG CG GCTTAAG5‘
5‘3‘
3‘CTAGTC
Denaturation
GATCAG mCG CG GCTTAAG5‘
5‘3‘
3‘
CTAGTC GCm GC CGAATTC
Bisulfite reaction
GATUAG mCG UG GUTTAAG5‘
5‘3‘
3‘
PCR with homologous or 
complementary primers with sense strand
GATTAG CG TG GTTTAAG5‘ 3‘
3‘ 5‘
GCm GC CGAATTC
UTAGTU GCm GU UGAATTU
CTAATC GC AC CAAATTC
Sense strand of PCR product is directly sequenced
Renaturation
not complementary
 
Figure 2. Bisulfite genomic sequencing procedure 
The originally complementary genomic double-stranded DNA was shown firstly. The 
methylated cytosine residues are shown in red. The unmethylated cytosine and their 
corresponding uracil and thymine conversion products are shown in blue. The image is 
adapted with minor modification (Clark et al., 1994).     
 
1.9.2 Roles of DNA methylation 
Gene knock-out studies indicate that CpG methylation in mammals is an indispensable 
process. Targeted deletion of Dnmt1 results in a marked reduction in the level of DNA 
methylation in embryonic stem cells (ES) (25–30% of wild-type levels) and is lethal early in 
embryogenesis (Li et al., 1992). However, that methylation somehow orchestrates changes in 
chromatin structure during normal development is not well-supported by experimental 
evidence. Importantly, with the exception of the few imprinted genes and those genes located 
on the inactive X chromosome in females, the CpG islands located in the promoter regions of 
genes are usually unmethylated irrespective of the expression status of the gene (Bird, 1992). 
Hence, DNA methylation in the promoter region does not appear to be a general regulatory 
mechanism in the expression of most CpG island-containing genes, even when they exhibit 
tissue-specific expression patterns. However, some have argued that hypomethylation 
frequently follows transcriptional activation in the tissue-specific expression of genes. 
Therefore, the link between methylation and gene quiescence may not be causal (Li et al., 
1992). 
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1.10 Goals: 
In order to find an alternative strategy for controlling mastitis, we hope to investigate the 
earlier events associated with pathogen-specific activation of the immune defence in the 
udder, which will be helpful to decrease incidence of mastitis by regulating the target 
molecules. This requires us firstly analyzing the tissue-specific activation of model genes. I 
selected the LAP gene and the IL-8 gene as the paradigms for an immune relevant effector 
gene and a “sentinel” gene in MEC, respectively. Subsequently, we need to analyze the 
pathogen-specific modulation. To achieve the two long-term goals, my goals are:  
 
 To validate LAP as a paradigm of high relevance to innate immune response; 
 To analyze molecular mechanism of pathogen-mediated activation of the LAP gene 
both at the transcriptional level and at the chromatin level; 
 To compare and contrast the regulatory mechanism between LAP and IL-8 as an 
alternative, even earlier regulated paradigm. 
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2. MATERIALS AND METHODS 
 
2.1  Materials 
2.1.1 Instruments 
 
 
2.1.2 Reagents 
Name Manufacturer 
2 % N,N’-methylene-bis-acrylamide Merck 
5--
32
P-dCTP (10 μCi / μl) GE Healthcare 
37% Formaldehyde Roth 
40 % Acrylamide Merck 
AHT (anhydrotetracycline)  IBA 
Bio-RAD protein assay Bio-Rad laboratories Inc. 
Dimethyl sulfoxide (DMSO) Roche 
DSG (Disuccinimidyl glutarate) Pierce 
FuGENE 6 Transfection Reagent Roche 
G418 sulfate  Serva 
BenchMark™ Pre-Stained Protein Ladder Invitrogen 
Lipofectamine™ 2000 Reagent Invitrogen 
Long-RangerTM gel solution AT Biochem, USA 
Nonidet P-40 Sigma 
Phenylmethylsulfonyl fluoride (PMSF)    Fluka 
Poly (dIdC)  Roche 
Protease Inhibitor Cocktails Sigma 
Roti®-Block Roth 
Strep-tag Protein Ladder (lyophilized) IBA 
The IRD800 labelled sequencing primers MWG BIOTECH 
TRIzol  Invitrogen 
UltraPure™ Glycogen (20mg/ml) GIBCOBRL 
 
 
 
 
 
Name Manufacturer 
Amp PCR system 9600 Perkin Elmer 
Bioscan QC2000 BioScan Inc 
Branson Sonifier 250 Branson 
Geltrockner Slab Gel Dryer SGD4050 Savant 
Homogenizator Ultra-Turrax® T25 basic IKA®-Werke 
Image Eraser Amersham Biosciences 
LI-COR model 4000L infrared fluorescence DNA sequencer MWG-Biotech 
Lightcycler  Roche Applied Science 
Luminometer Lumat LB9501 EG&G Berthold 
Mini Trans-Blot System Bio-Rad laboratories Inc. 
Phosphor Screen Amersham Biosciences 
Spectrophotometer NanoDrop ND-1000 UV/Vis NanoDrop Technologies 
Storm 840 Phosphor Image System Molecular Dynamics 
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2.1.3 Kits 
Name Manufacturer 
Chromatin Immunoprecipitation (ChIP) Assay Kit Upstate 
Dual Luciferase ®Reporter Assay System Promega 
EndoFree® Plasmid Maxi Kit (10) Qiagen 
EpiTect Bisulfite Kit (48) Qiagen 
Expand High FidelityPLUS PCR System Roche 
FastStart DNA MasterPLUS SYBR Green I Kit Roche 
FastStart Taq DNA Polymerase Roche 
GeneRacer™ Core Kit  Invitrogen 
GeneRacer Superscript™ II RT Module  Invitrogen 
High Pure PCR Product Purification Kit  Roche 
HotStarTaq Plus Master Mix Kit (250) Qiagen 
mini Quick Spin Columns Roche 
pGEM®-T-Easy-Vector-System I Promega 
SuperScript™ II Reverse Transcriptase Invitrogen 
Thermo Sequenase fluorescent labelled  
primer cycle sequencing kit 
Amersham Pharmacia 
 
2.1.4 Strains and plasmids 
Strain or plasmids           Manufacturer 
E. coli 1303 As described (Petzl et al., 2008) 
E. coli XL1-Blue Stratagene  
pASK-IBA3plus  IBA 
pBR328 Collection of our lab 
pCDNA 3.1+ Invitrogen 
pGEM®-T Easy   Promega 
pGL3 Basic  Promega 
phRL-TK  Promega 
 
2.1.5 Enzymes 
Name           Manufacturer 
DNA polymerase large (Klenow) fragment  Promega 
FastStart Taq DNA Polymerase Roche 
Proteinase K  Serva 
Restriction enzymes  MBI Fermentas 
RNase A  Serva 
RNase T1  Sigma-Aldrich 
Superscript II Reverse Transcriptase  Invitrogen 
T4 DNA ligase   Promega 
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2.1.6 Antibodies 
Name Cata. Num.   Origin Company 
anti-NF-B p65 (H-286) sc-7151x Primary Rabbit Santa Cruz 
anti-NF-B p50 (NLS) sc-114x Primary Rabbit Santa Cruz 
anti-C/EBP ( 198) sc-746x Primary Rabbit Santa Cruz 
anti-C/EBP (S-16) sc-31931x Primary Goat Santa Cruz 
anti-RNA Pol II (H-224) sc-9001x Primary Rabbit Santa Cruz 
anti-NF-AT C1  (k-18) sc-1149x Primary Goat Santa Cruz 
anti-Rabbit IgG AP A-3687 Secondary Goat Sigma 
Strep-Tactin AP conjugate 2-1503-001 Secondary  IBA 
 
2.1.7 Tissue samples  
All udder samples were collected in the abattoir of the FBN, Dummerstorf. Tissues were 
shock frozen in liquid nitrogen and stored at -80°C for extended periods. The preparation of 
experimental infected udder has been described (Vanselow et al., 2006).  
 
2.1.8 Cells and cell lines  
Cells Full name Source 
HC11 The murine mammary epithelial cell line Donated by Dr. Wolfgang Doppler, Austria 
pbMEC Primary bovine mammary epithelial cell Prepared by our lab 
HEK 293 Human embryonic kidney cell line Purchased from ECACC 
MAC-T bovine mammary alveolar cell line Donated by Dr. Ynte Schukken, USA 
 
 
Reagents Manufacturer 
Antibiotic antimycotic solution (100 ×) GIBCO 
Dulbecco's Modification of Eagles Medium (DMEM)  Biochrom AG 
Epidermal growth factor (EGF)  Biochrom AG 
Fetal calf serum (FCS)  Pan 
Gentamycin GIBCO 
Insulin Biochrom AG 
Kanamycin GIBCO 
L-Glutamine Biochrom AG 
Pen-strep GIBCO 
RPMI 1640 medium  Biochrom AG 
Sodium pyruvate Biochrom AG 
Trypsin/EDTA solution  Biochrom AG 
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2.2 Molecular cloning methods 
2.2.1 Preparation of plasmid DNA 
2.2.1.1 Mini-or midi-preparation of plasmid DNA 
The preparation for plasmid DNA in the study is based on alkaline lysis either in 
minipreparation or in midipreparation.  
Preparation of SI, SII and SIII as follows 
Solution I 50mM Glucose, 10mM EDTA, 25mM Tris-HCl (pH8.0) 
Solution II 0.2 N NaOH, 1% SDS, prepare freshly  
Solution III 3M KAc (pH4.8), 11% CH3COOH 
 
Preparation of plasmid DNA in different scales   
 Minipreparation Midipreparation 
Culture (ml) 1.4 50 
Centrifugation 14000 rpm, 1-5min 3750 rpm, 10-20min 
SI (ml) 0.1 2 
SII (ml) 0.2 4 
SIII (ml) 0.15 3 
TE (μl) 40 1400 
RNase A (10mg/ml) (μl) 1 5 
RNase T1 (100 U/μl) (μl) 0.1 0.3 
Proteinase K (20mg/ml) (μl) 0.2 2.5 
2% SDS (μl) 0.75 2.5μl of 20% SDS 
TE (μl) 40 200 
 
2.2.1.2 Preparation of endotoxin free plasmid DNA by Qiagen kit   
EndoFree® Plasmid Maxi Kit from Qiagen is used to prepare endotoxin free plasmid DNA 
used in transfection. The patented endotoxin free plasmid procedure from Qiagen integrates 
endotoxin removal into the standard plasmid purification procedure. The neutralized bacterial 
lysate is filtered and incubated with a specific endotoxin removal buffer. The endotoxin 
removal buffer prevents LPS molecules from binding to the resin in the QIAGEN-tips. The 
resulting plasmid DNA per μg contains less than 0.1U endotoxin. The procedures were done 
as recommended by manufacturer. 
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2.2.2 RNA techniques 
2.2.2.1 RNA extraction from cell culture and frozen tissue 
1) Aspirate the medium and lyse cells directly by adding 1 ml TRIzol reagent to the target 
well, and pipet the cell lysate up and down several times and transfer into a RNase-free 
tube. 
If RNA is extracted from frozen tissue, add 1 ml TRIzol reagent to 100 mg tissue and 
homogenize for 10 s with Homogenizator Ultra-Turrax T25. 
2) Incubate the homogenized samples for 5 min at room temperature (RT). 
3) Add 0.2 ml of chloroform per 1 ml of TRIzol reagent. Shake tubes vigorously for 15 s 
and incubate for 2-3 min at RT. 
4) Centrifuge at 11500 rpm (Eppendorf 5417R) for 15 min at 4 °C. 
5) Transfer the aqueous phase to a fresh tube. Precipitate the RNA by mixing with 1 volume 
of isopropanol. 
6) Incubate for 10 min at RT, and centrifuge at 11500 rpm for 10 min at 4°C. 
7) Discard the supernatant and wash the RNA pellet once with 1 ml of 70% ethanol per 1 ml 
of TRIzol reagent used for the initial homogenization. 
8) Centrifuge at 11500 rpm for 5 min at 4 °C.  
9) Briefly air dry the pellet and dissolve RNA in DEPC-treated water.  
10) Store at -80 °C.  
 
2.2.2.2 RNA electrophoresis 
1) In order to prepare RNA gel, melt 0.72 g of agarose in 43.27 ml of DEPC-treated water. 
2) Cool to 65°C in a water bath and add 10.73 ml of 37% formaldehyde (FA) and 6 ml 10× 
MOPS buffer. Mix thoroughly and pour onto the gel supporter.  
3) Mix 4 volumes of RNA sample (1μg) and 1 volume of 5RNA treatment buffer. Incubate 
for 3-5 min at 65°C and chill on ice. 
4) Prior to running the gel, equilibrate RNA gel in 1MOPS buffer. Then load the RNA 
samples onto the equilibrated gel. 
5)  Run the gel at 5-7 v/cm in 1  MOPS buffer. 
10 × MOPS buffer 400 mM MOPS, 100 mM NaAc, 10 mM EDTA 
RNA loading buffer 15% Glycerin, 0.4% Bromophenol blue, 0.4% Xylencyanol, 1mMEDTA 
5×RNA treatment buffer  10 μl Formamid, 3.5 μl Formaldehyde, 1 μl 10×MOPS buffer, 2 μl RNA 
loading buffer, 0.1μl Ethidium bromide 
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2.2.3 Polymerase Chain Reaction (PCR) 
2.2.3.1 Standard PCR and high fidelity PCR 
In the construction of expression vectors, in order to reduce the error rate of amplification and 
produce amplification fragments with better fidelity, Expand high fidelityplus PCR system 
from Roche was applied in high fidelity PCR. 
Standard PCR High fidelity PCR 
Template 10 -50 ng Template (μl) variable 
10× buffer with Mg2+ (μl) 2.5  5 × buffer with Mg2+ (μl) 5  
10 mM dNTP mix (μl) 0.5  10 mM dNTP mix (μl) 0.5  
25 μM forward primer (μl) 0.25 25 μM forward primer (μl) 0.25  
25 μM reverse primer (μl) 0.25 25 μM reverse primer (μl) 0.25  
FastStart Taq  (5U/μl) (μl) 0.1-0.2  Enzyme Blend (5 U/μl) (μl) 0.25  
H2O (μl) variable H2O (μl) variable 
Total volume (μl) 25 Total volume (μl) 25  
 
 
2.2.3.2 Reverse transcription PCR (RT-PCR) 
Reverse transcription PCR is done as the manual of SuperScript™ II Reverse Transcriptase 
kit recommended by the supplier (Invitrogen). A brief description of the First-Strand cDNA 
synthesis using SuperScriptase II for RT-PCR is given below. 
 
Step PCR programs Classic PCR program Touch-down PCR program 
1 Denaturation 95 °C 5 min 95 °C 5 min 
2 Denaturation 95 °C 30 sec 95 °C 30 sec 
3 Annealing 60 °C 30 sec 65 °C 30 sec, -1 °C/Cycle 
4 Extension 72 °C 1 kb/ min 72 °C 1 kb/ min 
5  Go to step 2,  35-40 cycles Go to step 2,  5 cycles 
6 Denaturation   95 °C 30 sec 
7 Annealing   60 °C 30 sec 
8 Extension   72 °C 1 kb/ min 
9    Go to step 6,  28 cycles 
10 Final extension 72 °C 7min 72 °C 7min 
11  6 °C Pause 6 °C Pause 
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Step1: add the following components to a nuclease-free microcentrifuge tube: 
 1-2 μg total RNA 
1 μl 50 μM oligo (dT)20, or 2 pmol of gene-specific primer 
1 μl 10 mM dNTP mix 
Add sterile, distilled H2O to 12 μl 
Incubate the mixture for 5 min at 65 °C, incubate for at least 1 min on ice.  
 
Step2: collect the mixture by brief centrifugation and add   
4 μl 5×First-Strand Buffer 
2 μl 0.1 M DTT 
1 μl H2O 
42 °C, 2 min. Add 1 μl  of SuperscriptTM II RT (200 U/ μl) 
Incubate for 50 min at 42 °C, inactivate the reaction for 15 min at 70 °C. 
 
Step3: purify the cDNA with the purification kit from Roche. 
 
2.2.3.3 Real-time PCR 
Real-time PCR is used to quantify the target template. It monitors the amount of fluorescent 
group incorporated during PCR amplifications as an indicator of the amount of PCR product 
during each PCR cycle (i.e. in real time). This signal increases in direct proportion to the 
amount of PCR product in a reaction. As the PCR product accumulates, fluorescence 
increases. The cycle threshold (Ct) is defined as the number of cycles required for the 
fluorescent signal to cross the threshold (i.e. exceeds background level). Ct value is inversely 
proportional to the amount of target nucleic acid in the sample. i.e. Ct reflects the amount of 
template DNA. According to the principle, a standard curve is prepared and used to quantify 
the copies of template DNA. In the study, template copies are measured by SYBR Green 
method in Lightcycler (Roche). The dye SYBR green nonspecifically binds to the minor 
groove of the double-stranded DNA but not to single strand DNA. For each reaction, 5 μl of a 
containing template solution (40-75 ng cDNA or other DNA) and 5 μl of master mixture (2.6 
μl H2O, 0.2 μl of 25 μM forward primer, 0.2 μl of 25 μM reverse primer and 2 μl master mix 
from kit) are combined.  
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2.2.3.3.1 Preparation of standard curve 
The standard curve is established from serial dilutions of a plasmid DNA harboring the target 
DNA region. The plasmid DNA is linearized with a restriction enzyme, purified and measured 
the DNA concentration. According to DNA molecular weight and concentration, the copy 
number is calculated in a definite volume. Serial dilutions are done to contain the copy 
numbers of 106, 105, 104, 103, 102 and 101 respectively in 5 μl volumes. The Ct values of 
resulting templates are measured in real-time PCR by the same reaction condition as the 
unknown concentration samples. The standard curve is plotted with the Ct values and log 
copies of the serially diluted DNA concentrations. The copy numbers of samples are 
calculated according to the established standard curve. 
 
2.2.3.3.2 Real-time PCR programs  
Program Pre-incubation (1 Cycle) 
Segment Number Temperature Target (°C) Hold Time (Sec) Slope (C°/sec) 
1 95 600 20 
Program Amplication (40 Cycles) 
1 95 15 20 
2 60 5 20 
3 72 20 20 
4 Depend on melting curve 5 20 
Program Melting Curve 
1 95 0 20 
2 65 15 20 
3 95 0 0.1 
Program Cooling 
1 40 60 20 
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2.2.4 Plasmid construction techniques 
2.2.4.1 DNA electrophoresis   
DNA fragments are resolved in 0.8-2 % agarose gel containing 0.5 μg/ml of ethidium 
bromide (EB) in 1×TBE buffer (90 mM Tris-base, 90 mM Boric acid, 2 mM EDTA pH 8.0). 
The loaded gel with DNA samples is run at constant voltage (5V/cm) until the target band is 
separated from others. 
 
2.2.4.2 Purification of DNA from agarose gel 
After DNA fragment is isolated from adjacent bands by DNA electrophoresis, the target band 
is retrieved with razor blade without DNA contamination on the UV tray. Excised DNA slice 
is weighted and add 300 μl binding buffer per 100 mg of DNA slice in the same tube, the 
subsequent procedures are conducted as recommendation of the High Pure Product 
Purification Kit from Roche. 
 
2.2.4.3 Restriction digestion of DNA fragment  
In order to prepare DNA fragment with two protruding termini, the resulting DNA fragment 
from PCR is digested with appropriate restriction enzymes (RE) which share the same 
restriction buffer or sequentially digestion with interest REs in the corresponding buffer. In 
general, 5-10 Units of RE is applied to digest 5 μg DNA in 50 μl reaction volume. The 
digestion reaction is incubated at the recommended temperature overnight. Purified interest 
fragment is ready for ligation. 
To generate one protruding end and one blunted end, the DNA fragment is blunted with 
Klenow firstly, followed with a RE digestion to generate a protruding terminus. It is common 
that the digestion reaction with Klenow is performed as follows. 
 
 
 
DNA fragment x μl 
dNTP 1 μl 
10× Klenow buffer 5 μl 
Klenow (5U/μl) 0.5 μl  
H2O y μl 
Total volume 50 μl 
React for 30 min at 37 °C, inactivate Klenow for 15 min at 75 °C. 
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2.2.4.4 Preparation of vector for cloning 
For the vector and fragment used in one ligation reaction, they are common digested with the 
same REs to produce the same target ends, the principle and order of digestion is similar to 
preparation of DNA fragment. In order to possess the same end, isocaudomer is alternately 
used. The digestion reaction is generally performed that 10-20 Units of RE is applied to digest 
10 μg of vector DNA in 100 μl reaction volume overnight. The digestion efficiency is 
checked in 0.8 % agarose gel. If desirable, the target band is retrieved for ligation reaction. 
 
2.2.4.5 Ligation                                                                                                                            
In the study, the ligation reaction is performed at 16 °C for 1-2 h or 4°C overnight. In general, 
the amount of DNA fragment is 3-fold molar excess of vector amount. 
DNA fragment vector 2× rapid ligation buffer T4 ligation enzyme H2O Total volume 
x y 5 μl 0.5 μl 10-x-y 10 μl 
   
2.2.5 Transformation 
2.2.5.1 Preparation of competent cells  
1) Pick a single colony of E. coli XL1-Blue from a freshly streaked tetracycline (Tet) plate 
(15μg Tet /ml LB medium) into 5 ml of SOB–medium, incubate overnight at 37 C with 
vigorous agitation.  
2) Inoculate 5 ml culture into 50 ml PSI medium in 1 l flask and continue to incubate until 
OD600=0.45-0.55. 
3) Transfer the culture into 50 ml Falcon tube, keep it on ice for 15 min. 
4) Harvest bacterial cells by centrifugation at 3000 rpm for 15 min at 4 °C, remove 
supernatant. 
5) Resuspend carefully in 15 ml of ice cold RF1 medium, incubate on ice for 10 min. 
6) Centrifuge at 3000 rpm for 15 min, remove supernatant. 
7) Resuspend the bacterial pellet in 4 ml ice cold RF2 medium, incubate on ice for 15 min. 
8) Snap freeze 40-80 μl aliquots in liquid nitrogen. 
9) Store at -80 °C. 
LB medium 10 g/l trypton, 5 g/l yeast extract, 10 g/l NaCl, adjust pH to 7.0 and autoclave to sterile 
SOB-Medium 2 % trypton, 0.5 % yeast extract, 20 mM NaCl, 2.5 mM KCl, after being autoclaved and 
add the steriled 10 mM MgSO4 and  10 mM MgCl2 
PSI-Medium 2 % trypton, 0.5 % yeast extract, 10 mM NaCl, 5 mM KCl,  
after being autoclaved and add the steriled 20 mM MgSO4  
RF1-Medium 100 mM RbCl, 50 mM MnCl2, 30 mM KAc, pH7.5, 15 % Glycerol, adjust pH to 5.8 , 
sterile by filtration 
RF2-Medium 
 
100 mM MOPS (pH 6.8), 10 mM RbCl, 75 mM CaCl2, 15 % Glycerol, adjust pH to 6.8, 
sterile by filtration 
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2.2.5.2  Transformation procedure 
1) Add 5μl of the ligated DNA constructs (ca.20 ng) into the tube containing 40-80μl 
competent cell, mix gently and incubate on ice for 30min.  
2) Incubate the tube at 42 °C waterbath for 90 sec exactly and chill on ice for 1-2 min. 
3) Add 0.4 ml LB medium without antibiotics and incubate for 45min at 37 °C with gentle 
agitation (<100 rpm). 
4) Spread appropriate volume of transformed cells onto LB plate. If necessary, supplement 
40 μl of 2 % X-gal and 7 μl of 20 % IPTG. 
5) Incubate at 37 °C overnight. 
 
2.2.6  PCR mediated mutagenesis  and deletion 
PCR mediated mutagenesis and deletion is used to generate mutation and deletion of cis-
elements. The principle of PCR-mediated deletion and mutagenesis is based on regular PCR 
technique. However, the sites which are intended to be deleted or mutated are introduced by 
the specific overlapping internal primers. PCR-mediated deletion is selected as an example to 
be described (Fig. 3). The two primary PCRs are performed with primer set P1 (BASEND_f: 
5-GTACTAACATACGCTCTCCATC-3) and dP3 (specific deletion primer3), dP4 (specific 
deletion primer4) and P2 (Luc_r: 5-GCCTTATGCAGTTGCTCTCCA-3), respectively. Two 
PCR products (product1 and product2) are achieved. Equal molar amount of product1 and 
product2 are mixed to run overlap extension PCR. After being denatured and annealed, the 
strands with complementary areas in internal primers are bound together and filled into full 
length PCR product3 by polymerase. After 5-10 cycles, outer primers P1 and P2 are 
supplemented into the PCR reaction to amplify the product3. The resulting DNA fragment has 
been deleted target area (Fig. 3 fragment d). The target DNA fragment and vector are digested 
with the appropriate RE, respectively. The subsequent procedures are similar to the classic 
cloning procedure.  
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Overlapping extension PCR
Primary PCRs
P1
dP3
P2
dP4
5´
3´
3´
5´
3´
5´
product1
product2
1  2   d   3  4
1´ 2´ d´ 3´ 4´
P1
P2
dP3
dP4
3´
5´
Mix, denature, anneal and extend 
5´
3´
5´
3´
product3
P1
dP4
5´
5´
3´
3´
dP3
P23´ 5´
3´ 5´ No product
P15´
P2
5´3´
3´
Amplify with outer primers P1 and P2
3´
3´
 
Figure 3. Schematic diagram of PCR-mediated deletion method 
In order to delete the target area named “d” and “d´” in red, two primary PCRs and one 
overlap extension PCR are required to be done. The adjacent areas are designated as 1, 2, 3 
and 4, respectively and their corresponding complementary strand as 1´, 2´, 3´ and 4´. Four 
primers are P1, P2, dP3 and dP4. Dashed lines are fill-in DNA sequences.  
 
2.2.7 Rapid Amplification of 5 cDNA Ends (5 RACE) 
5 RACE is a method to identify 5 ends of cDNA using known cDNA sequence. Since 
transcription start site (+1) locates at 5 end of cDNA and promoter commonly resides in the 
vicinity of transcription start site. Thus, 5 RACE is a valuable tool to further define promoter. 
5 RACE is conducted according to the manual of manufacturer (Invitrogen). This technique 
comprises the following steps. Firstly, calf intestinal phosphatase (CIP) selectively removes 
the 5 phosphates of truncated mRNA and non-mRNA. Secondly, tobacco acid 
pyrophosphatase (TAP) removes the 5 cap structure from intact, full-length mRNA. Thirdly, 
RNA Oligo from supplier is ligated to the 5 end of the decapped mRNA using T4 RNA 
ligase. Fourthly, mRNA is reverse transcribed with gene specific primer or oligo(dT) primer. 
The resulting cDNA is amplified, cloned and sequenced. Transcription start site is determined 
by comparing with genomic sequence.  
 
Materials and Methods 
30 
2.3 Protein techniques 
2.3.1 Determination of total protein concentration (Bradford assay) 
Bio-Rad's protein assay (from Bio-RAD laboratories inc.) is employed in the study. Bio-Rad's 
protein assay is based on the color change of Coomassie Brilliant Blue G-250 dye in response 
to various concentrations of protein. In a reaction, 200 μl Bio-RAD protein assay is diluted 
with 800 μl H2O, added the target protein solution or the standard protein, mixed well and 
incubated for at least 5 min at room temperature. The absorption at 595 nm (A595) is 
measured by spectrometer. The standard curve is plotted with A595 and the amount of 
standard protein bovine serum albumin (BSA). The total protein concentration of the 
unknown concentration sample is calculated according to the standard curve.   
 
2.3.2 Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
SDS-PAGE is a technique resolving proteins according to different molecular weights. It can 
be used to estimate relative molecular weight, to determine the relative abundance of major 
proteins in a sample, and to determine the distribution of proteins among fractions. In the 
present study, Laemmli method is used. 0.1 % Coomassie® Brilliant BlueR-250 acts as a 
staining reagent. The technique comprises a couple of steps: gel preparation, samples 
treatment, running gel, staining gel and destaining gel. All recipes are listed below. 
Reagents 10 % Separating gel  
 
5 % Stacking gel 
H2O 3.5 ml 2.2 ml 
40 % Acrylamide  2.5 ml 0.5 ml 
2 % N,N’-methylene-bis-acrylamide 1.4 ml 0.27 ml 
1.5 M Tris-HCl buffer 2.5 ml (pH8.8) 1 ml (pH 6.8) 
20 % SDS 50 μl 20 μl 
20 % APS (ammonium persulfate) 50 μl 20 μl 
TEMED (N,N,N',N'-
Tetramethylethylene diamine) 
8 μl 4 μl 
Total volume 10 ml 4 ml 
 
2 x Loading buffer 100 mM Tris-HCl pH6.8, 20 % glycerol, 4 % SDS, 0.2 % bromophenol blue, 5 % 2-mercaptoethanol 
1x Running buffer 25 mM Tris base, 250 mM Glycine, 0.1% SDS  
Staining buffer 40 % Methanol, 10 % Glacial acetic acid, 0.1 % Coomassie® Brilliant Blue R-250 
Destaining buffer 10 % Methanol, 10 % Glacial acetic acid 
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2.3.3 Western blot 
Western blot is used to detect specific proteins in a given protein sample. Protein molecules 
are resolved in SDS-PAGE gel according to different molecular weights and are subsequently 
blotted onto a membrane, such as nitrocellulose or polyvinylidene difluoride (PVDF). The 
protein on membrane is identified by diagnostic primary antibody. The latter is recognized by 
secondary antibody conjugated with alkaline phosphatase (AP) or horseradish peroxidase 
(HRP). Colorless substrates are converted into the colored product to visualize the interest 
protein. In our lab, we adopt two transfer membrane devices: sandwich devices by capillary 
action and by eletrophoretic transfer Mini Trans-Blot System from Bio-Rad laboratories, Inc..  
 
1) After SDS-PAGE, immerse the gel, membrane, filter papers and support pads in Transfer 
buffer to ensure that they are thoroughly soaked.  
2) Assemble the transfer sandwich to make the membrane directly contact the gel, avoid air 
bubbles trapped between the gel and the membrane.  
3) Put the ready sandwich device into the electrophoretic tank containing sufficient Transfer 
buffer and ensure the membrane closest to the anode. The electrophoretic transfer starts 
with an appropriate and constant current. The velocity of transfer depends on the current 
and molecular weight of interest protein. 
4) Place the marked membrane in Blocking buffer in a sealed bag and incubate at room 
temperature for 2 h with agitation or leave the blot overnight at 4°C. 
5) Wash the membrane three times for 5 min each in Washing buffer. 
6) Immerse the membrane in the diluted primary antibody solution by Washing buffer. 
Incubate at room temperature for 1 h with agitation. 
7) To remove unbound antibody, repeat step 5) and immerse the membrane in the diluted 
secondary antibody conjugated with alkaline phosphatase (AP) or horseradish peroxidase 
(HRP) and incubate 1 h at room temperature with agitation. In my study, AP is preferable. 
8) To remove unbound conjugate, wash the blot as step 5). 
9) Equilibrate the membrane in Detection III solution 
10) Incubate the membrane in the fresh AP substrate solution contain the substrate bromo-
chloro-indolyl-phosphate (BCIP) and a dye, Nitro Blue Tetrazolium (NBT). Since it is 
light sensitive, color development should be done in dark. 
11) After the desired bands are visible, the reaction is stopped by rinsing the membrane in TE 
buffer. 
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Transfer buffer 50 mM Tris-HCl, pH 8.5, 20 % methanol, 15 g/l Glycine  
10 × PBS (pH 8.2) 1.37 M NaCl, 78.10 mM Na2PO4, 26.80 mM KCl, 14.70 mM KH2PO4 
Blocking buffer 1× Roti-Block and 1× PBS pH 8.2 
Washing buffer 1 × Roti-Block, 0.2 % Triton X-100, 0.1 % SDS 
Detection III 100 mM Tris-HCl, pH 9.5, 50mM MgCl2, 100 mM NaCl 
Color solution 175μg/ml BCIP,  337.5 μg/ml NBT in Detection III 
TE buffer 10 mM Tris-HCl, pH8.0, 1mM EDTA  
 
2.4 Mammalian cell culture and reporter gene assay 
2.4.1 Cell types and media 
Cells Media 
HC11 RPMI supplemented with 10% FCS, 2mM L-Glutamine, 100 μg/ml Gentamycin,  
5 μg/ml Insulin, 10 ng/ml EGF  
pbMEC DMEM supplemented with 10% FCS, 4mM L-Glutamine, 50 μg/ml Gentamycin,  
1mM Sodium pyruvate  
HEK 293 DMEM supplemented with 10% FCS, 4mM L-Glutamine, 50 μg/ml Gentamycin,  
MAC-T DMEM supplemented with 10% FCS, 4mM L-Glutamine, 100 μg/ml Pen-strep 
 
2.4.2 Cell culture and cryopreservation 
2.4.2.1 Cryopreservation of cells 
Continuous cell culture can lead to the accumulation of unwanted karyotype alterations and 
also increases the possibility of contamination by bacteria or other unwanted organisms. The 
only insurance against loss of the cell line is to ensure that adequate numbers of vials are 
cryopreserved for future use.  
1) View the cultures under a phase-contrast inverted microscope to assess cell density and to 
confirm without contamination. Cells for cryopreservation should be in log growth phase 
with greater than 90% viability.     
2) Centrifuge the cells at 1500 rpm for 5 min and aspirate the supernatant from the tube. 
3) Suspend the cells into 1ml 100 % FCS, and add dropwise equal amount of the premixture 
containing 20 % DMSO and 80 % FCS. 
4) Quickly aliquot 1 ml [(1–2) × 106 cells] into each of the prepared cryovials.  
5) Place cryovials containing these cells inside a passive freezing container and stored at –
80°C overnight. 
6) Transfer to liquid nitrogen for the long-term storage. 
 
2.4.2.2 Thaw of the cryopreserved cells 
1) Prepare one tube containing 9 ml of growth medium prewarmed to 37°C. 
2) Remove one vial of cells from liquid nitrogen.  
3) Transfer the vial of cells to a 37°C water bath until the suspension is just thawed. 
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4) In the cell culture hood, transfer the contents of the vial slowly into the tube containing the 
growth medium. 
5) Centrifuge the cells at 1500 rpm for 5 min to obtain a pellet. 
6) Aspirate the supernatant containing DMSO and suspend the cell pellet in 10 ml complete 
growth medium. 
7) Transfer the cells to a tissue culture dish (100 mm) and incubate at 37°C, 5% CO2. 
8) Examine cultures daily using a phase-contrast inverted microscope to ensure that the 
culture was not contaminated during the freeze–thaw process and that the cells are 
growing well. 
 
2.4.2.3 Subculture of cells 
Maintenance of healthy, viable cells requires routine medium exchanges to ensure that the 
nutrients in the medium do not become depleted and that pH of the medium does not become 
acidic (i.e., turn yellow). 
In the study, cells are subcultured when they reach 70–80% confluence. 
1) Aspirate the medium and wash cells three times with prewarmed PBS to remove any 
residual growth medium. 
2) Add 1 ml of 0.25 % trypsin and incubate the dish for 3-5 min at 37 °C in a 5 % CO2 
incubator. Rock the dish, supplement adequate medium containing FCS to inhibit trypsin 
activity and centrifuge to collect cells. 
3)  Discard the medium and add fresh complete growth medium. Transfer a small aliquot of 
the well-mixed cell suspension into a fresh dish containing prewarmed complete growth 
medium, ensuring that the resulting cell density is in the optimal range. 
4) Repeat this subculture step every 2–3 d to maintain cells in an exponential growth phase. 
 
2.4.3 Transient transfection 
Transfection is a process of introducing nucleic acids into eukaryotic cells by nonviral 
methods. General transfection reagents, like calcium phosphate, DEAE-dextran or cationic 
lipid-based reagents, can coat DNA, neutralize or even create an overall positive charge to the 
molecule to make it easier for the DNA: transfection reagent complex to cross the negatively 
charged membrane. In the present study, lipofectamine™ 2000 Reagent is adopted as the 
transfection reagent to analyze transient expression of the transfected genes. Several reporter 
systems have been employed, such as luciferase (firefly and renilla), -galactosidase, alkaline 
phosphatase and green fluorescent protein (GFP). In the study, the target promoter sequence is 
inserted in the promoterless pGL3 Basic vector, which expresses firefly luciferase activity. 
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The luciferase activity reflects the extensity of the target promoter activity.  
 
2.4.3.1 Transient transfection mediated by lipofectamine™ 2000 Reagent 
Normally, transient transfection is done in 6-well plate containing the corresponding medium 
without antibiotics.  
1) Plate ca. 3× 105 cells in 6-well plate prior to one day before transfection so that the cell 
density will be 70 %-80 % at the time of transfection. 
2) Dilute DNA (less than 4 μg) in 100 μl of medium without serum, mix gently. 
3) Dilute the appropriate amount of lipofectamine™ 2000 in 100μl of serum-free medium 
[lipofectamine™2000(μl)/DNA(μg) =2:1]. Incubate for 5 min at room temperature. 
4) Combine the diluted DNA with diluted lipofectamine™ 2000, mix gently and incubate for 
additional 20 min at room temperature. 
5) Add the 200 μl of complexes to each well containing cells and medium. Mix gently by 
rocking the plate back and forth. Incubate cells at 37 °C in a 5 % CO2 incubator.  
6) Twenty four hours after transfection, cells are washed, trypsinized and distributed into 6 
wells of 24-well plate evenly. Three wells are kept untreated as control, the other three 
wells will be induced for the expected times with 1×107 heat-inactivated E. coli 1303/ml. 
In the study, the LAP reporter gene is induced for 24 h and the IL-8 for 6 h. 
7) Forty eight hours posttransfection, cells are harvested and assayed reporter gene activity 
according to the following protocol. 
 
2.4.3.2 Assay of reporter gene activity  
In the assay, Dual Luciferase® Reporter Assay System kit from Promega is used. The 
procedures are done according to the instruction of supplier. The activity measurement is 
conducted manually in Luminometer Lumat LB9501 of EG&G Berthold company. 
 
2.5 Electrophoretic Mobility Shift Assay (EMSA) 
EMSA provides a simple and rapid method for identifying DNA-binding proteins. The assay 
is based on the observation that DNA-protein complexes migrate more slowly than free DNA 
fragments or double-stranded oligonucleotides in a nondenaturing polyacrylamide gel. The 
assay is composed of 3 main steps: preparation of nuclear extract (NE); labeling of probe; 
preparation of EMSA reaction, electrophoresis and radioautography. 
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2.5.1 Preparation of nuclear extract from cultured cells 
1) Wash cells 3 times with ice-cold PBS.  
2) Trypsinize the cells and transfer cell suspension into a 1.5ml tube.  
3) Spin down for 5 min at 2400 rpm (Eppendorf 5417R) at 4ºC. Wash the pellet with ice 
cold PBS. 
4) Remove the supernatant, and resuspend cell pellet in 400 μl of buffer A. Incubate the tube 
for 15 min on ice.  
5) Add 25 μl of 10% Nonidet P-40 (NP-40), and shake for 1 min at 4ºC by hand.  
6) Pellet nuclei at 10000 rpm for 1 min at 4ºC.  
7) Remove the supernatant carefully and completely.  
8) Add 50 μl of buffer B to the tube, and shake vigorously for 20 min at 4ºC to lyse nuclei 
and release chromatin-associated proteins.  
9) Centrifuge at 14000 rpm for 5 min at 4ºC.  
10) Transfer the supernatant containing nuclear extract to a new tube.  
11) Determine protein content of the extract by Brandford method and store nuclear extracts 
at -80ºC. The extracts are ready for EMSA.   
Buffer A Buffer B 
10 mM HEPES (pH 7.9, adjusted with KOH)  
10 mM KCl  
0.1 mM EDTA  
 
0.1 mM EGTA  
1 mM DTT (add freshly)  
1 mM PMSF  
20 mM NaF  
1 mM Sodium Orthovanadate (Na3VO4)  
1/10 Proteinase inhibitor cocktail (Sigma)  
20 mM HEPES (as left)  
0.4 M NaCl  
1 mM EDTA  
1 mM EGTA  
1 mM DTT (add freshly)  
1 mM PMSF  
20 mM NaF  
1 mM Sodium Orthovanadate (Na3VO4) 
1/200 proteinase inhibitor cocktail (Sigma)  
 
2.5.2 Labeling and purification of probe 
1) Mix 5 μl of the longer primer (50μM) and 10 μl of the shorter primer (50μM),       
supplement with 30μl of H2O, boil for 5 min, chill on ice immediately. 
2) Prepare cold and hot probe reaction on ice according to the following table. 
Cold probe reaction Volume (μl) Hot probe reaction Volume (μl) 
Original primer mix 36 Original primer mix 0.72 
10× Klenow buffer 5 10× Klenow buffer 2 
dNTPs (10 mM each) 1 dNTPs (dATP,dGTP,dTTP,10mM each) 0.5 
  5--32P dCTP (10 μCi/μl) 2 
Klenow 1 Klenow 1 
H2O 7 H2O 13.78 
Total volume 50 Total volume 20 
 
The prepared cold probe reaction and hot probe reaction are incubated for 1h at 25°C, 
thermal inactivate Klenow for 10min at 75°C. 
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3) Purify hot probe by mini quick spin column (Roche), dilute 5 times and measure its 
activity (cpm/μl) by Bioscan QC2000 (BioScan Inc. Washington DC, USA). 
 
2.5.3 Preparation of EMSA reaction, electrophoresis and radioautography 
       EMSA reaction should be prepared on ice. 
1) Prepare 2 × binding buffer for NF-B and C/EBP  
2 × C/EBP binding buffer  2 × NF-B binding buffer  
10 mM MgCl2 
0.2 mM EDTA 
2 mM DTT * 
100 mM NaCl 
20% Glycerol 
20 mM HEPES (pH7.9) 
0.4 mM PMSF * 
20mM Tris-HCl (pH 8.0) 
20% Glycerol 
2 mM EDTA 
100 mM NaCl 
0.4 mM PMSF 
2 mM DTT * 
 
 *, PMSF and DTT should be added freshly. 
2) Prepare EMSA reactions according to the below table 
Standard binding reaction Competition binding reaction Supershift binding reaction 
X μl dd H2O X μl dd H2O X μl dd H2O 
1 μl PolydI/dC (1 μg/μl) 1 μl PolydI/dC (1 μg/μl) 1 μl PolydI/dC (1 μg/μl) 
10μl 2 × binding buffer 10μl 2 × binding buffer 10μl 2 × binding buffer 
Y μl Nuclear extract  
(2-20μg) 
Y μl Nuclear extract  
(2-20 μg) 
Y μl Nuclear extract 
(2-20μg) 
1 μl Hot probe(40fmol/μl) 1 μl Hot probe (40 fmol/μl) 1 μl Hot probe (40 fmol/μl) 
  1 μl Cold or mutant probe  
(4 pmol/μl) 
0.5-1μl Antibody (2 μg/μl) 
20μl Total volume 20μl Total volume 20μl Total volume 
10 min prior to the addition of hot probe, antibody is added into the supershift reaction 
and is incubated for 10 min on ice. Afterward, the reaction continues to be incubated for 
additional 20 min at room temperature. After 6% non-denaturing PAGE gel is run for 1h 
in advance, load the samples onto it.  
3) Run the big gel at 260 V for about 1.45 h in 0.5 x TBE running buffer.  
4) Dry the gel for 30 min-1 h at 75°C and expose it overnight. 
5) Scan the dried gel with Storm 840 Phosphor Image System from Molecular Dynamics. If 
necessary, quantify the target bands by Image Quant 5.2 software from the supplier.  
 
2.6 Chromatin Immuno Precipitation (ChIP) 
The chromatin structure plays important role in gene regulation by controlling promoter 
access for inducible transcription factors. DNase I footprinting assay is a common technique 
to identify the DNA region bound by a transcription factor by assessing nucleotides resistance 
to nuclease attack. Although it is able to provide the protein binding pattern to its natural 
chromatin, the technique can not efficiently identify the weak or partial DNA binding and is 
also powerless to precisely identify the prevented complex. In the study, in order to avoid 
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some drawbacks of DNase I footprinting assay, ChIP assay is used to investigate binding of 
transcription factors within natural chromatin context, and temporally change of the DNA-
protein complex at various conditions. In this assay, intact cells are fixed with the crosslinker 
formaldehyde to link protein to DNA. The cells are then sonicated to fragment chromatin. The 
crosslinked DNA-protein complex is enriched by immunoprecipitation. The retrieved 
complex is analyzed by real-time PCR to quantify the specific DNA targets. Chromatin 
Immunoprecipitation (ChIP) Assay Kit from Upstate is used and the protocol recommended 
by Upstate is modified and provided as follows. 
 
2.6.1 Preparation of cell lysate 
1) All cell dishes (3 ×100mm dishes) should be treated with 1×107 heat killed E. coli 
1303/ml medium for the expected times. Wash cells three times with room temperature 
PBS and add 10ml of PBS containing 1 mM MgCl2, pH8.0 into each dish exactly. 
2) Add 2 mM Disuccinimidyl glutarate (DSG) into cell dish directly while agitation. Cells 
are fixed with DSG for 45min at room temperature with gentle agitation. 
3) Cells are washed with room temperature PBS twice.  
4) Add 10 ml PBS/Mg2+, pH 8.0, containing 1 % formaldehyde and incubate for 10 min at 
room temperature with agitation. 
5) Quench formaldehyde by adding 125 mM glycine into the above dishes, whirl well and 
keep them at room temperature for 5 min, then transfer the dishes on the ice. 
6) Wash cells for three times with ice cold PBS. 
7) Add 1 ml ice cold PBS containing 0.5 % Protease Inhibitor Cocktail II and 1mM PMSF 
into dishes. 
8) Scrape cells into conical tubes. 
9) Spin at 1000 rpm for 5 min at 4°C to pellet cells. 
10) Remove supernatant. Resuspend cell pellet in 3×900 μl of L1 buffer (50 mM Tris-HCl, 
pH 8.0, 2 mM EDTA, 0.1% NP-40, 10 % glycerol) supplemented with proteases 
inhibitors and incubate for 15 min on ice to remove free cytoplasmic proteins. Precipitate 
nuclei by centrifugation at 1000 rpm for 5 min. 
11) Resuspend nuclei in 0.9 ml of SDS lysis buffer (Upstate) supplemented with 0.5 % 
Protease Inhibitor Cocktail II and 1mM PMSF, keep them on ice for 10 min. 
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2.6.2 Sonication to shear chromatin 
12) Shear chromatin with Branson sonifier (setting 2, duty 40 %) to 200-1000 bp. 
13) In order to analyze the size of the sheared DNA, 40 μl aliquot is transferred into new 
tubes and supplemented with 1.6 μl of 5M NaCl, 1 μl of 20% SDS and 0.4 μl of 20mg/ml 
proteinase K. Reverse the crosslink reaction for 1h at 65°C. Analyze the purified DNA in 
2% agarose gel. 
14)  If desired, spin the original sheared chromatin at 14000 rpm for 10 min at 4°C to remove 
insoluble materials and store the sheared crosslinked chromatin at -80°C. 
 
2.6.3 Immunoprecipitation (IP) of crosslinked protein/DNA 
15) Aliquot the sheared crosslinked chromatin for the number of desired 
immunoprecipitations and put on ice.  
16) Per 100 μl of the above chromatin is added with 900 μl of Dilution Buffer with 0.5 % 
Protease Inhibitor Cocktail II and 1mM PMSF. 
17) Preclear the diluted chromatin with Protein A agarose. In the study, add 80 μl of Protein 
A agarose for 320 μl soluble chromatin, incubate for 2 h at 4°C with agitation. 
18) Supplement 10 μg normal rabbit IgG and continue to incubate for additional 1 h. 
19) Pellet agarose by brief centrifugation at 3000-5000 g for 1 min at 4°C.  
20) Collect the supernatant and transfer 10 % (100μl) of the supernatant as Input and save at 
4°C until step 26.  
21) Aliquot 1 ml of supernatant fraction into fresh microfuge tubes and add 4 μg of the 
interest antibody or normal rabbit IgG, incubate overnight at 4°C with agitation. 
22) Add 80 μl of Protein A agarose for 3 h at 4°C with agitation. 
23) Pellet Protein A agarose by brief centrifugation at 3000-5000 g for 1 min and remove the 
supernatant fraction. 
24) Wash the Protein A agarose-antibody/chromatin complex by resuspending the beads in 1 
ml of the cold buffers in the order listed below and incubate for 3-5 min on a rotating 
platform followed by brief centrifugation at 3000-5000 g for 1 min and careful removal 
of the supernatant fraction: 
a. Low Salt Immune Complex Wash Buffer, one wash 
b. High Salt Immune Complex Wash Buffer, one wash  
c. LiCl Immune Complex Wash Buffer, one wash 
d. TE Buffer , two washes 
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2.6.4 Elution of protein/DNA complexes 
25) Prepare Elution Buffer (1% SDS and 0.1 M NaHCO3) for all IP tubes as well as all Input 
tubes (see step 20).  
26) For Input tubes (see step 20), add 200 μl of Elution Buffer and set aside at room 
temperature until reverse crosslink. 
27) Add 200 μl of Elution Buffer to each tube containing the antibody/agarose complex. Mix 
by flicking tube gently. 
28) Incubate for 15 min at room temperature. 
29) Pellet agarose by brief centrifugation at 3000-5000 g for 1 min and collect supernatant 
into new microfuge tubes. 
30) Add additional 100 μl of Elution Buffer to each tube, repeat steps 28-29 and combine 
eluates (total volume = 300 μl). 
 
2.6.5 Reverse crosslink of protein/DNA complexes to free DNA 
     To all tubes (IPs and Inputs) with 300 μl eluates, add 12 μl of 5 M NaCl  (0.2 M fc), 15 μl 
of 1 M Tris-HCl, pH 6.5,  6 μl of 0.5 M EDTA,  and 3 μl of 20 mg/ml Proteinase K, incubate 
for 4h at 65°C to reverse crosslink the DNA/protein complex.  
 
2.6.6 Purification of DNA 
     DNA is purified with phenol/chloroform extraction and dissolved into 36 μl H2O. During 
the step, 0.2μg/μl glycogen is used as a carrier to make DNA pellet visible. Purification kit is 
not recommended until test.  
 
2.6.7  Quantification of the template by real-time PCR 
    1-5 μl of template DNA is used in PCR reaction. PCR is run with gene-specific primers for 
40 cycles at 60 °C annealing temperature. The relative copies are calculated according to the 
formula (% input = 100 × copies of IPed DNA/ copies of Inputed DNA). 
 
2.7 Chromatin Accessibility by Real-Time PCR (CHART-PCR) 
It has been well documents that chromatin remodeling plays a role in the regulation of the 
inducible transcription in eukaryotes (Almer et al., 1986). CHART-PCR provides a sensitive, 
quantitative method to evaluate the chromatin remodeling events in vivo (Rao et al., 2001). Its 
basis is that the condensed chromatin restricts the accessibility of restriction enzyme whereas 
the loosed chromatin DNA is digested with restriction enzyme. Real-time PCR was used to 
measure the digestion extent of the target chromatin DNA, which reflects the alteration of 
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chromatin structure indirectly. The method comprises 4 steps: Nuclei preparation; Digestion 
of nuclei with restriction enzyme; DNA purification; Quantification of undigested DNA and 
analysis of data. In the present study, I originally applied two-enzyme digestion strategy to 
decrease the viscosity of genomic DNA and to increase the reproducibility of the method. The 
selection criterion of the second restriction enzyme is that no recognition site of the enzyme 
lies within the intended amplification region.       
1) 50-100 mg tissue is ground into powder under liquid nitrogen and suspended in 5 ml of 
ice-cold LS buffer with NP-40. 
2) Homogenize with Ultra-Turrax T25 for the optimal time by checking the nuclei under 
microscope. Add 4 ml of ice-cold LS buffer with NP-40 and mix. 
3) Filter the homogenate through siliconed glass wool. 
4) Spin down the nuclei at 1500 rpm for 2 min at 4°C. 
5) Wash the nuclear pellet with 2 ml of ice-cold 1× restriction buffer. 
6) Spin down at 2000 rpm for 2 min at 4°C.  
7) Resuspend the nuclei in 100 l of ice cold 1× restriction buffer.  
8) Estimate DNA concentration by diluting 1 l of aliquot with 9 l of 5% SDS solution and 
vortex.  
9) Restriction digestion is performed with ca. 2 g chromatin and 20 Units restriction 
enzyme (HindIII for LAP and BNBD5) for 60 min at 37°C in 200 l reaction volume. 
10) Thermal inactivate the first restriction enzyme (HindIII) at 65 °C for 20 min, followed by 
adding 5 Units of the second RE (EcoRV) and incubate at 37 °C overnight.  
11) Add 3 l of RNase A, 0.3 l of RNase T1 and 6.7 l of TE buffer per tube and incubate 
for 30min at 37°C. Add equal volume of proteinase K buffer with 3 l proteinase K (20 
mg/ml), and incubate for 4 h at 56°C. 
12) Purify DNA with kit and dissolve into 50 l water. 
13) Measure DNA concentration exactly by Nanodrop. 
14) Run real-time PCR with 25-50 ng DNA in 10 l reaction volume. 
LS buffer 10 mM HEPES, pH7.9, 1.5 mM MgCl2, 10 mM KCl, 0.5 mM DTT,  
0.5 % NP-40, 0.5% Protease Inhibitor Cocktail  
Proteinase K buffer+PK 50 mM Tris-HCl (pH 8.0), 150 mM EDTA,  100 mM NaCl,  supplemented 
freshly and orderly with 6 mM DTT, 0.27 μg/μl Proteinase K and 1 % SDS 
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2.8 DNA methylation analysis 
The methylation state of CpG dinucleotides site is thought to be linked to the structure of 
chromatin and to the regulation of promoter function by modulating DNA-protein 
interactions. The bisulfite sequencing PCR is applied to analyze changes of methylation 
status. In the bisulfite reaction, non-methylated cytosine residues in DNA are converted into 
uracil, while 5-methylcytosines remain unaltered. The converted DNA is amplified with gene-
specific primers and sequenced. All cytosine residues remaining in the sequence represent 
previously methylated cytosines in the genome. The procedures consisted of genomic DNA 
preparation, bisulfite conversion, amplification and sequencing. 
 
2.8.1 Preparation of genomic DNA from tissue and pbMEC cells 
1) 100 mg-1g tissue is ground into powder under liquid nitrogen. 
2) Add 250 mg tissue powder into 3 ml proteinase K buffer with 0.5 mg/ml proteinase K. 
(Harvest cells from 6-well plate and suspend cell pellet into proteinase K buffer.) 
3) Mix gently and incubate at 56 °C overnight. 
4) Cool down to room temperature. Add an equal volume of phenol/chloroform. Mix gently 
by inverting the tube for 10 min. 
5) Remove the upper aqueous phase to a new tube. Add 1/10 volume of 3 M NaAc (pH 5.2), 
mix. Add 0.6-1 volume of isopropanol and mix gently but thoroughly.  
6) Pellet the stringy DNA by centrifugation. 
7) Wash the DNA pellet with 70 % ethanol. 
8) Air-dry the pellet for 15-20 min at RT and dissolve in 200 μl of TE (pH 8.0). 
Proteinase K buffer 50 mM Tris-HCl (pH 8.0), 150 mM EDTA,  100 mM NaCl,  supplemented 
freshly and orderly with 6 mM DTT, 0.5 mg/ml Proteinase K and 1 % SDS 
TE (pH 8.0)  10 mM Tris-HCl, 1 mM EDTA (pH 8.0) 
 
2.8.2 Bisulfite conversion reaction 
Sodium bisulfite conversion reaction is done according to the manual of manufacturer 
(Qiagen). Briefly,  
1) Prepare bisulfite reactions according to the following table 
Component  Volume (μl)/reaction  
DNA solution (1 ng – 2 μg)  < 20  
RNase-free H2O  Variable 
Bisulfite Mix (dissolved)  85  
DNA Protect Buffer  35  
Total volume  140  
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2)  Run the following bisulfite conversion program in thermal cycler. 
Steps  Temperature (°C) Time (min) 
Denaturation  99 5  
Incubation  60 25  
Denaturation  99 5  
Incubation  60 85  
Denaturation  99 5  
Incubation  60 175  
Hold  20 Indefinite 
3) Cleanup of bisulfite converted DNA according to the manual of manufacturer. 
 
2.8.3 Bisulfite Sequencing PCR (BSP) 
2.8.3.1 Designation of methylation specific primers 
The primer design is critical and different from regular PCR. Generally, the double DNA 
strands are analyzed separately since they are no longer complementary. The PCR is initiated 
with the forward primer with G-rich and the reverse primer that should be C-rich. (The 
forward primer is homologous, but the reverse is complementary to the sequenced strand). 
 
2.8.3.2 Primary PCR , nested PCR and PCR program 
Primary PCR Nested PCR 
Component  Volume (μl) /reaction  Component  Volume (μl) /reaction 
Modified DNA 0.5 Purified primary PCR product 1.25 
10× buffer 2.5 10× buffer 2.5 
dNTP (10mM each) 0.5 dNTP (10mM each) 0.5 
Forward primer  0.25 Forward nested primer  0.25 
Reverse primer  0.25 Reverse nested primer  0.25 
Taq from Roche 0.1 Taq from Roche 0.1 
H2O 20.9 H2O 20.9 
Total volume 25 Total volume 25 
                     
Touchdown PCR Steps  Temperature  Time 
1 Denaturation 94°C  5 min 
2 Denaturation 94°C  30 sec 
3 Annealing 62°C -1°C/Cycle 30 sec 
4 Extension 72°C  2 min 
Go to step 2, 10 cycles 
5 Denaturation 94°C  30 sec 
6 Annealing 52°C  30 sec 
7 Extension 72°C 2 min 
Go to step 5, 28 cycles 
8 Final extension 72°C 7 min 
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2.8.4 Direct sequencing 
2.8.4.1 Direct sequencing by ABI 
The sequencing by ABI was done by Mrs. Fuchs who directs sequencing in our unit. 
 
2.8.4.2 Direct sequencing by Li-COR 
1) Preparation of 8 % polyacrylamide sequencing gel according to the following table 
Component 66cm sequencing gel 
Urea  21.0 g 
Long RangerTM 50% solution 4.3 ml 
10 × TBE 5.0 ml 
H2O 32 ml 
DMSO 500 μl 
10 % APS 350 μl 
Degas for 15min and store at least for 15min at 4°C, , add TEMED 
immediately prior to pour gel 
TEMED 50 μl 
 
2) PCR reaction 
H2O 7.6 μl 
DMSO 0.4 μl 
The IRD800 labelled Sequencing primer(2 pmol/μl) 1.0 μl 
PCR product (300ng/1000bp) X μl 
Mix 2 μl of the above mixture and 2 μl from the Thermo Sequenase 
fluorescent labeled primer cycle sequencing kit, add 5 μl liquid wax 
separately. Run PCR in Amp PCR system 9600 (Perkin Elmer) 
 
3) PCR program 
Steps Time (sec) Temperature (°C) 
1 Denaturation 300  95 
2 Denaturation 30  95 
3 Annealing 30  59  
4 Extension 60 72 
Go to step 2, 30 cycles 
After PCR, mix 4μl loading buffer (formamide dye), store the mixture in –20 °C. 
 
4) Electrophoresis  
Run the sequencing gel without any samples on Li-COR for 30 min to 1 h in 0.8×TBE buffer. 
Thaw the sequencing reaction samples for 2 min at 70 °C and immediately load 1μl to 
corresponding lane. Each sequencing reaction is loaded into four lanes A, C, G and T in 
adjacent orders. Run gel at a constant power of 50 watts, 2200 V, 37 mA, 45°C overnight. 
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2.8.5 Data analysis 
In order to quantify the C/T polymorphic sites, the sequence gel files are further processed 
and evaluated with the PHRED software, version 0.020425 as described (Vanselow et al., 
2005). The percentage of methylation is calculated as the portion of the C peak area [% 
methylation= peak area of 100 ×C / (peak area of C + peak area of T). In the study, to 
decrease the error of sequencing method, the percentage of methylation from different 
animals is regressed according to a regression equation. The similar equation was designed as 
described (Vanselow et al., 2005). The regression equation is established as follows. The 
clone with 100% C in target CpG site is combined with the one with 100% T by various 
proportions (two clones are donated by Dr. Jens Vanselow). The mixtures are used as 
templates to run PCR and PCR products are purified, sequenced and calculated by the similar 
method to the target samples. A plot is done by the theoretical percentage of methylation 
versus the actual one from the sequenced C/T peaks.  
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3. RESULTS 
 
3.1 Concepts and tools of the study 
To dissect the kinetics of NF-B-dependent gene expression and to determine which distinct 
mechanisms regulate the expression of different immune genes during mastitis, I selected the 
LAP and the IL-8 genes as the paradigms for an immune relevant “effector” gene and a 
“sentinel” gene in MEC, respectively. Heat-inactivated E. coli 1303, which causes a stronger 
effect than S. aureus, served as an inducer. The detailed study for regulatory mechanism of 
the LAP and the IL-8 genes will provide basic knowledge which in later steps may be 
scrutinized to eventually unravel pathogen-specific mechanisms of immune activation in the 
udder. 
For most genes, important regulatory events generally occur at the promoter regions. 
Therefore, I focused the regulatory events of the two target genes on the promoter regions, 
which mainly comprise the regulatory analyses at the transcriptional level and at the 
chromatin level.  
 
3.1.1 Construction of reporter genes with serial deletions and mutations of the LAP 
promoter       
Construction of reporter genes is the first step to determine the relevant cis-elements to gene 
expression and induction. To generate the LAP truncated promoter fragments with diverse 5 
ends and the same 3 end, PCR amplifications were run using the wild-type LAP promoter 
reporter construct as a template with the different forward primers and the same reverse 
primer (the different forward primers: GCAGATTCAAAGCCCTAAGCGA, 
TTTTCTGGGGATTTCCACAGCCTCATTAGCATA or 
GTGACTGACCCTGCTTTGTGCT. The same reverse primer: 
GCCTTATGCAGTTGCTCTCCA). PCR products were firstly blunted with DNA 
polymerase large (Klenow) fragment (Promega Corp.), afterward, digested with XhoI and 
inserted into the KpnI/Klenow/XhoI sites of the wild-type LAP promoter reporter. The 
validated clones were applied into reporter gene assay (Fig. 9).  
Serial mutation constructions (Fig. 10) were generated by PCR-mediated mutagenesis. PCRs 
were run similar to the PCR-mediated deletion technique as described (Fig. 3). Primer1 and 
primer2 (P1 and P2) were BASEND_f: 5-GTACTAACATACGCTCTCCATC-3 and Luc_r:  
5-GCCTTATGCAGTTGCTCTCCA-3. The mutated primers (mP3 and mP4) in PCR were 
listed in Table 1. All fragments obtained by overlapping extension PCR were digested with 
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restriction enzymes KpnI and XhoI, and inserted into the KpnI/XhoI sites of promoterless 
pGL3 Basic vector. All constructs were verified by restriction enzyme analysis and 
sequencing.
Table 1. Primers for serial mutations of C/EBP and NF-B binding sites in the LAP 
promoter  
 
Clones mP3* (reverse) mP4* (forward) 
CE1m 5’-AGACTTTCCATTGTTCCTTCGCTTAGGGCTTTGAA-3’ 5’-CGAAGGAACAATGGAAAGTCTGTGCCCCTGCCAG-3’ 
CE2m 5’-GGCAGGGGGACTAGTCGGGGCACAGACTTGCCTG-3’ 5’-GCCCCGACTAGTCCCCCTGCCCATCAGCTGA-3’ 
CE3m 5’-ATGAGGCGACTTAAATCCCCAGAAAAAGCTTTC-3’ 5’-GGGGATTTAAGTCGCCTCATTAGCATACGAGTG-3’ 
BmG 5’-CTGTGGAAATCCGCAGAAAAAGCTTTCCTGCTG-3’ 5’-TTTTCTGCGGATTTCCACAGCCTCATTAGCATA-3’ 
BmTTCC 5’-GAGGCTGTACTGATCCCCAGAAAAAGCTTTCCT-3’ 5’-TGGGGATCAGTACAGCCTCATTAGCATACGAG-3’ 
*: The mutated sequences are shown as the underlined bold letters. 
 
3.1.2 Construction of reporter genes with wild-type or serial deletions of the IL-8 
promoter 
The wild-type IL-8 promoter construct (-1294) was retrieved from bovine genomic DNA by 
primary PCR (forward primer: GCAAGGAGGTCCAACCAGTC; reverse primer: 
TTGGAAGTCATATTTGAACAAGAG) and nested PCR (forward primer: 
CCTGAGGCTGGGAGGGATTG; reverse primer: TTGGAAGTCATATTTGAACAAGAG). 
PCR product was blunted with DNA polymerase large (Klenow) fragment and inserted into 
the SmaI site of promoterless pGL3 Basic vector. The right-orientated clone was screened 
(Fig. 29 clone -1294). 
Clone -755 (Fig. 29) was from the wild-type construct -1294, which was digested with KpnI 
and followed by self ligation. The wild-type construct -1294 was digested with KpnI and 
PvuII, respectively, blunted with DNA polymerase large (Klenow) fragment and followed by 
self ligation. The resulting clone is the shorter promoter construct -345 (Fig. 29). The two 
deletion constructs -121 and -56 (Fig. 29) were generated by PCRs using the wild-type IL-8 
construct -1294 as a template. Forward primers in PCR are respective 
ATGCGGTACCGTGCTCTCAAAGGGCGGATG or 
ATGCGGTACCTGCACTTGTTCCCTCTTCTTAC. The same reverse primer 
(GCCTTATGCAGTTGCTCTCCA) is used in the two PCR reactions. Both resulting PCR 
products were digested with KpnI and XhoI and inserted into the KpnI/XhoI sites of pGL3 
Basic vector. To construct C/B (Fig. 29), PCR-mediated deletion technique was applied as 
described (Fig. 3). The PCR fragments from two primer sets 
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(CCTGAGGCTGGGAGGGATTG and 
GCACCATCATGTATGCAACCATCCGCCCTTTG; 
ATGGTTGCATACATGATGGTGCACTTGTTCCC and GCCTTATGCAGTTGCTCTCCA) 
were amplified by primary PCRs. The target fragment was obtained by overlapping extension 
PCR with the two primary PCR fragments. The resulting interest fragment was blunted with 
Klenow, digested with BglII and inserted into the SmaI/BglII sites of pGL3 Basic vector. 
Restriction enzyme mapping and sequencing confirmed all constructs. 
 
3.1.3 The cloning of NF-B p65 and p50 eukaryotic expression vectors 
In order to analyze the function of different NF-B factors for LAP and IL-8 expression, I 
cloned NF-B p65 and p50 as eukaryotic expression vectors. Total RNA from the infected 
udder for 24h was reversely transcribed into cDNA by the specific primers of NF-B p65 and 
p50. To retrieve the p65 fragment, the resulting cDNA was used as a template to run primary 
PCR with primers GGCGAATGGCTCGACAGTAG and TGGAGCCGAACATCAGGATA. 
The following nested PCR was performed with forward primer 
CAGTGGTACCATGGACGACCTCTTCCCCC and reverse primer 
AGTCCTCGAGGGAGCTGATCTGACTCAGAA containing KpnI and XhoI recognition 
sites, respectively. The nested PCR product was digested with KpnI and XhoI and cloned into 
the KpnI/XhoI sites of pASK-IBA43plus. Similarly, to retrieve the p50 fragment, primary 
PCR was carried out with primary primers TCAAACTCCAGAATGGCAGA and 
CACTGTCCCCGTTCTCATC, and nested PCR was performed using primer set 
CAGTGAATTCATGGCAGAAGACGACCCGT and 
AGTCGTCGACAGGGTCATTTTTAGATGGGGT. EcoRI and SalI recognition sites were 
introduced into the nested forward and reverse primers respectively. The nested PCR product 
was digested with EcoRI and SalI, and was cloned into the EcoRI/SalI sites of pASK-
IBA43plus. cDNA segments featuring with sequences of a 5 his-tag and  a 3 strep-tag were 
subsequently subcloned into pcDNA3.1+ (Invitrogen) respectively. A schematic diagram of 
recombinant NF-B p65 and p50 proteins is shown (Fig. 4). The clones were verified by 
sequencing. Their expressions were validated by western blot (Fig. 5) with specific 
antibodies, -p65 and -p50 (Santa cruz). As shown, HEK293 cells express multiple 
endogenous p50 molecules (Fig. 5 right lower). The recombinant p50 has greater molecular 
mass than the endogenous p50 due to those dual tags.  
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Figure 4. Schematic diagram of recombinant NF-B p65 and p50 proteins 
NF-B p65 and p50 recombinant proteins are constructed as dual-tagged proteins in the 
eukaryotes systems. Both proteins contain polyhistidine-linked amino acids (25 aa for p65, 21 
aa for p50) at their N-termini and a Strep-tag (21 aa for p65 and 19 aa for p50) at C-termini. 
They are illustrated as left hatched boxes and right checkered boxes, respectively. The other 
boxes represent distinct protein domains. Black boxes, DNA binding domains; Stippled 
boxes, Dimerization domains; NLS, the nuclear localization signal; TAD, transactivation 
domain, only in p65. Shown are amounts of amino acids in bovine recombinant p65 and p50 
proteins on the right margin. 
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Figure 5. The western blot of NF-B p50 and p65 in HEK293 cells 
HEK293 cells were transfected with the expression constructs of NF-B p50 and p65 and 
harvested to prepare the whole cell extract. Lane 1 and lane 3 are from the transfected cells 
with empty vectors, lane 2 and lane 4 are extracts from whole cells transfected with 
expression vectors of p65 or p50. Equal amounts of total protein were loaded into SDS-
PAGE, specific rabbit antibody against p65 or p50 was used to detect the expression of p65 or 
p50. Goat anti-rabbit IgG conjugated with AP was used as the secondary antibody. The 
molecular mass standard is shown on the left lane. The desired bands are shown by arrows. 
Reco. p50 stands for recombinant p50 and Endo. p50 for endogenous p50.  
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3.2 Time course of pathogen-induced expression of LAP and IL-8 differs 
To understand the time course of LAP and IL-8 in response to pathogen during mastitis, 
mRNA copy numbers of LAP and IL-8 were measured by real-time PCR at the different 
induction times with pathogen E. coli strain 1303. Maximal mRNA concentration of LAP was 
reached at 24h after stimulation within the tested induction times (Fig. 6). 105-fold induction 
over the untreated level was obtained in pbMEC. IL-8 mRNA concentration, in contrast, 
peaked (190-fold induction) already at 1 h after challenge with the same pathogen in pbMEC 
cells and was reduced thereafter to stable levels, but at much higher levels than found in the 
unstimulated control (Fig. 6). Obviously, the target genes LAP and IL-8 exhibit a markedly 
different temporal pattern of gene expression during the response of the cells to the 
extracellular pathogen. Hence, I classify LAP as a late-immune-gene and IL-8 as an early-
immune-gene according to their response to the pathogen E. coli. What is the difference in 
regulation between the late-immune-gene LAP and the early-immune-gene IL-8? In the 
present study, I have probed the regulatory mechanisms of the LAP and the IL-8 genes.  
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Figure 6. The transcription analysis of LAP and IL-8 in pbMEC by real-time PCR 
pbMEC from healthy cows were induced for the indicated times with 1×107 heat-inactivated 
E. coli 1303/ml medium. RNA were prepared, reversely transcribed and measured by real-
time PCR. Throughout the study, equal concentration of the same inducer was applied unless 
otherwise noted.  
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3.3 Transcriptional regulation of late-immune-gene LAP 
3.3.1 Definition of the LAP promoter 
3.3.1.1 The determination of the transcription start site (+1) of the LAP gene 
The primary step to analyze the transcriptional regulation of a gene requires identifying its 
promoter. The promoter commonly includes the DNA sequence in the vicinity of the 
transcription start site (+1) that directs activation or repression of transcription. On the basis 
of this definition, the location of the promoter region can be identified simply by mapping the 
transcription start site.  
Twenty three nucleotides upstream of the ATG of the published LAP mRNA sequence 
(Sequence # S76279) (Schonwetter et al., 1995) could not be found in contig of Bos taurus 
chromosome 27 genome (Sequence # NW_001502105.1), and no 5 UTR (untranslated 
region) of the LAP gene was reported. Therefore, it was necessary to define the transcription 
start site of the LAP gene for further analyses. The transcription start site for a gene may be 
determined by identifying the 5´ end of its mRNA. In the study, I adopted the GeneRacer™ 
method to conduct a 5 RACE amplification. The major transcription start site (+1, tss1) 
identified from the most prominent 5 amplicon was found to reside 125 nucleotides upstream 
from the start codon of translation (Fig. 7). The target sequence shows 100% identity with the 
genomic contig (Sequence # NW_001502105.1). The minor transcription start sites (tss2 and 
tss3) are located at +16 and +25 downstream of tss1, respectively. mRNA transcripts which 
are initiated from the three transcription start sites (tss1-tss3) include the start codon ATG at 
+125/+128. Their deduced translation products are 64-aa full length LAP peptides. The 
canonical TATAAA sequence resides downstream of all resulting transcription start sites. 
Taken together, LAP transcription is initiated by multiple transcription start sites, and these 
transcripts are initiated 5 to the TATA box (Fig. 7). 
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CAGATTCAAAGCCCTAAGCGAAGGTTCAGCAAGAAGTCTGTGCCCCTGCCAGGGGAAACAGGCAAGTCTG  -176
TGCCCCTTGCCACACCCCTGCCCATCAGCTGAACTGACTGCCAGGAAGAAGCTTCTGGTCAAAAGGGCAG  -106
CAGGAAAGCTTTTTCTGGGGATTTCCACAGCCTCATTAGCATACGAGTGACTGACCCTGCTTTGTGCTAT   -36
GAAGGCCACTCCCATGACACAAAGGGAAGAGGCTCAGTTAACCAGTTCCTAATAACTAAATCCACAGCCA   +35
GCGCGGAATTCCTCCCGAAACTTGGGACCTTTATAAAGCAGCAAACGCAGCCTCTTCTCCAGCATCAGCT  +105
GCAGAGCTCGGGACGCCAGC ATG A                                              +129
C/EBP1
C/EBP2
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+1 tss1
Start codon
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Figure 7. The sequence of the proximal LAP promoter  
tss, transcription start site in purple letters; CpG sites for methylation analyses are shown in 
red letters; C/EBP binding site, underlined letters; NF-B binding site, blue letters; The NF-
B probe used in EMSA is shown as arrow; Start codon of translation ATG, green letters; 
TATA box, rectangle box. Position numbers are indicated relative to the most 5´-located tss1 
(+1). 
 
3.3.1.2 In silico identification of putative transcription factors binding sites of the LAP 
promoter 
The computational analysis of the LAP promoter sequence with the MatInspector software 
shows one putative NF-B site and 3 C/EBP sites, which are termed as C/EBP site1, C/EBP 
site2 and C/EBP site3 from the distal to the proximal location, respectively (Fig. 8). The NF-
B binding site overlaps with the C/EBP site3 and a NFAT (nuclear factor of activated T cells) 
binding site. Within the 13 bp-sequence (GGGGATTTCCACA) at -89/-77, the ATTTCC 
motif is shared by NF-B and C/EBP site3 (Fig. 8). Detailed sequence information on the 
putative transcription factors binding sites is shown in Fig. 7. 
Results 
52 
C/EBP1 C/EBP2 C/EBP3
NFB
+1
-221  
NF-B site
C/EBP3 site
-89 -77
-170 +129-1411
GGGGATTTCCACA
 
Figure 8. Schematic representation of putative transcription factors bound to the LAP 
promoter 
The binding sites of putative transcription factors were analyzed with the software 
MatInspector (at http://www.genomatix.de). The core sequences of these binding sites are 
shown in Fig. 7. The transcription start site (+1) was determined by 5 RACE. TTCC with 
black background was discussed in section 3.3.5.1.  
   
3.3.2 Experimental identification of cis-elements crucially relevant to LAP expression 
and induction  
3.3.2.1 The mapping of relevant elements in the LAP promoter using promoter deletions 
in reporter gene assay 
To delineate the relevant region for LAP expression and induction, reporter plasmids 
harboring a series of 5´ deletion promoters were transiently transfected into HC11 cells. More 
than 25-fold basal activities over the promoterless pGL3 Basic vector were achieved for the 
LAP promoter. Heat-inactivated E. coli strikingly induced LAP expression more than 10-fold 
(Fig. 9). The data demonstrate that the basal activity of the LAP promoter is very strong, and 
that the HC11 cell line is a suitable cell model for regulation analysis of the LAP promoter. 
Both basal activity and induction were abolished after deleting the region containing the 
putative NF-B and C/EBP site3 at -95/-58 (Fig. 9). More upstream sequences are only of 
minor relevance. Hence, the region at -95/-58 is highly relevant to the basal activity and 
induction of the LAP promoter.  
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Figure 9. Identification of the key region to LAP expression and induction 
Serially 5 truncated promoter segments of the bovine LAP promoter were inserted into the 
promoterless pGL3 Basic vector, upstream of the firefly luciferase encoding gene and 
transiently transfected into HC11 cells. After 24h, 1×107/ml heat-inactivated E. coli 1303 
were added into the induction group. The basal activity of the longest promoter -1411 is set as 
1. The luciferase activities are shown as the mean ± S.E.M. from the representative of three 
independent experiments. 
 
3.3.2.2 Identification of NF-B and C/EBP3 binding sites as the highly relevant cis-
elements to LAP expression and induction 
To fine map the cis-elements crucial for LAP induction and expression, reporter genes were 
constructed either featuring a single point mutation or multiple-base substitutions in the 
putative transcription factor binding sites of the LAP promoter. Reporter gene assays were 
conducted in HC11 cells. The mutated sequences of mutants are shown in Fig. 10 left. Only a 
single base substitution of the NF-B site (BmG) dramatically reduced induction to 8% and 
basal expression to 50% (Fig. 10b). This shows that the NF-B site is indispensable for 
maintaining LAP induction and basal expression. Similarly, multiple-base substitutions of the 
NF-B site (BmTTCC) and mutation of C/EBP site3 (CE3m) decreased LAP basal activity 
and induction (Fig. 10f and e), adding supportive evidence that the putative NF-B/CEBP3 
site is crucial to LAP induction and expression. In contrast, mutation of the C/EBP site2 
(CE2m) did not influence both LAP basal activity and the extent of induced activity (Fig. 
10d). Mutating the distal C/EBP site1 (CE1m) significantly enhanced both LAP basal activity 
and induction (Fig. 10c). Thus, C/EBP site1 is a repressive site. Taken together, the findings 
firmly establish that the NF-B/CEBP3 overlapping site is crucial for LAP basal activity and 
induction.  
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Figure 10. Mutation analysis of putative NF-B and C/EBP binding sites of the LAP 
promoter in HC11 cells  
Alterations of the LAP promoter sequence are listed on the left. The positions of the core 
sequences of the individual binding motifs are indicated below the wild-type sequence. The 
mutated sequences in mutants are shown in bold letters. The unaltered sequences are indicated 
as hyphens. The stipples indicate not shown bases. The fragment with single point mutation or 
multiple-base substitution mutations of putative NF-B or C/EBP binding sites were inserted 
into the promoterless pGL3 Basic vectors. These clones were transfected into HC11 cells. 
Cells were kept untreated (control) or induced for 24h with heat-inactivated E. coli 1303 
before harvest. The control activity of the wild-type is set as 1. The data are shown mean  
S.E.M from the representative in triplicate, of three independent experiments.   
 
3.3.3 Effect of NF-B factors on LAP expression 
3.3.3.1 NF-B p65 and p50 factors bind to the NF-B binding site in the LAP promoter
in vitro   
The mapping and mutational analyses have clearly shown that the NF-B binding site is 
pivotal for the function of the LAP promoter. I wanted to know which factors of the NF-B 
family matter. To address the question, EMSA assays were performed using nuclear extracts 
from control or 2h induced HC11 cells. The 33bp-oligonucleotide probe derived from the 
LAP promoter containing the NF-B binding site and C/EBP site3 (Fig. 7). A representative 
gel is shown (Fig. 11A). Three specific complexes (C1-C3) were eventually formed (Fig. 11 
double-head arrows) and could be competed away with a 100-fold molar excess of the 
unlabeled wild-type competitor (Fig. 11A lane5 and lane7), but not by another unlabeled 
competitor featuring the mutation of the NF-B core sequence (BmTTCC) (Fig. 11A lane4 
and lane8). Thus, the bands are the specific NF-B-DNA complexes. To identify which 
member(s) (p65 and/or p50) of the NF-B factor family binds indeed to the LAP promoter, 
antibody against NF-B p65 or p50 was added into the EMSA reaction. Antibodies against 
NF-B p65 shifted away the complexes C1 and C2 forming “so called” supershifted bands 
(Fig. 11A lane2 vs. lane3 and lane10 vs. lane9). Anti-p50, however, shifted away all three 
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complexes, C1, C2 and C3 (Fig. 11A lane1 vs. lane3 and lane 11 vs. lane9). This apparently 
shows that NF-B p65 is contained in the complexes C1 and C2, and complexes C1, C2 and 
C3 possess NF-B p50. In conclusion, complex C1 contains p65 and p50. C2 also comprises 
p65 and p50. But the molecular weight of C1 is heavier than that of C2, therefore, C1 may 
contain unknown factor (s) in addition to p65 and p50.  
I wanted to know whether different mutants in Fig. 10 left influence the binding of NF-B 
factor, competition assays were done with nuclear extracts from 18h induction HC11 cells. 
The same wild-type probe was labeled. Three specific complexes (C1-C3) for NF-B were 
shown (Fig. 11B, lane 2, 3 and 4) similar to the left panel. Comparison of lane 2 (competitor 
BGm) with lane 4 (shift reaction) (Fig. 11B) showed that compositions of the bands were the 
same in two lanes except that the signal magnitude by BGm competitor was slightly lower. 
Hence, single-base mutation (GC) of NF-B binding site has effectively abolished the 
binding of NF-B factors. Additionally, the composition pattern of the complexes in lane 3 
was the same as that of shift reaction in lane 4 (Fig. 11B). It implies that the binding of NF-
B factors is completely disrupted by the mutation of BmTTCC. Taken together, both 
mutations (BGm, BmTTCC) block the binding of NF-B factors to the LAP promoter. 
Combined with data from Fig. 10, NF-B factor is crucial for LAP basal expression and 
induction. 
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Figure 11. Binding analyses of NF-B p65 and p50 to the LAP promoter by EMSA
EMSAs were performed using a labeled probe with NF-B binding site of the LAP promoter. 
Double-head arrows between panel A and B refer to NF-B specific complexes (C1-C3) and 
p65 or p50 supershift bands (ss) are shown on the left by arrows. Lanes are listed at the 
bottom of each image. A) Equal amounts of nuclear extracts (NE) were used in panel A1 and 
A2 taken from 2h induced and uninduced (control) HC11 cells. The assays (lane1-11) were 
resolved in the identical gel. Cwt and Cm indicate the wild-type and the mutated overlapping 
site competitors (BmTTCC). Their mutated sequences are the same as those of panel B. B) 
Competition assays, 10 μg of the nuclear extracts from HC11 cells induced for 18h were used 
in the reactions except for FP (free probe). Unlabeled competitors (the wild-type and the 
mutated probes) were applied in 100-fold molar excess. Cwt, CmG and Cm represent the 
wild-type, the mutated BmG and BmTTCC competitors, respectively. The mutated 
sequences are the same as the corresponding mutants (listed in Fig.10 left). 
 
3.3.3.2 Induction makes many more cells recruit NF-B p65/p65 homodimers to the 
LAP promoter in vivo 
To examine the recruitment of NF-B factor to the native chromatin, chromatin 
immunoprecipitation (ChIP) assays were carried out using pbMEC cells. The chromatins from 
pbMEC cells induced for different times were incubated with antibody against NF-B p65 
(sc-7151x), p50 (sc-114x) or normal rabbit IgG (sc-2027x), respectively. Twenty four hours 
of induction made many more cells open their LAP promoters for p65 binding [183-fold 
increase relative to the resting cells] (Fig. 12). Neither NF-B factor was detected on the LAP 
promoter in the resting cells (Fig. 12). Very few cells are accessible for NF-B p50 to the 
promoter after induction for 3h. In contrast, no DNA was detected when chromatin was 
incubated with control IgG (Fig. 12 open columns). Taken together, it is apparent that NF-B 
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p65 homodimers are recruited to the LAP promoter at 24 h after induction, and hence may be 
the key factor to LAP expression and induction.  
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Figure 12. ChIP analysis of recruitment of NF-B p65 and p50 to the LAP promoter 
Shown are the yields of DNA associated with p65 and p50 before and after induction. pbMEC 
were untreated (control) or induced for the indicated times. Four μg of specific antibodies or 
normal rabbit IgG was used in immunoprecipitations. The immune complexes were captured 
by protein A agarose. The purified DNA was used as template in real-time PCR. Details are 
given in Materials and Methods section. The yield (% input) of uninduced p65 is set as 1. 
After induction with heat-inactivated E. coli1303, the increase (fold) of cells bound by p65 is 
shown. To validate the specificity of the PCR, products were run on agarose gels after the 
real-time PCR amplification. Specific PCR products were confirmed by ethidium bromide 
staining. 
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3.3.3.3 NF-B p65 activates, but p50 inhibits the LAP promoter activity in a dose-
dependent manner 
To investigate the function of NF-B p65 and p50 in the transcriptional regulation of the LAP 
gene, their respective expression vectors were transiently transfected into HC11 cells together 
with the wild-type LAP reporter. In HC11 cells, p65 activates, but p50 down-regulates the 
LAP promoter activity (Fig. 13). To know the function specificity of p65 and p50, increasing 
amounts (10, 30, 100, 300 and 1000 ng) of p65 or p50 expression vector were cotransfected 
into HC11 cells with the wild-type LAP reporter. As the amount of p65 expression construct 
was increased, luciferase activity was enhanced gradually. High amount (1μg) of p65 also 
displayed 1.8-fold increase of luciferase activity relative to the mock group. In contrast, p50 
expression vector decreased luciferase activity with the increasing of p50 amount. Thus NF-
B p65 up-regulates, but p50 down-regulates the LAP promoter activity in a dose-dependent 
manner (Fig. 13A and 13B). The finding is consistent with the ChIP data that only NF-B p65 
significantly binds to the active LAP promoter. Taken together, NF-B p65 drives LAP 
expression and induction.  
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Figure 13. Functional analysis of NF-B factors in the LAP promoter 
HC11 cells were transiently transfected with 1000 ng of the wild-type LAP reporter construct 
together with increasing amounts of p65 (A) or p50 expression vector (B) (10 ng to 1000 ng). 
Total amount of transfected DNA was kept constant by adjusting with the empty vector. The 
luciferase activities were given relative to that of LAP reporter.  
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3.3.4 Effect of C/EBP factors on LAP expression 
3.3.4.1 EMSA shows that C/EBP- and - may function by direct binding to C/EBP site3 
The mutation analysis shows that the NF-B/CEBP overlapping site is crucial to LAP 
expression and induction. I wondered how C/EBP factors influence LAP expression and 
induction. To analyze the binding of different C/EBP factors to the C/EBP site1, site2 and 
site3 in the LAP promoter, EMSA was performed with equal amounts of nuclear extracts 
(NE) from HC11 cells transfected with empty vector (mock) or with expression constructs of 
dominant negative (DN)-C/EBP-, -, - or -(Fig. 14 and appendix Fig. 37). In order to 
avoid the disturbance of the endogenous C/EBP factors to effectively discriminate the specific 
binding of different C/EBP factors, the truncated C/EBP factors (DN-C/EBPs) in N-terminus, 
which possess the lighter molecular weight, were employed in EMSA analysis. Furthermore, 
to effectively recognize the specific binding bands of the C/EBP factors to C/EBP site3 and to 
make this recognition not be influenced by the binding of NF-B to the overlapping site, the 
mutated probe for NF-B (LAP_BmG) was used in EMSA (Fig. 14). Expectedly, no 
specific complexes for NF-B bound to the mutated probe (Fig. 14 lane2). This provides 
further evidence that BmG mutant completely disrupts the binding of NF-B factors. 
Respective contrast lane3, lane4, lane5 or lane6 with lane2 in Fig. 14 and contrast lane3, 
lane4, lane5 or lane6 with lane2 in Appendix Fig. 37, the specific C/EBP-, -, - and - 
bands were identified and indicated by arrows (Fig. 14 and Appendix Fig. 37). No C/EBP 
factors bound to putative C/EBP site2. C/EBP site 1 was weakly occupied with C/EBP-, -, 
- and - factors (Appendix Fig. 37). Only C/EBP- and - strongly bound to C/EBP site3 
(Fig. 14). Moreover, the affinity of the C/EBP site3 for C/EBP factors was higher than that of 
the C/EBP site1. Combined with the mutation analysis, C/EBP- and - may influence LAP 
expression and induction by direct binding. 
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Figure 14. Binding analysis of the different C/EBP factors in the LAP promoter by 
EMSA 
Nuclear extracts (NE) were from HC11 cells transfected with different expression constructs 
of DN-C/EBP-, -, - or -
 Equal amounts of NE (2 μg) were incubated with the labeled 
probes as indicated. FP, free probe, without nuclear extract. Radiolabeled probes derived from 
NF-B/CEBP3 overlapping site of the LAP promoter, but the binding of NF-B was blocked 
(LAP_BmG). The C/EBP specific complexes are indicated by arrows. Lanes are given at the 
bottom. 
 
3.3.4.2 Functional analysis of C/EBP factors in the LAP promoter 
3.3.4.2.1 All C/EBP factors down-regulate the LAP promoter activity 
As described in the previous part, C/EBP factors only bind weakly to the distal C/EBP site1 
but only C/EBP- and -strongly bind to the proximal C/EBP site3. To clarify which member 
of the different C/EBP factors matters in the regulation of the LAP promoter activity, equal 
amounts of C/EBP factors were cotransfected into HC11 cells together with the wild-type 
LAP reporter. The result showed that all C/EBP factors down-regulate the LAP promoter 
activity to different extents (Fig. 15). Taken the above data together, the LAP promoter 
activity may be down-regulated by C/EBP- and -via direct binding and by C/EBP- and - 
via indirect binding
  
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Figure 15. Functional analysis of C/EBP factors in the LAP promoter 
C/EBP-, -, - or - expression vector was cotransfected into HC11 cultures, along with 
equal amounts of the reporter vector. The luciferase activity of the wild-type LAP promoter is 
set as 1. pGL3 Basic vector is served as a reference to evaluate the activity of the LAP 
reporter. The relative luciferase activities are shown as the mean  S.E.M from three 
independent experiments. **, p < 0.01. *, p <0.05. 
 
3.3.4.2.2   C/EBP reduces basal activity but not inducibility, whereas C/EBP blocks 
LAP promoter completely 
The EMSA assay shows that C/EBP- and – directly and strongly bind to the key NF-
B/CEBP3 overlapping site of the LAP promoter. Hence, C/EBP- and – may play a more 
important role in regulating LAP promoter activity. To further determine the effect of C/EBP 
factors on the LAP promoter activity, increasing amounts of C/EBP- or C/EBP- were 
cotransfected into HC11 cells, together with constant amount of the wild-type LAP reporter 
plasmid. The result showed that less than 0.1 μg of C/EBPdid not influence basal activity of 
the LAP promoter (Fig. 16A). Increasing amounts of C/EBP gradually reduced the basal 
activity of the LAP promoter. However, the fold induction was barely changed (Fig. 16A). 
That is to say, high amounts of C/EBP reduced only the basal activity but not the induction 
extent of the LAP promoter. In contrast, 0.1 μg of C/EBPsignificantly down-regulated only 
the basal activity of the LAP promoter (Fig. 16B). However, increasing amounts of this factor 
reduced both basal and induced activity
 More than 0.9 μg of C/EBPequal amount to the 
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LAP wild-type reporter) abolished both basal and inducibility of the LAP promoter in HC11 
cells (Fig. 16B). Hence, C/EBP reduces both basal activity and induction of the LAP 
promoter in a dose-dependent manner. Taken together, C/EBP decreases only basal activity, 
and C/EBP down-regulates not only basal activity but also induction of the LAP promoter in 
a dose-dependent manner, although the reduction is much lower than the non-titration 
experiments. 
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Figure 16. Dose-dependent analysis of C/EBP and C/EBP for the LAP promoter in 
HC11 cells 
The constant amount of the wild-type LAP reporter (1.5 μg for panel A, 0.9 μg for panel B) 
and the increasing amounts of C/EBP or C/EBPwere transiently transfected into HC11 
cells. The heat-inactivated E. coli 1303 was incubated into the cell culture for 24h. The 
luciferase activity of the respective uninduced LAP reporter is set as 1. The total amount of 
DNA in each well is maintained constant by adding empty clone, **, p < 0.01. *, p <0.05. 
 
3.3.5 The combined effect of C/EBP and NF-B factors on LAP expression 
3.3.5.1 C/EBP represses the LAP promoter by TTCC motif, independent of the NF-B 
binding   
The previous results firmly established that NF-B factors and their site are essential for 
function of the LAP promoter, and the crucial C/EBP binding site3 overlaps with the NF-B 
binding site. Hence, I intended to analyze whether the repressive effect of C/EBP factors on 
the LAP promoter activity is exerted via interference with NF-B binding, or rather solely 
conveyed by C/EBP factors. Both C/EBP- and – factors avidly bind to this site and C/EBP 
was chosen to address this question. The repressive effects were compared after 
cotransfection of high amounts of this factor together with either the wild-type LAP reporter, 
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or the reporter genes harboring different mutations in the NF-B binding motif. The mutants 
comprise i) the mutant BmG, in which the single-base substitution blocks NF-B binding, 
and ii) the mutant BmTTCC, in which NF-B and possibly C/EBP binding are abolished. It 
was found that C/EBP repressed strongly the activity of that construct (BmG) abolishing 
NF-B binding only (Fig. 17). Hence, C/EBP factors diminish the LAP promoter activity by 
themselves, independent of the binding of NF-B. However, after the TTCC motif (Fig. 8) 
was mutated into CAGT (BmTTCC), the capability of C/EBP to further reduce the activity 
of the LAP promoter was abolished. Thus the TTCC motif is the repressive site of C/EBP. 
Taken together, C/EBP represses the LAP promoter through binding to the TTCC motif, 
independent of the NF-B binding. 
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Figure 17. Analysis of C/EBP repressive effect and acting site in the LAP promoter 
HC11 cells were transfected with 900 ng of the wild-type LAP reporter (wt) or equal amount 
of the mutated LAP reporter with NF-B single-base substitution (BmG) or multiple-base 
substitution BmTTCC, with/without 2700 ng of C/EBP expression vector. Luciferase 
activity was shown relative to the wt LAP reporter. **, p < 0.01.  
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3.3.5.2 C/EBP– and – also repress the LAP promoter by diminishing NF-B p65-
mediated activation  
As we have shown, NF-B p65 activates but C/EBP-- repress the LAP promoter activity 
independent of the binding of NF-B. To further investigate how C/EBP- and -play roles 
in the presence of NF-B p65, C/EBP- or - expression vector was cotransfected into HC11 
cells together with the wild-type LAP reporter and NF-B p65 expression construct. As 
described in the previous experiments, NF-B p65 was found to activate the LAP promoter. 
After addition of the expression vectors of C/EBP or C/EBP into the transfection system, 
the NF-B p65-mediated activations were diminished (Fig. 18). Thus, C/EBP- and – play 
the repressive roles in the LAP regulation by diminishing NF-B p65-mediated activation. 
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Figure 18. Functional analysis of C/EBP– or –in the LAP promoter, in the presence 
of NF-B p65 
HC11 cells were cotransfected with 1 μg of NF-B p65 expression vector, together with or 
without C/EBP- or –expression vector. 1 μg of LAP reporter gene and the respective 
C/EBPexpression vector were used. Luciferase activity of the wt LAP reporter plasmid is set 
as 1. Fold activations of transcription factors are shown as the mean  S.E.M. from the 
representative in triplicate of two independent experiments. 
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3.3.5.3 C/EBPand NF-B factors may compete for the overlapping site in the LAP 
promoter 
It was shown, so far, that C/EBP- and - or NF-B p65 and p50 can individually bind to the 
overlapping site of the LAP proximal promoter and that only NF-B p65 activates the LAP 
activity. Both C/EBP- and –repress the LAP promoter activity by diminishing NF-B p65-
mediated activation. In order to find the cause that C/EBP attenuates NF-B p65-mediated 
activation, I carried out EMSA with nuclear extracts from the untreated HC11 cells (Fig. 
19A). Also, the untreated HC11 which expressed DN-C/EBP(Fig. 19B) or the induced 
HC11 expressing DN-C/EBP(Fig. 19C). The result showed that the amount of NF-B 
binding to the probe was not changed, regardless of the presence or absence of overexpressed 
DN- C/EBP (Fig. 19A vs. 19B). Induction made more NF-B bind to the probe as previous, 
despite DN-C/EBPwas added into the reaction(Fig. 19B vs. 19C)
i.e. high amounts of DN-
C/EBP can not diminish the binding of NF-B factors to the probe. It shows that the probe 
has higher affinity for NF-B than for C/EBPand that C/EBP and NF-B bind to the 
different probe molecules in vitro. One factor (e.g., NF-B) maybe precludes the binding of 
another factor (e.g., C/EBP). Thus, the proportion of endogenous NF-B to C/EBP factors 
appears to be a main regulatory event for LAP expression.  
 
In conclusion, the molecular mechanism of the LAP promoter at the transcriptional level has 
been clarified. NF-B p65 triggers LAP expression and induction. Moreover, C/EBP factors 
play the repressive role by diminishing the activation of NF-B p65 to LAP expression and 
are independent of NF-B. C/EBP factors and NF-B competitively bind to the NF-
B/CEBP3 overlapping site in the LAP promoter. Hence, the proportion of endogenous NF-
B to C/EBP factors appears to be a main regulatory event for LAP expression. 
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Figure 19. EMSA analysis of NF-B p65 and C/EBP binding to the LAP promoter 
Oligonucleotide containing the NF-B/CEBP3 overlapping site in the LAP promoter was 
labeled. The labeled probes were incubated with 10μg nuclear extract from control HC11 
cells transfected with empty vector (A), control cells transfected with DN-C/EBP (B) and 2h 
induced HC11 cells transfected with DN-C/EBP (C). The unlabeled wild-type (Cwt) or 
mutated probe (Cm: BmTTCC) was used to compete the specific binding at 100-fold molar 
excess. The supershift binding reactions (-p65 or -p50) were incubated with specific 
antibodies for 10 min at room temperature prior to the addition of labeled probe. The 
complexes were resolved in 6 % non-denaturing polyacrylamide gel. The dried gel was 
exposed overnight and scanned by Storm 840. The supershift bands, NF-B specific 
complexes (C1-C3) and DN- band are indicated on the right. S: shift reaction.  
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3.4 Role of chromatin remodeling in induction of -defensin encoding gene 
3.4.1 Time course and induction extent of LAP and NF-B are uncoupled 
The above evidences show that transcription factor NF-B p65 drives LAP expression and 
induction. Hence, its alteration directly affects LAP expression and induction. It is necessary 
to know the alteration of NF-B at the different induction times. 
 
3.4.1.1 NF-B rapidly increases only two-four fold after induction in HC11 cells 
The NF-B motif of the LAP promoter was used as a probe in EMSA to monitor NF-B 
alteration. Nuclear extracts were from HC11 cell cultures induced for the indicated times (Fig. 
20A). Image Quant 5.2 software from Molecular dynamics was used to quantify the 
supershifted bands of NF-B p50 (Fig. 20B filled squares) and p65 (Fig. 20B filled triangles), 
respectively. The data showed that the change patterns of the two factors were similar. Both 
the amount of NF-B p50 and p65 were increased to 2-4 fold after induction for 2h. 
Afterwards, it decreased slowly. Differently, the previous results showed that LAP expression 
was activated by only NF-B p65 and repressed by p50. I wanted to further check alteration 
of active NF-B at the different induction times.     
To the end, another technique---reporter gene assay was applied. HC11 cells were transfected 
with ELAM reporter harboring five tandem NF-B attachment sites. Cells were harvested 
after induction for the indicated times and renilla activities were assayed. The result 
demonstrated that NF-B activity peaked by 3-fold increase at 6h after induction and 
afterward decreased (Fig. 20B open circles). Although the time point with the maximal NF-
B activity was shifted from 2h (in EMSA) to 6h (in reporter gene assay), the profile in vivo 
was similar to the data from EMSA in vitro. Taken together, 3-fold more active NF-B is 
increased in cells at 6h after induction.  
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Figure 20. Alteration of NF-B in HC11 cells 
A) EMSA was performed with nuclear extracts (NE) from HC11 cells without inducer or 
incubated with 1×107 /ml heat-inactivated E. coli strain 1303 for the indicated times (0, 2h, 
12h and 24h). 10 μg NE was incubated with labeled 33-oligonucleotides probe as previous. 
The complexes were resolved in 6 % non-denaturing PAGE, and dried gel was exposed 
overnight, scanned with Storm480 and analyzed by Image Quant 5.2 software of Molecular 
dynamics. B) Alterations of NF-B p50 (filled squares) and p65 (filled triangles) in HC11 
derived from the quantified image on the left. NF-B activities in HC11 (open circles) were 
from transfection assay. 20 ng ELAM reporter construct harboring five tandem NF-B 
attachment sites was transfected into HC11 cells. Inducer was added for the indicated times 
prior to the harvest. Renilla activities were assayed. The maximal values in three graphs were 
set as 100 %. 
 
Results 
70 
3.4.1.2 LAP mRNA accumulation is much stronger and later than NF-B activation. 
The resting LAP promoter is insulated against NF-B factor 
The above reporter gene assay shows that active NF-B is increased 3-fold at 6h after 
induction in HC11 (murine MEC cells). Previous results show that NF-B p65 drives LAP 
expression and induction. I wanted to detect whether similar change happened in LAP 
promoter activity in primary bovine MEC (pbMEC). To address the question, the wild-type 
LAP promoter reporter was transiently transfected into pbMEC cells. The cells were induced 
for the indicated times prior to the harvest. The result showed that the extent of the LAP 
promoter reporter activity was increased gradually with the prolongation of the induction time 
and reached the highest at 12h. No apparent change between 12h and 24h time point. 
Consistent with increase (3-fold) of active NF-B in murine MEC (Fig. 20B open circles), 
only 2.6-fold of LAP promoter reporter activity was achieved relative to the uninduced level 
in bovine MEC (Fig. 21 open circles). However, LAP mRNA concentration in pbMEC (Fig. 
21 filled triangles) was increased to more than 100-fold 24h after induction, which was much 
stronger than increase of LAP promoter activity (2.6-fold) and active NF-B (3-fold). More 
importantly, in udder, much more (700-fold) increase of LAP mRNA concentration was 
reached (Fig. 21 filled squares). Obviously, peak of LAP mRNA (24h) is much later than that 
of NF-B (2h) (Fig. 20). Taken together, LAP mRNA accumulation and NF-B activation are 
uncoupled and the former is much stronger and later than the latter.  
Comparison of the minimal with the maximal activities, LAP promoter activity increased 
from 38 % up to 100 % maximal activity 12 h after induction. However, LAP mRNA copies 
of the resting cultures reached only 1% of the maximal level (100 %) 24h after induction in 
pbMEC. The difference in LAP mRNA concentration between resting (unstimulated) (0.14 %) 
and 24h after full pathogen induction (100 %) was even stronger in udder. Contrast the levels 
at the resting stage at the three lays, 38 % of maximal LAP promoter activity was higher than 
1 % or 0.14 % of maximal LAP mRNA concentration in pbMEC or in udder. The data clearly 
shows that the LAP promoter exhibits different levels of insulation against NF-B in the 
resting stage, the order of insulation magnitude is udder > pbMEC >> reporter.  
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Figure 21. Alteration of LAP promoter activity and mRNA concentration in pbMEC 
and udder 
pbMEC cells from healthy cows were transient transfected with the wild-type LAP reporter, 
harboring the LAP promoter and expressing firefly activity, and induced for the indicated 
times. The firefly activity reflects the LAP promoter activity (open circles). LAP mRNA level 
in pbMEC (filled triangles) is adapted from Fig. 6. In the two experiments, 1×107/ml heat-
inactivated E. coli strain 1303 induced pbMEC cells for the indicated times before harvest. In 
order to obtain udder samples from 4 healthy and lactating cows, four different udder quarters 
of each cow was infected for the indicated times with 500 CFU E. coli strain 1303 before 
culling. The same measurement technique of LAP mRNA copies for udder samples was 
applied as Fig. 6. Ordinate is shown as logarithmic scale. The maximal values in three graphs 
are set as 100 %. 
 
3.4.2 -defensin induction is associated with decompaction of chromatin in udder 
In the resting cells of udder, LAP promoter insulates against NF-B to a greater extent. I 
wanted to investigate whether chromatin structure in udder is remodeled after induction to be 
accessible to NF-B p65. CHART-PCR (Chromatin accessibility by real-time PCR) was 
performed to detect alteration of chromatin structure. CHART-PCR is based on the fact that 
the condensed chromatin restricts transcription factors, as well as restriction enzyme, access 
to DNA, whereas the loosed chromatin DNA is accessible for them, hereby can be digested 
with restriction enzyme. Real-time PCR is used to detect the digestion degree reflecting the 
degree of chromatin compaction. Chromatin from control and infected udder samples was 
digested with restriction enzyme HindIII for 1h. The active transcriptional regions of the LAP 
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and the BNBD5 (-defensin gene 5) genes were chosen as target regions in which encompass 
the NF-B/CEBP overlapping site. Two HindIII sites lie in the region of the LAP promoter 
and one HindIII site in the BNBD5 target region. The result showed that protection 
percentage of LAP chromatin was high significantly  reduced from 95.1% (Fig. 22A open 
diamonds, ordinate) down to 59.7% (Fig. 22A filled diamonds, ordinate) after induction for 
24h (p<0.01). Similarly, protection percentage of BNBD5 chromatin was significantly 
reduced from 100.8 % down to 82.5 % (not shown) after induction for 24h (p<0.05). The data 
show that induction decompacts the chromatin around crucial sites of -defensin promoters. 
Combined with the mRNA copies (Fig. 22A abscissa), it shows that -defensin induction is 
associated with decompaction of chromatin in udder. In contrast, the control s1-casein gene 
data (Fig. 22B) from the same animals show that s1-casein induction is associated with 
compaction of chromatin in udder. 
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Figure 22. Alterations of chromatin compaction and mRNA copies for the LAP gene and 
s1-casein gene 
The ln mRNA copies (abscissa) of control (open diamonds) or 24 h infected (filled diamonds) 
udder samples (n=4 animals) are plotted against the degree of chromatin protection from 
HindIII for LAP or from DdeI for s1-casein (ordinate, from CHART-PCR). Shown are mean 
values from two independent experiments. Chart PCR data of s1-casein has been described 
(Vanselow et al., 2006). *, p < 0.05, **, p < 0.01.  
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3.4.3 Chromatin decompaction of the LAP promoter during induction is associated with 
hypermethylation 
The previous results demonstrated that the LAP chromatin compaction is loosed in the active 
transcription region (Fig. 22) possibly modulating the accessibility for transcription factors to 
their target binding sites. I wanted to know whether DNA methylation correlates with the 
chromatin remodeling. To address the question, I analyzed and quantified the degree of the 
DNA methylation of LAP promoter region with the bisulfite sequencing technique. Udder 
tissues were derived from 7 healthy Holstein cows. After milking at the fourth month of their 
first lactation, one quarter was challenged with 500 CFU of E. coli strain 1303 for 24h before 
culling and one quarter was left untreated as control. All 17 CpG sites in the 1.5-kb LAP 
promoter were analyzed. No methylation alteration happened in CpG 1-9 (located at -1411/-
730) and CpG 16-17 (located at +81/+130) before and after infection (not shown). However, 
the methylation patterns of CpG sites 10-15 at -220 to +81 are differential in different animal 
individuals. Surprisingly, in all individuals, no demethylation was found in CpG sites 10-15 
after infection. Hypermethylation was displayed in the some individuals except for the animal 
individuals not showing alteration of methylation (not shown). The hypermethylation region 
covers ~140 bp upstream and downstream of the NF-B binding site. The student t-test show 
that only CpG site 11 display hypermethylation (p <0.05) in all 7 tested animal individuals in 
a statistically significant fashion (Fig. 23). CpG site10 and site11 are encompassed 
respectively in the forward and reverse primers used in CHART-PCR. i.e., CpG in the loosed 
chromatin is hypermethylated but not hypomethylated. However, DNA methylation is known 
to be relevant to silencing genes in most cases (Jaenisch and Bird, 2003; Li, 2002).  
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Figure 23. Methylation analysis of the LAP promoter in udder 
Genomic DNAs were prepared from the uninfected and 24h infected udder quarters of same 
animals. Total 7 different animals are indicated with lower case letters (a-g). EpiTect Bisulfite 
Kit from Qiagen was served to carry out the bisulfite conversion reaction. Purified DNA with 
converted U or C was used as a template to amplify the target fragment with specific 
methylation primers in primary PCR and secondary PCR. PCR products were sequenced 
directly by ABI sequencing system. The symbols from the same animal (open triangles:  
control quarter, grey dots: infected quarter) are connected with dashed lines. All symbols for 
the same CpG site are shown by compartments. Mean values from 7 animals are listed in 
table. 
 
CpG Quarters Site 10 Site 11 Site 12 
Infection 62.7 50.7* 91.0 Mean value 
(% C) Control 38.8 22.0 71.3 
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Our lab has reported that NF-B is essential for pathogen-mediated activation of the -
defensin gene 5 (BNBD5) (Yang et al., 2006), which is another pivotal member of bovine -
defensins. I wanted to know whether NF-B plays a different role in LAP and in BNBD5 
regulation.  
 
3.5 Lower affinity for NF-B of the -defensin gene 5 (BNBD5) promoter is a key cause 
of lower expression compared with the LAP promoter 
3.5.1 Both basal and induced activities of the BNBD5 promoter are much lower than 
those of the LAP promoter  
To our knowledge, LAP expression explains 65 %-80 % defensin messages among five 
bovine -defensins (LAP, BNBD5, TAP, EBD and BNBD4) (Wei Yang’s thesis). LAP is the 
predominant member of the five peptides in the infected pbMEC and udder. To investigate the 
cause of the differential transcription, equal amounts of the wild-type LAP reporter and the 
BNBD5 reporter were transfected into HC11 cells respectively. The result apparently showed 
that more than 50-fold activities for LAP basal activity and only 2.4-fold for BNBD5 were 
found over the promoterless pGL3 Basic. After induction, the LAP basal activity was 
enhanced to 5.9-fold relative to the unstimulated level. Only 2.3-fold induction was achieved 
in the BNBD5 case (Table 2). This shows that both basal activity and induction of the LAP 
promoter are significantly higher than those of the BNBD5 gene. This result is consistent with 
the finding that LAP is the most abundant -defensin encoding gene in MEC among the tested 
five members of that gene family.   
Table 2. Contrast basal activity and inducibility between the LAP promoter and the 
BNBD5 promoter 
Fold of pGL3 Basic 
Promoters 
Control Induction Fold induction 
BNBD5 2.4±0.3 5.4±1.4 2.3 
LAP 50.1±10.9** 296.8±58.6** 5.9 
HC11 cells were transiently transfected with 1.5 μg of the wild-type LAP promoter or the 
BNBD5 promoter, and either left uninduced or induced with 1×107 / ml heat-inactivated E.
coli 1303 for 24h. Shown were the luciferase activities relative to the uninduced promoterless 
pGL3 Basic. Results represent the mean  S.E.M. of two independent experiments. **, p < 
0.01.  
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3.5.2 The function of NF-B p65 or p50 in BNBD5 regulation is equivalent to that in 
LAP 
Since NF-B is essential for pathogen-mediated induction of the BNBD5 encoding gene in 
mammary epithelial cells (Yang et al., 2006), I wanted to know what function of the NF-B 
factors exert in regulating the BNBD5 expression. HC11 cells were transiently transfected 
with p65 or p50 expression vector and the BNBD5 reporter. The result showed that NF-B 
p65 transactivated the BNBD5 promoter to 40-fold in HC11 cells relative to mock group (Fig. 
24), whereas, NF-B p50 significantly repressed BNBD5 basal activity from 1 to 0.5 in the 
same cell line. In conclusion, the patterns of p65 activation and p50 repression to the BNBD5 
promoter are comparable to those of the LAP promoter as described in the previous part (cf. 
Fig. 13).  
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Figure 24. Functional analysis of NF-B in the BNBD5 promoter 
HC11 cells were transiently transfected with the wild-type BNBD5 reporter and equal 
amounts of NF-B p65 or p50 expression vector. Luciferase activities from whole cell lysate 
were assayed at 48h after transfection and were shown as the mean  S.E.M relative to the 
wild-type BNBD5 promoter.   
 
3.5.3 Both the NF-B-like site and the C/EBP-like site3 in the BNBD5 promoter differ 
from the canonical sites in the LAP promoter 
To find the reason for the differential levels of expressions between the BNBD5 promoter and 
the LAP promoter, the attachment sites of NF-B and C/EBP transcription factors in the two 
promoters were aligned. The data show that both C/EBP site1 and site2 are well conserved in 
the two promoters despite the locations are distinct (not shown). Combination with the data 
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from the LAP promoter, I focused on comparison of the crucial NF-B/CEBP3 overlapping 
site (Table 3). A canonical NF-B site (GGGGATTTCC) is encompassed in the LAP 
promoter, but only a NF-B-like site (GGGGTTTCC) in the BNBD5 promoter according to 
the consensus sequence of NF-B (GGGPuNNPyPyCC, Pu: purine, N: any nucleotide, Py: 
pyrimidine) (Ivanov et al., 1995; Weih et al., 2001). Comparison of the NF-B binding sites 
between the LAP- and the BNBD5 promoters indicates that the fifth base A is missing within 
NF-B binding site of the BNBD5 promoter (Table 3). Likewise, Comparison the C/EBP 
site3 sequence (TTTGGAAAC) in minus strand of the BNBD5 promoter with C/EBP 
consensus sequence T(T/G)NNGNAA(T/G) (Akira et al., 1990), the ninth conserved T/G 
within consensus sequence is changed into C in minus strand of the BNBD5 promoter. 
Similarly, this alteration results from the absence of the same base A in the NF-B/CEBP3 
overlapping site. Hence, the BNBD5 promoter contains two noncanonical sites, the NF-B-
like site and the C/EBP-like site3. 
Combining with the cotransfection data, the absence of single-base A has no effect on the 
function of NF-B in the BNBD5 promoter. I wanted to investigate whether the absence of 
base A influences the binding ability of NF-B to the BNBD5 promoter.  
Table 3. Sequence comparison of the NF-B/CEBP3 overlapping site between the 
BNBD5 promoter and the LAP promoter 
Promoter NF-B/CEBP3 overlapping site(+ strand) 
LAP GGGGATTTCCACA (-89/-77) 
BNBD5 GGGG TTTCCAAA (-191/-181) 
Note: the positions in the LAP promoter were determined relative to the major transcription 
start site (in the study). For the BNBD5 promoter, the transcription start site s1 was used as a 
reference (Yang et al., 2006). NF-B binding sites are indicated in underlined letters. The core 
sequences of C/EBP site3 in plus strand are shown in reverse arrows.   
 
3.5.4 NF-B factors bind with lower affinity to the BNBD5 promoter than to the LAP 
promoter  
To explain the above question, EMSA assays were conducted with nuclear extract from the 
uninduced HC11 cells and 18 h induced cells (Fig. 25). The labeled probes derived from the 
BNBD5 promoter and the LAP promoter, which contained respective NF-B binding sites. 
All complexes in Fig. 25A or Fig. 25B were resolved in the identical gels and nearly equal 
activity (cpm) of labeled probes was added in the BNBD5 and LAP reactions. In the BNBD5 
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case, p50 supershift bands were visible and induction increased the binding amount of NF-B 
to the BNBD5 promoter (Fig. 25A lane4 vs. lane6). This pattern was comparable with that of 
the LAP promoter (Fig. 25A right panel). However, it was obvious that stronger NF-B p50 
binding bands (3-fold) were found in the labeled LAP probe than the BNBD5 probe. Hence, 
the binding capability of NF-B p50 to the LAP promoter is stronger than that to the BNBD5 
promoter. In order to contrast the binding fashion of NF-B p65 to the two promoters, another 
EMSA (Fig. 25B) was conducted with equal amount of nuclear extract of the induced HC11 
cells for 2h, shorter than panel A (Fig. 25A, 18h). Similarly, more NF-B p65 bound to the 
LAP promoter than to the BNBD5 promoter (5.8-fold). Hence, the LAP promoter possesses 
much stronger binding ability for NF-B p65 than the BNBD5 promoter.  
Taken together, the absence of single-base A within NF-B binding site of the BNBD5 
promoter obviously attenuates the NF-B binding. The low affinity of NF-B cis-element for 
NF-B factors may be an important cause of lower basal activity and induction of the BNBD5 
promoter.  
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Figure 25. Comparison of binding ability of NF-B to the BNBD5 promoter and the 
LAP promoter by EMSA 
NEs were prepared from the uninduced HC11 cells and the induced cells for the indicated 
times. The labeled probes contained NF-B binding site from the BNBD5 promoter or from 
the LAP promoter, respectively. For the supershift reactions, antibodies were added prior to 
the labeled probes. FP: free probe, without NE; Cwt: the wild-type competitor; Cm6: the 
mutated competitor of NF-B site in the BNBD5 promoter as described (Yang et al., 2006) 
Cm: the mutated competitor (BmTTCC) of NF-B site in the LAP promoter (in the study); S: 
shift reaction; -p65, -p50: antibodies against p65 and p50; p65 ss and p50 ss: supershift 
bands indicated as arrows; C1, C2 and C3: NF-B specific complexes; ns: non-specific band. 
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Activity was analyzed by Image Quant 5.2 software of Molecular Dynamics and normalized to 
activity per cpm. A) 5 μg NEs were subjected into the reactions. 1 μg of anti-p50 is from 
rabbit origin. The activity of p50 ss from control NE to the BNBD5 probe is set as 1. B) 10 μg 
of NEs were explored except for FP. anti-p65 was added in the supershift reactions. The 
activity of p65 ss from 2h NE to the BNBD5 probe is set as 1. 
 
In conclusion, for the late immune -defensin genes, two main regulatory events happen in 
vivo. Firstly, induction decompacts chromatin which hereby becomes accessible for 
transcription factors.  Secondly, NF-B p65 is selectively recruited to the native chromatin 
and activates expression of the late -defensin genes. During the recruitment, affinity of 
promoters for NF-B p65 limits the expression of -defensin genes, and C/EBP factors play 
the repressive role by diminishing the activation of NF-B p65.  
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3.6 Transcriptional regulation of the early-immune-gene IL-8  
Considering the differential responses of proinflammatory genes and late immune genes to 
extracellular pathogen stimulus, I investigated the regulatory mechanism of the early-immune-
gene IL-8.   
 
3.6.1 Definition of the IL-8 promoter 
3.6.1.1 Time course of the IL-8 induction 
As described in section 3.1.2, I constructed the wild-type IL-8 promoter reporter gene, to 
confirm the inducibility of the construct and to select an optimal time span of induction, I 
analyzed the relative IL-8 promoter activity at the different induction times (10min, 20min, 
30min, 1h, 3h and 24h) in HC11 cells. The result showed that the IL-8 promoter activity did 
not increase until 1h after induction (Fig. 26 insert), and subsequently increased rapidly and 
reached maximal activity at 6h after induction. The continuous prolongation of the induction 
time reduced the IL-8 promoter activity and 69 % of the maximal activity was kept at 24h 
after induction (Fig. 26). Hence, I adopted 6h as time span for treatment with the inducer 
throughout the study. Furthermore, the data also indicate that the time course of the IL-8 
promoter activity in reporter gene assay in HC11 cells differs from that of the transcription of 
IL-8 in pbMEC cells (Fig. 6). Maybe, the transfected and “naked” promoter conceivably 
recruits a complement of TFs differing from that of the promoter of the residing endogenous 
gene. 
 
Figure 26. Induction of the IL-8 promoter 
HC11 cells were transiently transfected with the wild-type IL-8 promoter and induced at the 
different time points. The duration of pathogen in cells ranged from 10min to 24h. The cells 
were lysed with 100 μl passive lysis buffer (Promega) for 20 min at room temperature. The 
supernatant of lysate was measured firefly luciferase activity. The uninduced luciferase 
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activity is set as 1. The relative luciferase activity is given in y-axis. The experiment was 
duplicated independently and a representative experiment is shown. The error bar (S.E.M.) is 
from 3 parallel assays. The alteration of luciferase within 3h after induction is shown by 
insert. 
 
3.6.1.2 Determination of the transcription start site (+1) of the IL-8 gene 
A similar strategy as applied for analysis of the regulation of the late-immune-gene was used 
to analyze the transcriptional regulation of the IL-8 gene. A 5 RACE amplification 
experiment was applied to determine the transcription start site of the IL-8 gene. The 5 UTR 
identified here conforms by 100% with the Bos taurus chromosome 6 genomic contig 
(Sequence # NW_001495205.2) as deposited in the EMBL database. The TATA box lies in  
-29/-24 upstream the transcription start site (+1). The start codon of translation ATG resides 
at position +85 (Fig. 27).  
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Figure 27. The determination of the transcription start site (+1) of the IL-8 gene 
Total RNA, which derived from pbMEC induced for 1h with 1×107/ml heat-inactivated E.
coli strain 1303, was dephosphorylated, decapped sequentially. The RNA Oligo was ligated to 
decapped mRNA and reversely transcribed into cDNA. The resulting cDNA end was 
amplified by primary and nested PCR. The strongest fragment was purified and ligated into 
pGEM®-T Easy. Five clones were sequenced and the sequences were blasted with bovine 
genomic DNA. A) 2% agarose gel stained by ethidium bromide, lane 1: DNA marker, lane2: 
the nested PCR products amplified with the GeneRacer™ 5 nested primer and the IL-8 
specific reverse primer (s1112, IL8_R3). B) Alignment of 5UTR and genomic DNA, the 
numbers indicate the position of the last base in each line.  
  
3.6.1.3 In silico identification of putative transcription factor binding sites in the IL-8 
promoter 
Analysis of the promoter sequence with the MatInspector software reveals four putative AP1 
binding sites, two NFAT binding sites, three C/EBP binding sites and one NF-B binding site 
in the retrieved 1389 bp-IL-8 promoter. The C/EBP binding site closest to the transcription 
start site (+1) is designated C/EBP site1. Among three potential C/EBP sites, C/EBP site2 is 
overlapping with a NF-B binding site in the proximal IL-8 promoter (Fig. 28).  
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Figure 28. Analysis of putative transcription factors bind to the IL-8 promoter 
The binding sites of putative transcription factors were analyzed with software MatInspector 
in http://www.genomatix.de. The transcription start site (+1) was determined by 5 RACE.  
 
3.6.2 Experimental identification of cis-elements crucially relevant to IL-8 expression 
and induction  
To define the elements relevant for IL-8 expression and induction, a series of deletion 
plasmids were constructed on the basis of computational analysis of putative transcription 
factors and were transiently transfected into HC11 cells. After induction for 6h with heat-
inactivated E. coli, the IL-8 reporter gene activity was found to be 5.3-fold higher than that of 
the uninduced control (Fig. 29). Serially shortening the promoter from -1294 down to -345 bp 
altered neither the basal activity nor the extent of activation. However, deleting the area 
between -121 and -56 bp effectively diminished both basal and induced promoter activity. 
The importance of this short element was verified by selectively removing the short segment 
of 29 bp out from the wild-type reporter plasmid (-1294). This short deletion (C/B) 
completely abolished the promoter activity. One putative NF-B site and two proximal 
C/EBP sites are included within the short segment. Hence, the 29 bp segment (-93/-64) with 
putative NF-B and two C/EBP binding sites is pivotal for IL-8 basal activity and induction 
(Fig. 29). 
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Figure 29. Identification of elements relevant to IL-8 expression and induction in HC11 
cells 
Schematic representative of 5 serial deletions and the deletion (C/B) of the proximal 
region of the IL-8 promoter is shown on the left. The names of clones are indicated on the 
left. The relative positions of various transcription factors are shown by vertical rectangle 
with different fills on the wild-type IL-8 promoter (-1294). Except that clone C/B deletes 
29 bp of the proximal region, the other IL-8 promoter luciferase reporter constructs contain 
different 5 ends and the same 3 end at + 95 bp relative to the transcription start site. HC11 
cells were transiently transfected with 1 μg of the wild-type IL-8 luciferase reporter constructs 
or serial deletion constructs. 42h after transfected, cells were induced for 6h with 1×107 /ml 
heat-inactivated E. coli 1303. The luciferase activity of the wild-type IL-8 promoter is set as 
1. 
 
3.6.3 Induction quickly converts NF-B p65/p65 homodimers to p65/p50 heterodimers 
in vivo 
The transcription of the IL-8 gene is already increased strongly at 1h after induction by E. coli 
(Fig. 6). I wanted to know whether the promoters of more cells are occupied by RNA 
polymerase II molecules at the same time point in vivo. To this end, I analyzed the 
recruitment of RNA polymerase II to the IL-8 promoter with the ChIP assay. The data showed 
that induction led to more cells (4-fold) opening their promoters for RNA Polymerase II 
relative to the uninduced cells (not shown). Hence, the assay provides convincing evidence 
that an increase of cells having recruited RNA polymerase II is the cause of stronger 
transcription at 1h after induction.  
Furthermore, I analyzed the recruitment of NF-B p65, p50 and C/EBP to native IL-8 
chromatin. I precipitated the chromatin with specific antibodies (anti NF-B p65, p50 and 
C/EBP) and non-specific control IgG. ChIP assay showed that NF-B p65, but not p50 
occupied the inactive IL-8 promoter. However, induction quickly recruited p50 to the active 
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promoter. After induction for 24h, no NF-B bound to the IL-8 promoter, and the IL-8 
promoter went back to basal activity (Fig. 30A). Therefore, induction alters the composition 
of NF-B from p65/p65 homodimers on the quiescent promoter to p65/p50 heterodimers on 
the maximally stimulated IL-8 promoter. Surprisingly, cells having recruited C/EBP were 
not significantly increased after 1h stimulation with heat-inactivated E. coli (Fig. 30B).  
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Figure 30. ChIP analysis of recruitment for NF-B and C/EBP to the IL-8 promoter in 
pbMEC  
ChIP assays were carried out with chromatin from control and the induced pbMEC cells as 
the indicated times with heat-inactivated E. coli 1303. Antibody against NF-B p65, NF-B 
p50, C/EBP or control IgG is indicated. Immunoprecipitated DNA was amplified by 
quantitative real-time PCR with specific primers for the IL-8 promoter.   
 
3.6.4  Functional analysis of NF-B or C/EBP in the IL-8 promoter 
3.6.4.1 NF-B regulates the IL-8 promoter activity in a cell-type specific fashion 
To examine the function of NF-B in regulation of the IL-8 gene, equal or increasing amounts 
of the expression vectors for NF-B p65 or p50 were cotransfected into pbMEC or HEK 293 
cells, together with the reporter gene driven by the wild-type IL-8 promoter. In the human 
embryonic kidney cell line, HEK293, NF-B p65 strongly activated the IL-8 promoter to 3.5-
fold over the untreated level, and p50 did not affect the promoter activity (Table 4). This 
result could be expected, since NF-B p65 is known to have a transactivation domain, which 
is deficient in NF-B p50.  
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Table 4. The effect of NF-B factors on the IL-8 promoter in HEK293 cells  
NF-B  
- p65 p50 
IL-8 reporter activity 1.000.05 3.540.08 1.040.01 
1 μg of NF-B p65 or p50 expression construct was cotransfected in human embryonic 
kidney cell (HEK293) together with 1μg of the wt IL-8 reporter. The amount of total DNA 
was kept constant by supplement with empty vector pCDNA 3.1+. 
 
Surprisingly, NF-B factors diminished the IL-8 promoter activity in pbMEC (primary bovine 
MEC) cells. With the increasing amounts of transfected p65 or p50 from 0.1, 0.5 to 1.5 μg, 
the basal activity and extent of induced expression of IL-8 were reduced in a dose-dependent 
manner. The effect of p65 was quicker than that of equal amounts of p50 (Fig. 31). Taken 
together, both NF-B p65 and p50 regulate the IL-8 promoter activity in a cell-type specific 
manner. 
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Figure 31. NF-B regulates the IL-8 promoter activity in a cell-type specific manner  
Constant amount of the wt IL-8 reporter and increasing amounts of NF-B p65 or p50 
expression construct (0.1, 0.5 and 1.5μg) were cotransfected into primary bovine MEC 
(pbMEC). The activity of the wt IL-8 promoter is always set as 1. The other details were 
described in Materials and Methods.  
 
To validate the observation, I preincubated pbMEC cells with the inhibitor PDTC (pyrrolidine 
dithiocarbamate), known to block NF-B activation, and evaluated the alteration of IL-8 
transcription by real-time PCR. The data showed that IL-8 was de-repressed and mRNA copy 
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numbers were increased to 6 fold after preincubation with PDTC (Fig. 32). This provides 
further evidence that NF-B represses IL-8 basal expression in MEC cells.  
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Figure 32. Effect of NF-B inhibitor PDTC on IL-8 transcription in pbMEC 
pbMEC cells were pretreated with 50 μM PDTC for 1h. Total RNA was prepared with TRizol 
reagent, and reversely transcribed into cDNA. mRNA copy numbers were measured by real-
time PCR as described in Materials and Methods.  
 
To determine the relevant site of the transfected NF-B effect in IL-8 regulation, clone  
C/B lacking NF-B binding site was cotransfected into HC11 cells together with the 
expression construct of p65 or p50. Compared with the wild-type IL-8 promoter, the mutant 
blocked the cell-type specific effect of NF-B completely (not shown). The data show that the 
region from -93 to -64 is the acting site of NF-B factor.  
Hence, NF-B regulates IL-8 expression via motif -93/-64 in a cell-type specific fashion.  
 
3.6.4.2 C/EBPs activate IL-8 expression mainly through the proximal C/EBP sites  
To inspect the function of C/EBP members in the IL-8 expression, HC11 cells were 
transiently transfected with equal amounts of full length C/EBPs expression vectors (, ,  
and ) or equal amounts of DN-C/EBPs (Dominant Negative-C/EBPs) expression vectors, 
together with the wild-type IL-8 reporter (clone -1294). The data showed the overexpressed 
C/EBP members (, ,  and ) markedly activated the IL-8 promoter with the different 
efficiencies (Fig. 33A) in HC11 cells. The activation folds of the respective factors (the 
luciferase activity of the untreated is set as 1) were 20-, 10-, 7-, 2-fold for C/EBP---, 
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and -respectively. Hence, the amount of endogenous C/EBP is a rate-limiting factor to the 
IL-8 promoter. The similar activation (2-fold activation) is obtained in pbMEC cells 
cotransfected with C/EBP (not shown. In contrast, DN-C/EBP members diminished IL-8 
activity due to the absence of transactivation domains (not shown). Hence, the transactivation 
domains of C/EBPs are indispensable to activate IL-8 expression in MEC.  
Furthermore, to decide the main acting site of C/EBP factors, the mutant C/B was 
cotransfected together with C/EBP factors into HC11 cells. C/EBP-mediated activation to the 
IL-8 promoter was decreased dramatically relative to those of the wild-type promoter (Fig. 
33B). However, C/EBP still activated the mutant C/B to 5.2-fold relative to the activity of 
the wild-type IL-8 promoter, even if the two proximal C/EBP sites were deleted. This shows 
that C/EBP activates the IL-8 promoter not only by the proximal sites but also by the distal 
site (-601/-593, Fig. 28). Taken together, the two proximal C/EBP sites from -93 to -64 are 
the main acting sites of C/EBPs.  
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Figure 33. Effect of C/EBPs alone or combined with NF-B p65 on the IL-8 promoter in 
HC11 cells 
HC11 cells were transiently transfected with 1 μg of the wild-type IL-8 reporter (clone -1294) 
(A or C) or the deletion-construct, IL-8 C/B (B) and 1μg of C/EBPs expression vectors 
and/or equal amounts of NF-B p65. Cells were induced for 6h with heat-inactivated E. coli 
1303 before harvest (black column) or without treatment (hatched column). Fold activation 
was presented relative to the luciferase activity of the IL-8 promoter. Total amount of 
transfected DNA was kept constant by adding empty vector. After transfection for 48h, cells 
were lysed and assayed luciferase activity according to the manufacturer’s manual. 
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3.6.5 NF-B p65 attenuates the C/EBP-mediated activations of the IL-8 promoter 
To analyze synergistic effects of C/EBPs (, ,  and ) and NF-B p65 on the IL-8 promoter, 
the wild-type IL-8 reporter gene was cotransfected with or without NF-B p65 and C/EBPs 
expression vectors into HC11 cells. Compared Fig. 33C with Fig. 33A, NF-B p65 reduced 
the activation of C/EBP factors on the IL-8 promoter. Only C/EBP kept its partial potential 
to activate the IL-8 promoter in the presence of p65. Other C/EBP- and - had no 
obvious effect on the IL-8 promoter activity in HC11 cells at the same condition (Fig. 33C).  
 
The data together show that overexpression of NF-B p50 quenches the IL-8 promoter 
activity in pbMEC cells, also in HC11 cells. However, NF-B p65 has different effects in 
pbMEC cells compared with in HC11 cells on the IL-8 promoter activity. In pbMEC cells, 
p65 always and strongly reduces the IL-8 promoter activity. In HC11 cells, NF-B p65 does 
not alter the IL-8 promoter activity (not shown). Furthermore, it disrupts the activating effect 
of the C/EBP-and
Taken ChIP data that NF-B p65 homodimers reside on the 
resting IL-8 promoter together, NF-B p65 homodimers insulate the IL-8 promoter against 
active C/EBP factors by the proximal site. 
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4. DISCUSSION 
 
4.1 The concepts in inflammatory/immune response and mastitis 
TLR receptors (Fig. 34) recognize pathogens and activate downstream adaptor molecules such 
as MyD88 or TRIF (Akira and Takeda, 2004). As a result, latent cytoplasmic NF-B factors 
are activated and translocate into the nucleus. NF-B heterodimers or homodimers recognize 
the cognate binding site (Leung et al., 2004) and induce expression of NF-B-dependent 
genes. These include inflammatory mediator genes, such as IL-8, TNF, and also effector 
genes of innate immunity, such as -defensin encoding genes. IL-8, as a chemoattractant, 
recruits neutrophils to the site of inflammation (Fig. 34). Afterwards, neutrophils release their 
toxic contents. Since the toxic contents do not discriminate between the extracellular pathogen 
and the host itself, the collateral damage to host is unavoidable (Nathan, 2002). Hence, the 
inflammatory response of the host must be tightly regulated. However, on the other hand, the 
expression of antimicrobial peptide encoding genes, such as LAP and BNBD5, protects the 
host from infection. Hence, it is valuable to investigate the precise modulation of the innate 
immune response and inflammation for selective control.  
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Figure 34. The activated TLR signalling pathway by E. coli or LPS 
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Moreover, chronic mastitis, as a prevalent inflammation in dairy cows, also results from the 
interplay between host and pathogen. In order to find alternative strategies to decrease the 
incidence of chronic mastitis, one needs to understand the key regulatory event of 
inflammatory and innate immune response in the mammary gland. To date, little is known 
about regulation of inflammation and immune defence in this organ.  
It has been known that mammary epithelial cell (MEC) is the dominant cell type in 
parenchyma of mammary gland. It is a front line which meets pathogens invading the 
mammary gland. Its relevance for inflammation surveillance and also for immune defence has 
only recently been well appreciated (Gunther et al., 2009; Strandberg et al., 2005). Hence, 
MEC is suitable cell model for exploring the immune and inflammatory response mechanism 
of mammary gland.  
Proinflammatory cytokine and antimicrobial peptide are typical samples of NF-B-dependent 
target genes and play completely different roles in host defence system. In bovine MEC, E.
coli strongly induces the expression of proinflammatory cytokine IL-8 (Yang et al., 2008), 
and LAP is the dominant antimicrobial peptide in the identical cells (Wei Yang’s 
dissertation). Therefore, in the study, I chose the IL-8 and the LAP gene as paradigms for 
“sentinel” and “effector” respectively to identify at the molecular level the key regulators for 
mammary immune defence and inflammation.   
        
4.2 NF-B and C/EBP factors are crucial for inflammation and innate immune response 
In the present study, four lines evidences indicate that both NF-B and C/EBP factors are 
crucial for inflammatory and immune response genes (IL-8 and LAP) expression.  
Firstly, serial deletion and mutation analyses indicate that both NF-B and C/EBP binding 
sites are essential for basal activity and induction of early (IL-8) and late (LAP) immune 
responsive genes in bovine (Fig. 9, 10 and 29).  
Secondly, NF-B and C/EBP can bind to the LAP probe in EMSA assay (Fig. 11 and 14). 
Thirdly, ChIP data show that only p65 is recruited to the activated LAP promoter (Fig. 12). 
Differently, the active IL-8 promoter is occupied with p65/p50 and C/EBP factors (Fig. 30). 
Finally, cotransfections of NF-B or C/EBP expression vectors demonstrate that they play 
important roles in both IL-8 and LAP activation (Fig. 13, 15, 31 and 33A).  
In agreement with the current findings, NF-B is long known to induce multiple 
inflammatory genes expression, for example, pro-inflammatory cytokines IL-8 (refers to the 
following section), IL-6 (Libermann and Baltimore, 1990), GM-CSF (Cakouros et al., 2001), 
adhesion molecules [ICAM-1] (Rajan et al., 2008). As stated in the introduction section, 
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C/EBP is also known as key trans-acting factors in inflammation and immune response. 
C/EBP-deficient mice impair expression of proinflammatory cytokine IL-12, TNFG-
CSFetc. (Screpanti et al., 1995; Tanaka et al., 1995). C/EBP and NF-B p50 are also 
implicated in cytokine-induced regulation of the CRP encoding gene (Singh et al., 2007).  
 
4.3 Roles of AP1, NF-B and C/EBP factors in IL-8 regulation 
Extensive studies were focused to elucidate the roles of transcription factors in the regulation 
of human IL-8 expression. However, little is known about their roles in regulating the 
expression of the bovine IL-8 encoding gene, especially in the MEC. Alignment of the bovine 
and the human IL-8 promoters reveals that the binding sites of AP1 and NF-B share 100 % 
identity between the two species. In the bovine proximal IL-8 promoter, there are two C/EBP 
binding sites (C/EBP site1 and C/EBP site2). C/EBP site2 overlaps with NF-B site at -93/-
81, and C/EBP1 stands alone. In contrast, the human IL-8 promoter only features one C/EBP 
site residing upstream of the NF-B binding site, not overlapping with the latter one 
(Roebuck, 1999). This indicates that the two transcription factors may play different roles in 
the two species in regarding the regulation of the IL-8 promoters.  
Several previous studies show that NF-B, C/EBP and AP1 display distinct roles in the 
human IL-8 regulation, dependent on different cell-types and various stimuli (Roebuck, 
1999). For example, induction of the human IL-8, by IL-1phorbol myristate acetate (PMA), 
Pseudomonas aeruginosa or TNF requires synergistic activation of NF-B and C/EBP 
(Kunsch et al., 1994; Mukaida et al., 1990; Stein and Baldwin, Jr., 1993; Venza et al., 2009). 
AP1 is involved in the human IL-8 activation in response to an IL-1 or a bradykinin stimulus 
in human vascular or airway smooth muscle cells (Jung et al., 2002; Zhu et al., 2003). In 
contrast to these reports, the current result shows that the deletion encompassing two proximal 
AP1 binding sites does not obviously influence the bovine IL-8 induction in MEC, and only 
slightly decreases basal activity (Fig. 29). It seems that AP1 is not essential for the bovine IL-
8 regulation after stimulation of MEC by heat-inactivated E. coli. However, it was reported 
that both AP1 and NF-B binding sites are responsible for activating the human IL-8 gene 
expression in other epithelial cell lines (Okamoto et al., 1994; Yasumoto et al., 1992). This 
discrepancy may result from i) different cis-elements of the IL-8 promoter in the two species; 
ii) cell-type specificity; iii) stimulus specificity; or iv) all these differences together.  
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4.3.1 Role of NF-B factors in bovine IL-8 regulation 
My results show that NF-B p65/p65 homodimers block IL-8 basal expression. In support of 
this, ChIP experiments conducted in vivo in bovine MEC cells indicate that NF-B factors 
p65 homodimers, but not p65/p50 heterodimers reside on the resting IL-8 promoter. 
Consistent with the observation, functional analyses show that NF-B p65 represses the IL-8 
promoter in pbMEC cells. PDTC, extensively used as an inhibitor of NF-B activation 
(Brennan and O'Neill, 1996), allowed to further evaluate the effect of NF-B on the IL-8 
promoter activity. The data indicates that after NF-B activation is blocked by inhibitor 
PDTC, the IL-8 promoter is derepressed and the mRNA expression is increased to 6-fold (Fig. 
32). All these results show that p65/p65 homodimers block IL-8 basal expression. This is in 
contrast to the previous notion that NF-B complexes are absent in nuclei and solely 
sequestered in cytosol in the unstimulated cells. However, as shown in Fig. 20, NF-B is 
present in substantial amounts in nuclei of the resting cells amounting to 20-30% of that at 2h 
after induction. In agreement with the observation, recent findings show that NF-B 
dynamically shuttles between cytosol and nucleus (Birbach et al., 2002; Huang et al., 2000; 
Tam et al., 2000). Therefore, a steady state and low level of NF-B p65 is always present in 
the nuclei irrespective of the presence or absence of stimulus. Furthermore, Wada et al. 
reported that p65/p65 homodimers have DNA binding activity (Wada et al., 2001). Hence, it 
is reasonable to find that NF-B p65 resides on the resting IL-8 promoter.  
However, p65 is known to contain transactivation domain necessary to activate genes 
(Schmitz and Baeuerle, 1991). The key issue is which mechanism makes NF-B p65 repress 
but not activate the basal transcription of IL-8. It is possible that NF-B p65 interacts with 
transcriptional corepressor factors to block the IL-8 gene activity. Lee et al reported that the 
cotransfection of SMRT corepressor (the Silencing Mediator of Retinoic acid and Thyroid 
hormone receptors) together with p65 decreases p65-mediated activation (Lee et al., 2000). 
Another supportive report is that HDAC1, known to have deacetylation activity, is involved 
in NF-B p65-mediated repression to the death gene Bnip3 (Shaw et al., 2006). Additionally, 
HDAC1 interplays with NF-B p65 and the HDAC inhibitor trichostatin A (TSA) causes an 
increase of both basal and induced expression of the hIL-8 promoter (Ashburner et al., 2001). 
More evidences confirm that deacetylation of p65 represses genes expression (Yeung et al., 
2004).  
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More importantly, the occupancy of p65/p65 homodimers in the IL-8 promoter also provides 
a clue that the chromatin of the IL-8 promoter in the resting pbMEC cells appears to be 
accessible to transcription factors.  
In contrast to NF-B p65/p65 homodimers binding to the resting promoter, only stimulus-
induced NF-B p65/p50 heterodimers are necessary for bovine IL-8 activation. Since ChIP 
data indicate that induction rapidly alters NF-B p65/p65 homodimers into NF-B p65/p50 
heterodimers (Fig. 30A). NF-B p65/p50 heterodimer is reported to be the most abundant 
form of NF-B and is known to act as a strong transactivator (Chen and Ghosh, 1999). I 
surmise that the repressive NF-B p65 in resting cells seems to be different from the p65 
molecule in the active state. NF-B p65 binding to the active promoter has possibly been 
phosphorylated. Four phosphorylation sites (Ser276 and Ser311 in RHD and Ser529 and Ser 536 in 
TAD) were found to be crucial for the complete activation of p65 (Duran et al., 2003; Perkins, 
2006; Wang et al., 2000; Zhong et al., 1998). The previous report also indicates that LPS 
stimulation causes the nuclear translocation of the NF-B complexes containing 
phosphorylated p65 by PKA to activate transcription (Zhong et al., 2002).  
  
4.3.2 Role of C/EBP factors in bovine IL-8 regulation 
A well documented event is that C/EBP factors are involved in inflammatory response and 
immunity (Cloutier et al., 2009; Singh et al., 2007). In agreement with these findings, my data 
demonstrate that C/EBP activates the proinflammatory gene IL-8 expression following a 
pathogen stimulus. Transient transfection assays show that different C/EBP factors activate 
the bovine IL-8 promoter at different extents. The activation potentials for the factor C/EBP-
andin descending order are20-, 10-, 7- and 2-fold, respectively (Fig. 33A).  
Surprisingly, ChIP data show that C/EBPfactors seemingly unchangedly occupy the IL-8 
promoter at all times irrespective of induction (Fig. 30B). As my study has been completed, a 
recent observation showed that the C/EBP factor is constitutively bound to the human IL-8 
promoter, both in resting and LPS-activated neutrophils (Cloutier et al., 2009). This 
observation perfectly matches my finding. I surmise that C/EBP seems to be activated by 
phosphorylation. Interestingly, C/EBPis induced by phosphorylation of Thr235 by a Ras/ 
MAPK pathway (Nakajima et al., 1993) and the inductive expression of IL-8 is regulated by a 
mitogen-activated protein kinase pathway (MAPK) (Jung et al., 2002; Smith et al., 2001).  
Alternatively, it is also known that C/EBP factors have multiple isoforms from different AUG 
initiation codons with the same open reading frame (Welm et al., 1999). Among them, 
C/EBP has three dominant isoforms and various isoforms display different transcription 
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activation potentials (Ossipow et al., 1993). Conceivably, selective binding of different 
C/EBP isoforms leads to the different activities of the IL-8 promoter before and after 
stimulation. A supportive evidence is that synthesis of the different C/EBP isoforms is 
regulated by LPS in liver (An et al., 1996). Combination of different isoforms is dependent on 
cell type and culture conditions (Descombes and Schibler, 1991). The results suggest that a 
complicated mechanism regulates synthesis of C/EBP isoforms in a given cell line. More 
experiments are required to elucidate the issue. 
In conclusion, C/EBP but not NF-B factors activate IL8 activity. NF-B p65 homodimers 
insulate the IL-8 promoter against C/EBP factors. 
 
4.4 Molecular mechanism of LAP 
Regarding molecular mechanism controlling -defensin expression, extensive researches have 
previously seen to understand the regulation of the human hBD-2 and the bovine TAP, 
BNBD5. Very little is known about regulation of the predominant member of bovine -
defensin in bovine MEC, which is LAP. My study provides a detailed analyses regarding 
molecular control mechanism of that important late immune responsive gene both at the 
chromatin level and at the transcriptional level.  
 
4.4.1 Roles of chromatin remodeling and DNA methylation in LAP regulation 
A number of genes have been shown to be regulated by chromatin remodeling (Albrecht et 
al., 2004; Holloway et al., 2003; Rao et al., 2001). Moreover, only delayed accessible genes, 
but not fast accessible genes, require stimulus-dependent chromatin remodeling to make the 
NF-B sites accessible (Saccani et al., 2001). Consistent with the reports, the present study 
demonstrates that the chromatin structure within the binding region of NF-B and C/EBP 
factors is significantly remodeled in the LAP promoter after challenging the udder with live 
pathogens for 24h. The tightly condensed LAP promoter is opened (Fig. 22). However, a 
different pattern appears in the cell model pbMEC. The CHART result indicates that the LAP 
promoter chromatin in pbMEC is not significantly remodeled after induction. The degree of 
protection of the chromatin at the different conditions (unstimulated, 6h and 21h after 
induction) is unchanged and maintains at about 85% (data not shown). It seems that in the 
MEC model cell, chromatin is always open for transcription factors. Thus, the cell model 
pbMEC can not completely reflect all those physiological mechanism operating in the udder 
tissue. This assumption is supported by a recent report (Gunther et al., 2009).  
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It is generally assumed that DNA methylation within the promoter region represses the gene 
transcription (Nan et al., 1997; Newell-Price et al., 2000). As stated above, the LAP 
chromatin is decompacted and transcription is more active in response to pathogen-stimulus. 
However, pathogen invasion causes unusual hypermethylation of CpG site11 (located at -50) 
contiguous to NF-B binding site (-89/-80) at the identical time point. That is, in this case, the 
hypermethylation is associated with chromatin decompaction. This is unexpected. 
Interestingly, it is well-documented that methylation of the promoter for an immediate-early 
“frog virus3” encoding gene and adenovirus promoter do not inhibit transcription. Trans-
acting protein of the host or the virus-induced can override the inhibitory effect of 
methylation to facilitate the transcription (Thompson et al., 1986; Thompson et al., 1988). 
Furthermore, it is also possible that Coactivator-associated Arginine Methyltransferase 
(CARM1), which is responsible for histone H3 methylation of NF-B-dependent genes, 
enhances NF-B p65 recruitment to the LAP promoter by interaction. The supportive 
evidence is that CARM1 enhances NF-B p65 recruitment to the target promoters (Covic et 
al., 2005). Although many possibilities are given for the unusual case here and someone also 
argues that the association between DNA methylation and gene silence may not be causal (Li 
et al., 1992), it remains open for further analyses if and how the observed hypermethylation at 
the LAP promoter influences the transcription of the LAP gene. 
 
4.4.2 Role of transcription factors in LAP regulation 
4.4.2.1 NF-B p65 drives the late-gene LAP expression 
NF-B factors are crucial in -defensin regulation. LPS activates the NF-B p65/p50 
heterodimer binding to the NF-B binding site in the proximal hBD-2 promoter (O'Neil et al., 
1999; Tsutsumi-Ishii and Nagaoka, 2002), resulting in upregulation of hBD-2 transcription. 
Serial deletion of the TAP promoter and EMSA show that NF-B p50 and p65 are involved in 
the TAP regulation (Diamond et al., 2000). Another evidence stems also from NF-B SN50, a 
peptide inhibiting translocation of the p50-containing NF-B active complex to the nucleus, it 
reduces TAP mRNA expression in bovine tracheal epithelial cells (Legarda et al., 2005). A 
more recent report shows that the bovine BNBD5 induction depends on binding of NF-B 
(Yang et al., 2006). In the present study, deletion and mutation analysis of the LAP promoter 
clearly shows that the NF-B binding site is crucial for the basal activity of LAP and also for 
its induction (Fig. 9 and 10). NF-B factors both p65 and p50 can bind to the site as 
evidenced in EMSA assays (Fig. 11A). Cotransfection experiments demonstrate that only p65 
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strongly activates the LAP promoter (Fig. 13). This conclusion is augmented by ChIP 
analysis. Twenty four hours after induction, the percentage of cells having recruited p65 to the 
active LAP promoter is dramatically increased. Thus, NF-B p65 is the major activator for 
LAP expression. This is convincing, since NF-B p65 possesses transactivation domain 
(TAD). This coincides with a previous observation that the fusion construct of full-length p65 
sequences to DNA binding domain of the yeast GAL4 transcription factor strongly increased 
a CAT reporter activity (Schmitz and Baeuerle, 1991). The mutation of Ser529 in the TAD of 
p65 into Ala blocks the ability of p65 to activate transcription in response to TNF(Wang 
and Baldwin, 1998). 
 
4.4.2.2 C/EBPs repress the late-gene LAP expression 
In contrast to NF-B, C/EBPs repress p65-mediated activation of LAP expression. In accord 
with my observations, a previous report has shown that C/EBP suppresses the NF-B-
mediated transactivation of the HCMV IE1/2 promoter (Human Cytomegalovirus IE1/2 
promoter). EMSA analysis has demonstrated that NF-B and C/EBP synergistically bind to 
the same oligonucleotide probe and form a heavier complex (Prosch et al., 2001). In contrast, 
my EMSA assay shows that NF-B and C/EBP can not bind to the same oligonucleotide 
molecule (Fig. 19). They may competitively bind to the NF-B/CEBP overlapping site. 
Probably spatial hindrance makes the overlapping site inaccessible for simultaneous binding 
of both factors. This conclusion is supported by another report that the NF-B-like Bpi 
protein (a cytokine inducible protein) competes with the constitutive C/EBP-like BPcs protein 
(constitutive proteins) for the NF-B/CEBP overlapping sites on the APRE (Acute-Phase 
Response Element) promoter (Brasier et al., 1990). My EMSA also shows that the LAP 
promoter has higher affinity for NF-B factor than for C/EBP factor. It seems that the 
proportion of endogenous NF-B over C/EBP factors is another regulatory mechanism in 
LAP regulation. 
 
4.5 Both the IL-8 and the LAP genes are regulated in a cell-type specific manner   
As stated previously, whether a specified transcription factor is involved in the target gene 
regulation appears to depend on cell types. Now, even if the same factor is involved in the 
regulation of a given gene, it displays distinguishable functions in different cell types. We 
chose the predominant factors of NF-B family, p65 and p50 to address the question. I 
contrasted the activation extent of the two factors for the target paradigm genes, the IL-8 gene 
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and the LAP genes, in MEC and in HEK293 cells. The MEC model is the mouse MEC (HC11 
cell line). HEK293 is an embryonic kidney cell line. The results are summarized in Table 5. 
The data shows that, in the case of IL-8, i) p65 displays an opposite pattern in MEC versus in 
HEK293. p65 significantly decreases the activity of the IL-8 luciferase reporter gene in MEC. 
Especially in pbMEC, a stronger decrease is observed. Contrarily, in HEK293, p65 obviously 
increases the activity of the same reporter gene. ii) p50 reduces the IL-8 luciferase reporter 
gene activity in MEC but has no effect in HEK293. Taken the above data together, the bovine 
IL-8 gene is regulated in a cell-type specific manner, which is comparable with the human IL-
8 regulation (Roebuck, 1999).  
Regarding the LAP encoding gene, p65 activates the LAP promoter-driven luciferase activity 
both in MEC and HEK293, stronger in HEK293 than in MEC. However, p50 regulates the 
activity in opposite directions contrasted in MEK with in HEK293. Hence, the LAP gene is 
also regulated in a cell-type specific manner. 
The cell-type specific regulation possibly results from the cell-type specific complement of 
auxiliary transcription factors present in different cell types. These may be mandatory to relay 
the effect of those key transcription factors (e.g. NF-B, C/EBP) onto the promoter of the 
respective target genes. 
 
Table 5. Summary for cell-type specific regulation of the IL-8 and the LAP genes   
 
 MEC HEK293 
 IL-8 LAP IL-8 LAP 
p65 Blocked Activated Activated Activated 
p50 Blocked Blocked Neutral Activated 
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4.6 Two-level tight regulation results in expression in temporal order of different 
effector genes in inflammatory and immune response 
IL-8 
LAP
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Figure 35. Model for transcriptional regulation of IL-8 and LAP in response to heat-
inactivated E. coli 
On the basis of the present findings, a model is proposed (Fig. 35). As a paradigm for 
“sentinel” gene, early IL-8 gene initiates rapidly transcription (refer to fig. 6) in response to 
heat-inactivated E. coli stimulation. Once being stimulated, the IL-8 promoter replaces 
immediately the p65/p65 homodimers from shuttling with the translocated and the activated 
NF-B p65/p50 heterodimers. Interestingly, NF-B p50 is known to physically interacts with 
C/EBPto induce CRP expression (Cha-Molstad et al., 2000). Hence, p65/p50 heterodimers 
probably interact with the active C/EBP factors to activate pathogen-mediated IL-8 
expression. The early gene may enhance its inducible expression by fast post-translation 
modification of transcription factors. Regulation of the gene expression is rapid and tight.  
In contrast, continuous expression of the late induced LAP gene is beneficial for protecting 
the host from infection. As the present data indicate, the late LAP gene is regulated at two 
levels. The first one is regulation at the chromatin level. The chromatin is strictly condensed 
in the resting state, and transcription is almost blocked and the basal expression is very low. 
Twenty-four hours after challenged with live E. coli pathogens, the LAP promoter chromatin 
is opened (Fig. 22), and NF-B p65 is recruited (Fig. 12) to activate the LAP promoter 
activity (Fig. 13). However, chromatin remodeling mechanism cannot be studied in detail, 
since the most adequate cell model, the pbMEC, apparently does not display these changes in 
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chromatin compaction at the LAP promoter. Nevertheless, the ChIP data clearly show that 
induction greatly increases the percentage of cells having recruited p65 onto the LAP 
promoter. This occurs independently from chromatin remodeling. Unexpectedly, amount of 
cells having recruited p65 is not obviously increased within 3h after induction (Fig. 12). It is 
not consistent with the fact that NF-B molecules in nuclei are nearly the most at the same 
time point (Fig. 20). Hence, factors independent from chromatin structure are also highly 
relevant for NF-B p65 recruitment onto the LAP promoter.  
Extensive evidences support the current findings that the two groups of NF-B-dependent 
genes (inflammatory mediator and antimicrobial peptide) exhibit differential expression and 
modulation (Fig. 35). Recent studies suggest that TLR-induced genes in an in vitro system of 
LPS tolerance are categorized into two classes, class T and class NT. The former includes 
pro-inflammatory mediators. The latter includes antimicrobial gene. They display distinct 
patterns of histone modifications (Foster et al., 2007). Interestingly, another report shows that 
NF-B binding occurs in two distinct “waves” in LPS-stimulated macrophages, a fast 
recruitment to constitutively and immediately accessible promoters and a late recruitment to 
inductively and lately accessible promoters. The latter promoters require stimulus-dependent 
modifications in chromatin structure to make NF-B site accessible (Saccani et al., 2001). A 
validated microarray data analysis and hierarchical clustering have also shown distinct 
expression profiles of NF-B-dependent genes in response to TNF (Tian et al., 2005). These 
observations strongly match findings in the study. Thus, the two types of pathogen-induced 
responses are differentially regulated and can be dissociated. The present data highlight a 
remarkable role of C/EBP factors for pathogen-induced IL-8 expression. Hence, C/EBP 
factors might be a novel therapeutic target for selective control of inflammation and innate 
immunity. This is quite a novel perspective. 
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5. SUMMARY 
 
Mammals perceive pathogens by TLR-receptors which are known to subsequently 
activate the NF-B family of transcription factors in the cytoplasm. This study analyzed at 
the molecular level how this common stimulus differentially activates in Mammary 
Epithelial Cell (MEC) the expression of the genes encoding IL-8 and LAP, serving as 
paradigms for either quickly activated proinflammatory cytokines or slowly responding 
effectors of immune response, respectively.  
  
 The kinetics of pathogen-induced expression of both genes is very different. The 
IL-8 mRNA concentration peaks quickly (1h) after pathogen contact, while LAP 
mRNA accumulates steadily with induction time after a time lag of 1 h in response 
to pathogen contact. 
 
 NF-B and C/EBP factors play opposite roles in pathogen-induced expression of 
both genes. The quiescent IL-8 promoter is occupied by NF-B p65 homodimers. 
Activation recruits NF-B p50 which may cooperate with the activated C/EBP 
factors to induce the IL-8 promoter activity. On the contrary, chromatin in the 
quiescent LAP promoter is tightly compacted prohibiting NF-B or C/EBP factor 
binding. The pathogen stimulus results in de-compaction of the chromatin and 
subsequently NF-B p65 homodimers greatly enhance the promoter activity. 
C/EBP factors conversely attenuate the LAP promoter activity.  
 
 Core data were obtained with Chromatin Immunoprecipitation techniques and 
validated further by establishing and using vectors capable to over-express all 
those relevant bovine transcription factors in reporter gene assays. Application of 
those vectors also highlighted that the roles of NF-B factors in regulating IL-8 
and LAP expression are cell type specific.  
 
The data show that induction of inflammation and mounting the -defensin protection in 
the udder are controlled by different mechanisms. This might offer novel strategies to 
selectively control inflammation and separately activate effectors of innate immunity in 
the udder. 
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APPENDIX 
I. Supplementary data 
I.I Sonication to fragment the chromatin in ChIP 
In ChIP assay, sonication was used to fragment the chromatin into pieces comprising 200 bp 
to 1000 bp. The shorter the fragments are, the higher the resolution is but the lower the yield 
is. The effect is shown in Fig. 36A, B and C. Comparison of panel A with panel B reveals that 
the smaller chromatin fragments were increased and the bigger molecules were decreased 
accordingly. Reversal of cross-linking for two nucleosomes generated about 400 bp naked 
DNA. This indicates that sonication efficiently fragments chromatin. 
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Figure 36. Analysis for pbMEC chromatin after sonication 
A) The sheared chromatin of pbMEC by sonication was resolved on 0.8 % agarose gel and 
stained by ethidium bromide. Lane 1: 	 DNA/HindIII marker, lane 2: the sheared chromatin 
for 20 sec. B) The sheared chromatin of pbMEC for 9×20 sec, Lane 1: 	 DNA/HindIII marker, 
lane 2: two nucleosomes, lane3: pBR328/HinfI marker. C) Naked DNA after chromatin 
reversal of cross-linking from B. 
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I.II Binding analysis of C/EBP factors to C/EBP site1 and site 2 in the LAP promoter 
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Figure 37. Affinity analysis of the C/EBP binding motifs for different C/EBP factors in 
the LAP promoter by EMSA 
Nuclear extracts (NE) were from HC11 cells transfected with different expression constructs 
of DN-C/EBP-, -, - or -
 Equal amounts of NE (2 μg) were incubated with the labeled 
probes as indicated. FP, free probe, without nuclear extract. Radiolabeled probes derived from 
C/EBP site1 (LAP_C/EBP site1), C/EBP site2 (LAP_C/EBP site2). The C/EBP specific 
complexes are indicated by arrows. Lanes are given at the bottom. 
 
I.III Distribution of CpG sites and hypermethylated site 11 of the LAP promoter 
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Figure 38. Map of CpG sites and hypermethylated site 11 of the LAP promoter  
The vertical lines refer to CpG sites. Distributions of CpG sites in the LAP promoter are listed 
by the actual scale. The actual positions are given at the bottom. The transcription start site 
(+1) was determined by 5 RACE. The core sequence of NF-B binding site is located at -89/-
80. Hypermethylated region was defined by bisulfite genomic sequencing. CHART PCR 
region is indicated by a dashed rectangle. *, p < 0.05. 
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II. List of primers 
II.I List of primers for EMSA 
   Series No. Name Sequence (5-3) 
336 Nf_Bf AGCTTTTTCTGGGGTTTCCAAAGCCTCATT  
337 Nf_Br AATGAGGCTT  
1333 LAP_B_Efm TTTTCTGGGGATCAGTACAGCCTCATTAGCATA 
1334 LAP_B_Er TATGCTAATG 
1335 LAP_B_Ef TTTTCTGGGGATTTCCACAGCCTCATTAGCATA 
1336 LAP_CE_Efm AAGCGAAGGAACAATGGAAAGTCTGTGC 
1337 LAP_CE_Er GCACAGACTT 
1338 LAP_CE_Ef AAGCGAAGGTTCAGCAAGAAGTCTGTGC 
1339 LAP_CE_mr AGACTTTCCATTGTTCCTTCGCTTAGGGCTTTGAA 
1340 LAP_CE_mf CGAAGGAACAATGGAAAGTCTGTGCCCCTGCCAG 
1388 LAP_CE2_Er CAGGGGTGTGGCAAGGGGCACAGACTTG 
1389 LAP_CE2_Erm CAGGGGGACTAGTCGGGGCACAGACTTG 
1390 LAP_CE2_Ef CAAGTCTGTGC 
1473 LAP_B_Efm3 TTTTCTGCGGATTTAAGCAGCCTCATTAGCATA 
1474 LAP_B_Efm2 TTTTCTGGGGATTTAAGCAGCCTCATTAGCATA 
1475 NFAT_r TATGAAACCAA 
1476 NFAT_f CGCCCAAAGAGGAAAATTGGTTTCATA 
1486 CEBP_con_r TGCAGATTG 
1487 CEBP_con_f TGCAGATTGCGCAATCTGCA 
1488 CEBP_con_rm TGCAGAGAC 
1489 CEBP_con_fm TGCAGAGACTAGTCTCTGCA 
1512 NFATcon_f CGCCCAAAGAGGAAAATTTGTTTCATA 
1513 NFATcon_r TATGAAACAAA 
1533 LAP_B_Efm4 TTTTCTGCGGATTTCCACAGCCTCATTAGCATA 
1674 LAP_CE3_Ef TTTTCTGGGGATTTAAGTCGCCTCATTAGCATA 
 
II.II List of primers for measuring mRNA copies 
   Series No. Name Sequence (5-3) 
689 uDef_f AGGCTCCATCACCTGCTCCT 
690 uDef_r GAAACAGGTGCCAATCTGTCTC 
792 Oligo(dT)20 TTTTTTTTTTTTTTTTTTTTN 
951 cas_427f AACAATCCATGACCATCCTGAC 
981 BT_TNFa_f1 CTTCTGCCTGCTGCACTTCG 
982 BT_TNFa_r2 GAGTTGATGTCGGCTACAACG  
983 BT_TNFa_r1 CTGTGAGTAGATGAGGTAAAGC  
1112 IL8_R3 GGCCCACTCTCAATAACTCTC 
1159 LAP_sr CCTGCAGCATTTTACTTGGGCT 
1160 LAP_sf AGGCTCCATCACCTGCTCCTT 
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II.III List of primers for cloning 
Series No. Name Sequence (5-3) 
72 5_Lucr GCCTTATGCAGTTGCTCTCCA 
92 BASENDf GTACTAACATACGCTCTCCATC 
587 730_mu_NF GCAGGAAAGCTTTTTCTGGAGATCTCAAAGCCTCATTAGC
715 LAP_r AGCATTTTACTTGGGCTCCGAG 
718 LAP_Kpn_f TAGGTACCGTCTTTCTCCACTTTAACTGTTCC 
719 LAP_Xho_r ATCTCGAGGCTGGCGTCCCGAGCTCTGC 
1330 LAP_Pcf GTGACTGACCCTGCTTTGTGCT 
1331 LAP_B_mr GAGGCTGTACTGATCCCCAGAAAAAGCTTTCCT 
1332 LAP_B_mf TGGGGATCAGTACAGCCTCATTAGCATACGAG 
1391 LAP_CE2_mr GGCAGGGGGACTAGTCGGGGCACAGACTTGCCTG 
1392 LAP_CE2_mf GCCCCGACTAGTCCCCCTGCCCATCAGCTGA 
1462 IBA_Hind_Xho_f ATGCAAGCTTCTCGAGATGGCTAGCAGAGGATCGC 
1463 IBA_Strep_BamHI_r ATGCGGATCCTTATTATTTTTCGAACTGCGG 
1535 bBD5_Bm2_r TTTGGAAACCGCAGAAAAAGCTTTCCTGCTGC 
1536 bBD5_Bm2_f GCTTTTTCTGCGGTTTCCAAAGCCTCATTAGC 
1537 bBD5_Bm_r GGCTTTGAGATCTCCAGAAAAAGCTTTCCTGCTG 
1538 bBD5_Bm_f TTTCTGGAGATCTCAAAGCCTCATTAGCATACAAG 
1539 bB_p50SalI_r AGTCGTCGACAGGGTCATTTTTAGATGGGGT 
1540 bB_p50EcoRI_f CAGTGAATTCATGGCAGAAGACGACCCGT 
1541 bB_p50_r2 CACTGTCCCCGTTCTCATC 
1542 bB_p50_r1 GGCGTTGGCGTGCTGCTT 
1543 bB_p65XhoI_r AGTCCTCGAGTTAGGAGCTGATCTGACTC 
1544 bB_p65KpnI_f CAGTGGTACCATGGACGACCTCTTCCCCC 
1545 bB_p65_r2 TGGAGCCGAACATCAGGATA 
1546 bB_p65_r1 TCTGCCTAAGCACCTCCAAA 
1557 pcDNA3,1_f ACCCACTGCTTACTGGCTTA 
1558 pcDNA3,1_r GGGGGAGGGGCAAACAAC 
1596 pEGFP_f     CCAAAATGTCGTAACAACTCCG 
1597 pEGFP_r CTCCTCGCCCTTGCTCAC 
1600 LAP_CE3_mr ATGAGGCGACTTAAATCCCCAGAAAAAGCTTTC 
1601 LAP_CE3_mf GGGGATTTAAGTCGCCTCATTAGCATACGAGTG 
1602 LAP_BG_mr CTGTGGAAATCCGCAGAAAAAGCTTTCCTGCTG 
1649 bB_p50_f1 TCAAACTCCAGAATGGCAGA 
1650 bB_p65XhoI_r2 AGTCCTCGAGGGAGCTGATCTGACTCAGAA 
1651 bB_p65_f1 GGCGAATGGCTCGACAGTAG 
1673 bB_p50SalI_r AGTCGTCGACTCAAGGGTCATTTTTAGATGGGGT 
1681 CGFP_r CTTTGATTCCATTCTTACCGC   
1682 CGFP_f TCTACTGTTTCTCCATACCCG 
1683 NGFP_r CTAGTTATTGCTCAGCGGTG 
1684 NGFP_f ACGTTCCCATCATGGCAGACA 
1685 bB_p50SmaI_r GCATCCCGGGAGGGTCATTTTTAGATGGGGT 
1686 bB_p65SmaI_r3 GCATCCCGGGGGAGCTGATCTGACTCAGAA 
1689 bIL8__luc_r TTGGAAGTCATATTTGAACAAGAG 
1690 bIL8_luc_f GCAAGGAGGTCCAACCAGTC 
1698 bIL8_luc_f2 CCTGAGGCTGGGAGGGATTG 
1720 bIL8_luc_r2 GCACCATCATGTATGCAACCATCCGCCCTTTG 
1721 bIL8_luc_f5 ATGGTTGCATACATGATGGTGCACTTGTTCCC 
1722 bIL8_luc_f4 ATGCGGTACCGTGCTCTCAAAGGGCGGATG 
1723 bIL8_luc_f3 ATGCGGTACCTGCACTTGTTCCCTCTTCTTAC 
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II.IV List of primers for CHART-PCR and ChIP 
         Series No. Name Sequence (5-3) 
1042 BN5_CHf CTGGAAGGGTGAGGGTGGGT 
1039 LAP_PCHr CAAAGCAGGGTCAGTCACTCG 
1040 LAP_PCHf GCAGATTCAAAGCCCTAAGCGA 
1041 BN5_CHr CCTGGAGGAATTCCATGCAGA 
1161 TNF_Pf TTGAACCCTTCTGAAAAAGACAC 
1162 TNF_Pf2 GGTGGAGAAAGAGGTGTCTTC 
1163 TNF_Ir TCTGCTTACTCATTCGTCCAAC 
1409 CAS_CHr CACAAAATACCACTGAGAAATACCT 
1410 CAS_CHf TAGGGTTGGATAAGGAAATGCT 
1647 bTNF_B_f CCTAAAGGAACGGAAACAGTG 
1648 bTNF_B_r TCTCATTCAACCAGCGGAAAA 
1652 BN5_CHf3 CACAGGAAAACAGTGGGCAGT 
1653 BN5_CHf2 AGGTGCCATTTCCTTCTGCAC 
1664 bTNF_B_r2 TTGGTGGAGAAACCCATGAG 
1665 BT_IL8_CHr CGTAAGAAGAGGGAACAAGTG 
1666 BT_IL8_CHf ACTACCATTGACAACAATGTATC 
1687 bTNF_B_r3 CATTCAACCAGCGGAAAACT 
1688 bTNF_B_f2 CCCTAAAGGAACGGAAACAGT 
1696 BN5_CHf3 GTCTGGGGAGCGGGTAAGCA 
1697 BN5_CHf4 TGGAAGGGTGAGGGTGGGT 
1765 BT_IL8_CHf2 ACAAAGCTTGGGTCACACAG 
1766 bTNF_B_f3 CCGAGCGGGCGGAGTGTA 
1769 LAP_PCHf2 CCAGGAAGAAGCTTCTGGTC 
1807 bIL8_Ch_PolIIf CACTTGTTCCCTCTTCTTACG 
1808 bTNF_Ch_PolIIr GCTGCTTGTCTCTCTCCTG 
1809 bTNF_Ch_PolIIf GTTTTCCGCTGGTTGAATGAG 
1810 LAP_Ch_PolIIr TGATGGAGCCTCATGCTGG 
1811 LAP_Ch_PolIIf AGAGGCTCAGTTAACCAGTT 
 
II.V List of primers for methylation 
        Series No. Name Sequence (5-3) 
1136 LAP_P_ID GGGGAGATAGGTTTTTTGAGGT 
1135 LAP_bi_f GATTGTGAGTTTTGATTGTATGG 
1134 LAP_bi_r AACATAACCAAACATACACATACAC 
1440 LAP_P_ID3 GGAGATAGGTTTTTTGAGGTAGG 
1441 LAP_P_ID2 TTTTGATGGAGGGGAGATAGG 
1499 LAP_bi_r2 AAACACAAACTTCTTACTAAACCT 
1500 LAP_bi_r1 AAACTTCTTCCTAACAATCAAT 
1501 LAP_bi_f1 TAGGAAGAAAGTTATTAGGAAA 
1534 LAP_bi_f2 TGTTTAGATTTAGTGGGTAAAG 
1563 LAP_bi_r3 CTAACTTCTCAAAAACATCAAA 
1564 LAP_bi_r4 CACCTAACCCAACAAACAAAAC 
1565 LAP_bi_f3 TTTTTGTAAAAGGAATTATAGATA 
1566 LAP_bi_r5 AATTAACTAAACCTCTTCCCTTT 
1567 LAP_bi_f4 AAAGGGAAGAGGTTTAGTTAATT 
Dr. Vanselow GE843f TTGGTTAGGGAATTGGATTTTATATGTT 
Dr. Vanselow GE845r ATTCCAACAATTCACAACTATATTCCT 
Dr. Vanselow GE919*f AAGTGTTATAAGTAAGATTTGGTATAGT 
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V. Abbreviation list 
A  
Ab Antibody 
AP-1 Activator protein-1 
AP Alkaline phosphatase 
APRE Acute-phase response element 
APS Ammonium persulfate 
  
B  
BCIP Bromo-chloro-indolyl-phosphate  
BNBD -defensin gene 5 
bp Base pair 
BSP   Bisulfite genomic sequencing PCR 
BSA Bbovine serum albumin  
bZIP basic leucine zipper motif 
  
C  
CARM1 Coactivator-associated arginine methyltransferase 
CBP Cyclic AMP response element binding protein (CREB)-binding protein 
C/EBP CCAAT/enhancer binding proteins 
CFU Colony form unit 
CHART-PCR Chromatin Accessibility by Real-Time PCR 
ChIP Chromatin Immuno Precipitation 
CIP Calf intestinal phosphatase 
CRP C-reactive protein 
  
D  
d Day 
DC Dendritic cells 
DMEM Dulbecco's Modification of Eagles Medium 
DMSO Dimethyl sulfoxide 
DN Dominant negative 
Dnmt1 DNA methyltransferase 1 
DSG Disuccinimidyl glutarate 
DTT Dithiothreitol  
  
E  
EB Ethidium bromide  
EBD Enteric  defensin 
E.coli Escherichia coli 
EDTA sodium ethlenediaminetetraacetate
EGF Epidermal growth factor 
ELAM Endothelial leukocyte adhesion molecule 
EMSA Electrophoretic Mobility Shift Assay 
ES Embryonic stem cells 
  
F  
FA  Formaldehyde 
fc final concentration 
FCS Fetal calf serum 
  
G  
g gram 
G-CSF Granulocyte colony-stimulating factor 
GFP Green fluorescent protein 
GTFs General transcription factors 
  
H  
h hour 
HAT Histone acetyltransferase 
hBD human beta defensin 
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IX 
HDAC Histone deacetylase 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HIV Human immunodeficiency virus 
HMG High mobility group protein 
HRP Horseradish peroxidase 
  
I  
IFN-	 Interferon-	 
IgG Immunoglobulin G 
IB Inhibitory B  
IKK IB kinase 
IL Interleukin 
IP Immunoprecipitation 
IPTG Isopropyl--D-thiogalactopyranoside 
  
K  
kg   kilogram 
  
L  
l liter 
LAP   Lingual antimicrobial peptide 
LAP1 ,LAP2 Liver-enriched transcriptional activating proteins 
Lf   Lactoferrin 
LIP Liver inhibitory protein 
LPS    Lipopolysaccharide 
LTA Lipoteichoic acid 
LTR   Long terminal repeat 
  
M  
MAPK Mitogen-activated protein kinase 
MEC Mammary epithelial cells 
MG Mammary gland 
min minute 
μl microliter 
ml milliliter 
mRNA messenger RNA 
MSP Methylation specific PCR 
MyD88 Myeloid differentiation marker 88 
  
N  
NBT Nitro Blue Tetrazolium 
NE Nuclear extracts 
NFAT Nuclear factor of activated T cells 
NF-B Nuclear factor kappa B chain 
ng nanogram 
NLS Nuclear localization sequence 
NP-40 Nonidet P-40  
  
P  
PAGE Polyacrylamide gel electrophoresis 
PAMP Pathogen-associated molecular patterns 
pbMEC primary bovine mammary epithelial cell 
p/CAF the CBP associated factor 
PCR Polymerase chain reaction 
PDTC Pyrrolidine dithiocarbamate 
PMA Phorbol myristate acetate 
PMSF Phenylmethylsulfonylfluorid 
Pu Purine 
PVDF Polyvinylidene difluoride 
Py   Pyrimidine 
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R  
5 RACE Rapid Amplification of 5 CDNA Ends 
RE Restriction enzyme 
RHD Rel-homology domain 
RT Room temperature 
RT-PCR Reverse transcription PCR  
  
S  
S.  aureus staphylococcus aureus 
S. agalactiae staphylococcus agalactiae 
SAA Serum amyloid A 
SAP Stress associated protein 
SDS Sodium dodecyl sulfate 
S.E.M. the standard error of the mean 
STAT 6 Signal transducer and activator of transcription 6 
T   
TAD Transactivation domain 
TAP Tracheal antimicrobial peptide 
TAP Tobacco acid pyrophosphatase 
TBE Tris-borate- EDTA 
TEMED N,N,N',N'-Tetramethylethylene diamine 
TGF Transforming growth factor 
TLR Toll-like receptors 
TNF Tumour necrosis factor 
TRIF   TIR-domain-containing adaptor protein 
Tss Transcription start site 
U  
UTR Untranslated region 
W  
Wt Wild-type 
V  
V Voltage 
X  
X-gal 5-Bromo-4-Chloro-3-Indolyl--D-Galactoside  
 
VI. Amino Acid Abbreviations 
Full name One-letter code Three-letter code 
Alanine A Ala 
Cysteine C Cys 
Aspartate D Asp 
Glutamate E Glu 
Phenylalanine F Phe 
Glycine G Gly 
Histidine H His 
Isoleucine I Ile 
Lysine K Lys 
Leucine L Leu 
Methionine M Met 
Proline P Pro 
Arginine R Arg 
Serine S Ser 
Threonine T Thr 
Valine V Val 
Tryptophan W Trp 
Tyrosine Y Tyr 
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